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 Background 1.1
1.1.1 Importance of the dermal route of exposure in risk assessment 
Dermal contact is an important exposure route, as people are exposed to a variety of 
substances and products via the dermal route, either directly or indirectly while at work, at 
home or in public space (WHO, 2013).  
Under occupational conditions, dermal exposure occurs mainly as a result of splashes, spills 
or drifts, during the application itself or from contact with contaminated surfaces. 
Pesticides, organic solvents and metalworking fluids are seen to be important contributors 
to adverse health effects due to occupational exposure via the dermal route (WHO, 2013).  
In non-occupational settings, cosmetics, clothing and household products are the most 
relevant commodities with respect to dermal exposure, because of their conditions of use. 
For example, the use of cosmetics and clothing results in repeated direct skin contact, often 
of a large body surface area over a prolonged period of time (WHO, 2013).  
In the context of dermal exposure, three different types of toxicological effects can be 
distinguished: local effects, sensitization and systemic effects (WHO, 2013).  
Local effects are effects that occur at the portal of entry without the toxic compound 
becoming systemically available (ECHA, 2012a). Examples of local effects are skin irritation 
and skin tumours. By definition, absorption is of no relevance for these effects, although 
penetration of one or more skin layers may be relevant, e.g. in the case of tumours of the 
dermis, which lies immediately below the epidermis (see section 1.1.2 for more details on 
skin anatomy). In the latter case, comparative dermal penetration data (between tested 
animal and human), preferably including skin distribution, may be of importance in risk 
assessment in order to extrapolate animal dermal toxicity data to human exposure 
conditions.  
Sensitizing effects are allergic responses in susceptible individuals, in which, after a first 
initialising (sensitising) dermal exposure, subsequent dermal exposures may cause allergic 
contact dermatitis or atopic dermatitis, characterised by symptoms such as erythema, 
oedema, and vesiculation (ECHA, 2012b). At first contact (the induction phase of skin 
sensitization), a chemical allergen enters the viable epidermis, after passing the stratum 
corneum, and forms a stable association with a protein (“haptenation”), which leads to the 
local secretion of proinflammatory cytokines and other signal proteins (Kimber et al., 2011). 
The signal proteins activate Langerhans cells, which take up the haptenated allergen and 
move it from the epidermis to draining lymph nodes, where they initiate the cellular 
interactions leading to sensitization. Adverse health effects now may be initiated by 
renewed exposure of the sensitized person to this allergen, as allergen-specific T-cells 
gather at the place the chemical entered the viable epidermis, become activated and initiate 
 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 13 
the immune reactions that lead to the symptoms of allergic contact dermatitis (elicitation 
phase). Both in the induction and the elicitation phase, the chemical allergen only needs to 
pass the stratum corneum and reach the viable epidermis to induce the adverse effect, 
without the need to become systemically available. In general, skin penetration data are not 
used in risk assessment with respect to skin sensitization, as in most cases the available data 
do not allow a quantitative assessment (ECHA, 2012). For sensitizers for which dose 
response data are available (mainly Local Lymph Node Assays aimed at establishing EC3-
values), the contribution of the degree of epidermal bioavailability to their potency is not 
clear (Jaworska et al., 2013), which hampers the extrapolation of animal sensitization data 
to human exposure conditions or the distinction between one human exposure condition 
and another. 
Systemic effects are effects that normally occur away from the portal of entry, after a 
substance has passed a physiological barrier like the skin, and has become systemically 
available (ECHA, 2012), i.e. has entered systemic circulation. Once a substance has passed 
from the portal of entry into the systemic circulation it is considered to be absorbed (WHO, 
2006). This means that the degree of absorption of a substance is one of the determinants 
of its potency to cause systemic effects. Since the degree of absorption of a substance may 
vary with species, skin type and exposure conditions (section 1.1.5), dermal absorption data 
are of importance in toxicological risk assessment to extrapolate experimentally determined 
external dose levels to the expected levels of internal exposure. Furthermore, since in many 
cases mainly oral animal toxicity data are available, extrapolating oral animal toxicity data to 
human dermal exposure conditions is another issue that needs to be solved in dermal risk 
assessment. Also in this situation, data on absorption are needed. In some cases, when 
animal dermal toxicity data are available, risk assessment involves translating animal dermal 
exposure conditions to the expected human dermal exposure conditions, in which case 
comparative absorption data (for tested animal and exposed human) are needed. This thesis 
focuses on further developing, validating and improving methods to use dermal absorption 
data in the risk assessment of systemic toxic effects. 
1.1.2 Skin structure 
The outer most layer of the skin is the epidermis (Figure 1-1). It mainly consists of 
keratinocytes, cells that are generated by the innermost unicellular layer of basal cells (the 
stratum germinativum) by mitotic cell division and subsequent differentiation. From the 
thus formed stratum spinosum, keratinocytes move to the next layer of cells, the stratum 
granulosum. All these epidermal layers consist of living cells. The epidermis is topped by the 
non-living stratum corneum, which consists of cells called corneocytes. Corneocytes are 
mainly composed of keratin, elongated protein molecules interlinked by disulphide bridges. 
They possess a protein-rich cornified cell envelope and are linked to and surrounded by non-
polar extracellular lipids. In humans, the stratum corneum is usually 15-20 cells thick 
(approximately 10-50 µm). Corneocytes are lost from the outer side of the stratum corneum 
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by a process called desquamation. The turnover time of keratinocytes is estimated to be 17 
to 71 days, dependent on the region of the skin: e.g. 32-36 days for the human palm and 58 
days for the anterior surface of the forearm (WHO, 2006). 
The epidermis possesses two other types of cells, melanocytes and Langerhans cells. These 
are so called dendritic cells because of their branch-like extensions. The melanocytes are 
located directly next to the stratum germinativum and produce melanin, the main skin 
pigment. The Langerhans cells are situated in epidermal layers; they contain xenobiotic 
metabolising enzymes and have a function in the immune reactions of the skin (e.g. allergic 
reactions to sensitizers, see section 1.1.1). (WHO, 2006) 
 
Figure 1-1 The skin and routes of absorption (based on figures published by Solanas & Aznar (2013) and 
Patient.co.uk (http://www.patient.co.uk/diagram/skin-cross-section-diagram). 
Below the epidermis, the dermis is located which feeds the epidermis, which does not 
possess any vasculature. This skin layer is approximately 0.25 cm thick and consists mainly 
of a fibrous protein matrix (with a.o. collagen) embedded in an amorphous colloidal ground 
substance (WHO, 2006). 
In the dermis also the sensory organs, blood vessels and lymph vessels of the skin are found. 
Two distinct layers can be observed in the dermis: the papillary dermis, directly underneath 
the epidermis and the reticular dermis (Young et al., 2014). The papillary dermis contains the 
capillary network feeding the epidermis, while the reticular dermis contains coarse collagen 
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and elastic fibres and the larger vessels that transport blood in and out of the capillaries in 
the papillary epidermis (Young et al., 2014). 
The skin bears a number of appendages like sweat glands, sebaceous glands and hair 
follicles. The appendages all originate from the reticular dermis from where they cross the 
papillary dermis and the epidermis to terminate in an orifice at the outer skin surface 
(stratum corneum) enabling secretion of their products to the skin surface (or, in the case of 
hair follicles, to allow their hair filament to protrude from the skin) (WHO, 2006). 
1.1.3 The process of dermal absorption 
Dermal absorption is defined as the passage of chemicals from the outside of the skin into 
the systemic circulation (OECD, 2004a). It can be divided into three processes. The first is 
penetration, which is the entry of a substance into a particular skin layer or structure, the 
second is permeation, which is the passage of a substance through one layer of the skin into 
another and the third is resorption, which is the uptake of a substance into the dermal 
blood or lymph capillaries, thus entering directly or indirectly1 systemic circulation (WHO, 
2006).  
In principle, there are three main pathways of skin absorption (Figure 1-1) (WHO, 2006): 
1. The transcellular route 
2. The intercellular route 
3. The appendageal route 
The surface area of the orifices of the appendages is relatively small (approximately 0.1 to 
1% of the total skin surface). Therefore, the appendageal route is probably of little 
importance for most chemicals. Furthermore, the cornified envelope of the corneocytes is 
relatively impenetrable to most compounds hampering the transcellular route and 
rendering the intercellular route via the convoluted pathway of extracellular lipids between 
the corneocytes the major route of permeation of the stratum corneum (Figure 1-1) (WHO, 
2006).  
The crossing of the stratum corneum is mainly driven by passive diffusion, as active 
transport and facilitated diffusion by carrier proteins does not take place in this layer of 
dead cells (Jepps, et al. 2013). Since the matrix between the corneocytes consists mainly of 
apolar lipids, the stratum corneum is the main barrier for hydrophilic substances. On the 
other hand, the viable epidermis and the dermis are more likely to be the rate limiting 
barrier for lipophilic substances. 
In the viable parts of the skin, active transport and facilitated diffusion may play a role in the 
absorption process. However, although the expression of many carrier proteins has been 
                                                     
1 The lymph enters into the venous blood flow via large collecting lymph vessels (the thoracic duct and the 
right lymph duct), at the junction of the left or right internal jugular and subclavian veins (Guyton 1991a). 
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observed in the viable skin, so far no studies on the kinetics and thus of the importance of 
their contribution to skin absorption have been published (Jepps, et al. 2013). Until now the 
focus of research has been on passive diffusion as the most important driver of skin 
absorption. 
Diffusion of substances across membranes is a chance process driven by the random 
thermal motion of molecules and a concentration gradient in the direction of their lower 
concentration (Eckert and Randall 1988). The rate of diffusion at steady state of a solute is 
described by Fick’s first law, modified for membranes assumed to be pseudo-homogeneous 
(WHO, 2006): 
−
dM
dt
= C × kp × A Equation 1-1 Fick’s first law 
in which  
−
dM
dt
  = mass flux across the membrane in mg/h (expressed as decrease at the outer side), 
C = the concentration of the substance in the vehicle in mg/cm3 (assuming ideal sink 
conditions, at which the concentration underneath the membrane will be virtually 
zero). 
kp  = permeation constant in cm/h and 
A  = the exposed skin area in cm2. 
It is assumed that the maximum flux of a permeant from saturated solutions across the skin 
is not dependent on the nature of the vehicle, unless the vehicle changes membrane 
permeability. Commonly, the stratum corneum is the rate limiting barrier and controls the 
rate of absorption. Therefore, when comparing permeant fluxes from different vehicles, the 
vehicle effect can be considered a change in the vehicle/stratum corneum partition 
coefficient KSC/veh, which greatly influences the velocity with which a chemical penetrates 
the stratum corneum. The better soluble the penetrant in the vehicle, the more probable is 
its retention in the vehicle. This is described by Equation 1-2 in section 1.1.4.6.3 on page 30. 
A more elaborate treatment of the mathematics of skin absorption can be found in section 
1.1.4.6.3 (page 30 and further) and chapter 6. 
1.1.4 Methods to estimate dermal absorption 
The ultimate goal of measuring dermal absorption for toxicological risk assessment is to 
have a quantitative measure of human systemic exposure. Therefore, the studies most 
closely approaching real life human exposure are in vivo studies with humans, and the 
studies farthest away are in vitro studies with synthetic membranes. In this section the 
methods to measure dermal absorption of substances are discussed in decreasing order of 
resemblance with the human exposure situation. 
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1.1.4.1 In vivo human studies 
In in vivo human studies the potential permeant is normally applied on the forearm or back 
skin, while whole-body exposure may be applied for vapours. There are basically two 
different parameters used to measure absorption in humans in vivo: systemic absorption or 
local penetration/permeation at the skin application site. For the former, the amounts of 
permeant and/or its metabolites present in plasma, excreta and exhaled air are determined 
(systemic recovery). Relative absorption can then be estimated as follows (WHO, 2006): 
1. by comparing dermal systemic recovery with recovery after i.v. administration (100% 
systemic “absorption”), 
2. by comparing recovery from the stratum corneum, excreta and exhaled air with the 
amount applied (mass balance method), 
3. by comparing dermal systemic recovery with data from another administration route 
(e.g. oral). 
Using these methods, systemic availability can be ascertained or at least approached, but kp 
cannot be directly measured. 
There are three experimental approaches to determine local penetration and/or 
permeation: cutaneous microdialysis, tape-stripping and dislodgeable dose (WHO, 2006).  
Cutaneous microdialysis uses perfused dialysis to collect substances from the extracellular 
space beneath the skin for subsequent chemical analysis (WHO, 2006). One of the analytes 
can be a permeant that has been applied to the skin. The microdialysis appliance consists of 
microinjection pumps and microdialysis probes with semipermeable membranes. The 
probes can be inserted into blood vessels, the dermis, or the subcutaneous tissue. Receptor 
fluid passing through the microdialysis tubing represents the blood flow beneath the skin 
surface and collects the compounds diffusing from the surrounding tissue into the probes. 
This method is, amongst others, applied to study dermal absorption kinetics. The amount of 
permeant recovered by microdialysis is only a small proportion of the amount present in the 
tissue, and results are usually expressed in terms of relative recovery. Therefore, 
microdialysis is principally of importance to compare the relative influence of different 
formulations and permeation enhancers on dermal absorption of specific compounds, e.g. 
drugs (Azeredo, et al. 2014). As long as recovery cannot be reliably established, it cannot be 
used to determine systemic bioavailability (Azeredo et al., 2014) or a kp. 
Tape stripping of human stratum corneum is often applied to assess skin penetration and 
barrier function (WHO, 2006). The method is simple, cheap, and hardly invasive. The 
permeant is applied to a limited skin area for a certain period of time. Subsequently, the 
exposed stratum corneum is removed by repeated application and removal of strips of 
adhesive tape, and the mass of permeant on the tape strips is analysed.  
One method to quantify kp uses the concentration-depth profile of the permeant in the 
stratum corneum (WHO, 2006). By measuring the amount of stratum corneum on each tape 
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strip, the thickness of the skin layer removed can be assessed. The concentration-depth data 
are fitted into a solution of Fick’s second law (Equation 1-5, page 31) to estimate the 
stratum corneum/vehicle partition coefficient (KSC/veh) of the permeant and its diffusivity (D). 
Using the formula kp = KSC/veh ∙ DSC/LSC (WHO, 2006), in which LSC = thickness of the stratum 
corneum, kp can then be calculated when the thickness is measured or assumed (e.g. on the 
basis of measurements as described by Xiao & Imhof (1997)). 
An example is the study by Herkenne et al. (2008) on ibuprofen: for this drug, based on 
fitted concentration profile data, a kp of 0.024 cm/h can be calculated2 when dissolved in 
propylene glycol/water (25/75 v/v), while the EDETOX database lists a value of 0.036 cm/h 
for water as a vehicle and 0.088 cm/h for phosphate buffer of pH=3, values that are quite 
comparable. It should be noted that when using this method in human volunteers, usually 
no radiolabel can be applied and therefore sensitive analytical methods need to be 
available, certainly when the permeant hardly penetrates. 
Another, simpler approach is one in which the permeant is applied and left on the skin for a 
certain period of time and then the amount washed off as well as the amount collected on 
tape strips after the washing procedure is determined (WHO, 2006). The amount absorbed 
is calculated by subtracting the sum of the amounts in the skin wash and the tape strips 
from the amount applied. This method is only reasonably precise when the amount 
absorbed is in the same order of magnitude as the amount applied. 
1.1.4.2 In vitro studies with human skin 
 In in vitro studies with human skin, an excised piece of skin is used to measure permeation 
                                                     
2 The article lists a partition coefficient KSC/veh of 98 and a value of 0.12 h
-1 for D/LSC
2 (D= diffusivity of ibuprofen 
in the stratum corneum (SC) and LSC is the thickness of the SC). These parameters were determined by fitting. 
The authors also determined LSC
2 by transepidermal water loss measurements, but did not list their values. 
Therefore, I have used a default thickness of 20 µm based on Xiao & Imhof (1997). Since kp = K ∙ D/ LSC (WHO, 
2006), for ibuprofen, based on the tape strip data, it will be equal to 98 (KSC/veh) × 0.12 h
-1 (D/ LSC
2) × 0.002 cm 
(LSC) = 0.024 cm h
-1. It can be noted that nowadays confocal Raman spectroscopy is the gold standard method 
to measure SC thickness (Mateus, et al. 2013).  
 
Figure 1-2 Franz cell for in vitro dermal absorption measurements (modified from Karpanen et al. (2008)) 
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across the skin of chemicals applied to it (WHO, 2006). In 2004, the OECD has adopted and 
published a test guideline for in vitro dermal penetration (OECD, 2004b). The following 
descriptions are based on this guideline. The permeant is applied to the surface of a skin 
sample separating the two chambers of a diffusion cell, the donor compartment and the 
receptor compartment (Figure 1-2). These diffusion cells may vary from a simple “static” 
Franz cells to complex multi-jacketed flow-through cells.  
The amount of permeant and/or its metabolites moving from the donor to the receptor 
compartment is measured over time. After a specified time, e.g. 8 or 24 hours, exposure is 
terminated by removing the permeant from the skin.  
The static Franz diffusion cell is one of the most commonly used appliances to measure skin 
absorption in vitro (Figure 1-2). The receptor fluid beneath the skin is sampled at specific 
time intervals. The removed volume of receptor fluid is substituted by an equal volume of 
fresh receptor fluid. An important issue is the solubility of the permeant in the receptor 
fluid: A sufficient sink capacity has to be maintained to ensure that the concentration 
gradient across the skin is not significantly decreased by permeant accumulating in the 
receptor fluid. In flow-through cells receptor fluid is continuously replaced, which mimics in 
vivo blood flow. This method is particularly useful when a permeant hardly dissolves in the 
receptor fluid: The continuous replacement of receptor fluid maximises the concentration 
gradient. Skin permeability measurements using static and flow-through cells yield 
comparable results (Jakasa and Kezic, 2008). 
By measuring, after exposure has been terminated, the amounts of permeant recovered 
from tape stripping and from the underlying viable skin also the penetration of the 
permeant into the stratum corneum and the underlying tissues can be determined. Often 
female abdominal and/or breast skin obtained from cosmetic surgery or autopsy is used, 
although cadaver skin from various body regions may be applied as well (WHO, 2006). 
Different skin preparations may be used (OECD, 2004b): 
1. Full-thickness skin, including the stratum corneum, viable epidermis, and dermis. 
Systemic absorption may be underestimated as the dermis can act as a reservoir, 
especially for lipophilic substances (Jakasa and Kezic, 2008; Williams, 2006). Therefore, 
this skin preparation is less appropriate for regulatory use, unless the skin reservoir is 
included in the amount absorbed (the sum of the amounts in the receptor fluid and in 
the skin is often termed “potential absorption”). 
2. Dermatomed skin, from which the lower dermis has been removed, also called split-
thickness skin. 
The excised skin is cut with a dermatome to obtain more uniform and reproducible 
preparations with respect to shape and thickness. 
3. Epidermal membranes, consisting of the viable epidermis and the stratum corneum. 
The epidermis is separated from the dermis by applying heat, chemicals or enzyme 
treatment. The skin preparations used in chapter 6 are of this type. Epidermal mem-
branes may overestimate human in vivo absorption (van de Sandt et al., 2000). 
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4. Isolated stratum corneum. 
The stratum corneum is separated from epidermal membranes by treatment with 
trypsin. Isola-ted stratum corneum is principally applied in mechanistic studies and 
partition coefficient measurements. 
The permeability coefficient kp is determined (in of cm/h or cm/s) by dividing the steady-
state flux (in μg/h per cm2) by the permeant concentration (measured in μg/cm3) in the 
vehicle present on the skin (WHO, 2006). 
Steroids are well known for their skin reservoir effects. Another example of such a reservoir 
forming substance is didecyldimethylammoniumchloride (DDAC) (chapter 5). Depending on 
the physicochemical properties of the permeant and its interaction with skin components, 
e.g. proteins, it may form a reservoir in the stratum corneum, in the viable epidermis, or in 
the dermis. From the reservoir, the permeant may continue to diffuse further into the skin 
after exposure has terminated, in the end becoming systemically available via the lymphatic 
or sanguine capillary network in the dermis (WHO, 2006).  
1.1.4.3 In vivo animal studies 
The degree of dermal penetration and systemic absorption of the permeant can be assessed 
with greater precision in in vivo studies with animals than in studies with humans, since at 
the end of the study a full mass balance can be determined. In vivo dermal absorption 
studies are normally performed in rodents, mostly rats. Using rats has the advantage that 
other toxicity and toxicokinetic studies are mostly performed in this species. A major 
disadvantage is that animals have different skin permeability (Figure 1-4) and metabolism, 
distribution and excretion in comparison with humans. Also care must be taken to prevent 
the animals from directly or indirectly ingesting the permeant via grooming or the 
contamination of their surroundings.  
In 2004, the OECD has adopted and published the guideline for determination of in vivo 
dermal absorption (OECD, 2004c). The following description is based on this guideline. The 
permeant is applied to 5-10% of the total skin surface in a suitable vehicle for a set period of 
time. The exposed area is often confined by a gauze covered ring to avoid spreading of the 
permeant and to ensure the animal does not tamper with the application site. Excreta are 
collected at set time intervals, and the amount of permeant and/or metabolite(s) in the 
samples is quantified. Expired air is also collected when excretion of permeant and/or its 
metabolites is to be expected via this route. As the degree of absorption is proportional to 
the exposure time, this time should be relevant to the scenario under consideration (usually 
6 or 24 h). After exposure, the permeant is removed and excreta are continued to be 
collected until sacrifice of the animals. 
Dermal absorption is normally expressed as a percentage of the dose applied, which is 
calculated by summing all amounts recovered from excreta, body fluids, expired air, and 
carcass, including the cleansed dose skin, and cage wash. Like in humans, occasionally tape 
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stripping is applied to study the process of penetration of the stratum corneum. Should the 
animals not be sacrificed, then an indirect measure of absorption can be used as is done in 
human volunteer studies (section 1.1.4.1).  
In addition to OECD guideline 427 type of studies, also in animals cutaneous microdialysis 
may be performed to study dermal penetration (for a more elaborate description see 
section 1.1.4.1). 
1.1.4.4 In vitro studies with animal skin 
Instead of human skin, also animal skin can be used in vitro. The principles of the 
measurement are the same as described in section 1.1.4.2 for human skin. Rat skin is often 
chosen when the in vivo toxicity studies have been performed in rats, but also mouse, 
guinea pig and pig skin are frequently used. Furry animal skin is shaved before use to avoid 
non-uniform and badly reproducible dosing, and to better represent human skin (OECD, 
2004b). 
1.1.4.5 In vitro studies with artificial skin 
Different types of synthetic skin equivalents have been developed. When used to simulate 
skin for instance for dermal absorption experiments in Franz cells, they are silicone based: 
e.g. polydimethylsiloxane (PDMS) or carbosil (Ng et al., 2012). These membranes are 
hydrophobic, inert and do not show biological variation, which in principle makes them a 
good alternative for the stratum corneum. Karadzovska and Riviere (2013) compared 
absorption of five substances (cortisone, diclofenac, mannitol, salicylic acid and 
testosterone) by porcine skin mounted in diffusion cells with absorption values for three 
different artificial membranes (IPM, certramide and Strat-M™) determined using a high 
throughput technique with 96 wells plates. Correlation between porcine skin and artificial 
membrane absorption values was poor (R2 = 0.38 to 0.56); the absorption values for artifi-
cial membranes tended to be lower.  
Also living skin equivalent artificial models consisting of skin membranes grown in tissue 
culture are employed, these models may be monolayers (2D) or multi-layered, resembling 
more or less in vivo skin (3D) (Brohem et al., 2011). However, percutaneous absorption 
cannot properly be assessed in 2D-models because they do not represent the functional 
physiology of the skin. 3D-models do represent this functional architecture, but are not able 
to form a well organised flat cornified epithelium (=stratum corneum) (Brohem et al., 2011). 
Since the stratum corneum is the principal barrier of the skin (see a.o. WHO, 2006), also 3D-
models are not a good option to measure skin absorption for regulatory purposes. This is 
confirmed by several researchers, e.g. Heylings et al. (2001) demonstrating that 3D 
reconstituted epidermis shows an abnormally high transepidermal water loss. Garcia et al. 
(2002) found that the permeability of reconstituted epidermis to caffeine is 20-25 times as 
high as that of normal human skin biopts, and Schmook et al. (2001) observed that the 
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permeability of a living skin equivalent and reconstituted epidermis for hydrocortisone, 
clotrimazole and terbinafine was several hundred times higher than for excised human skin. 
1.1.4.6 In silico models 
Besides actually measuring dermal absorption parameters for a specific permeant, they also 
may be calculated, or rather predicted, without doing experiments by applying in silico 
models. These models range from simple rules of thumb to complex models mimicking all 
toxicokinetic processes (absorption, distribution, metabolism and excretion) the permeant 
may be subjected to.  
1.1.4.6.1 Rules of thumb 
In Europe, simple rules of thumb to determine relative dermal absorption based on 
properties of the permeant are used as part of a tiered approach (see also section 7.7, 
Application in regulatory risk assessment).  
In the REACH guidance (ECHA, 2012b), it is advised to use molecular weight and log KOW of a 
chemical to estimate its dermal absorption in humans, when no acceptable experimental 
data on dermal absorption are available, based on a proposal published by de Heer et al. 
(1999): If its molecular weight is less than 500 and/or its log KOW is between -1 and 4, dermal 
absorption is considered to be 100%, in all other cases the default is 10%.  Although 
originally this approach was also used for pesticides within the legal framework for plant 
protection products (see e.g. EC, 2004), ECHA has redefined these rules of thumb, 
introducing the active substance concentration (= pesticide) as an additional criterion 
(ECHA, 2012b): If log KOW < -1 or > 4 and MW > 500 a default dermal absorption value of 
10% may be applied, else a value of 25% may be applied for products containing > 5% active 
substance and a value of 75% for products or in use dilutions containing ≤ 5% active 
substance. 
Bos and Meinardi (2000) proposed the 500 Dalton rule for pharmaceuticals, stating that the 
molecular weight (MW) of a compound must be under 500 Dalton to permit skin 
absorption. This empirical rule was based on the observation that nearly all known contact 
allergens are smaller than 500 Dalton, that the most commonly used topical skin 
therapeutics are all under 500 Dalton, that all topical drugs used in transdermal drug-
delivery systems are under 500 Dalton and that systemic cyclic immunosuppressants of ca. 
800 Daltons and more are not effective when applied to the skin. However, this anecdotal 
evidence seems too weak a basis for such an absolute statement, principally because the 
dermal absorption of only very few drugs larger than 500 was assessed. Also the foremost in 
vitro dataset used in derivation of QSARs predicting dermal absorption, the Flynn database 
(section 1.1.4.6.2), does not contain many molecules greater than 500 Dalton (Figure 1-3). 
Moreover, the permeation constant data of the Flynn database do not show a clear trend 
towards an abrupt drop in absorption for molecules larger than 500 Dalton.  
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1.1.4.6.2  QSARs 
In general, Quantitative Structure Activity Relationships (QSARs) are quantitative predictions 
of some form of biological activity of chemicals based on one or more measures of their 
physicochemical and/or structural properties (Cronin and Schultz, 2003). Since strictly 
speaking, skin permeation is not a biological activity, but the result of a passive diffusion 
process (section 1.1.3), some authors use terms like Quantitative Structure Permeability 
Relationship (QSPR) or Quantitative Structure Permeation Relationship (QSPeR) (e.g. Geinoz 
et al., 2004; Moss and Cronin, 2002). In this thesis the abbreviation QSPR will be used to 
indicate QSARs for dermal permeation parameters. 
Most QSPRs developed to predict skin permeation of chemicals target the permeation 
constant (kp), and a few maximum flux (Jmax) (Mitragotri et al., 2011). Occasionally, also 
QSPRs for percentage absorption have been developed (e.g. by Gute et al., 1999), but 
although preferred from a regulatory point of view, they have limited value, since this 
parameter is highly influenced by exposure conditions like duration and dermal loading (see 
also section 1.1.5). Typically, QSPRs are based on training sets derived from in vitro dermal 
absorption experiments (Moss and Cronin, 2002). 
A number of useful reviews of QSPRs have been published. Geinoz et al. (2004) provide an 
excellent historical overview of the different types of approaches used, combined with a 
statistical re-evaluation of landmark QSPRs and an appraisal of the most influential chemical 
properties determining the rate of dermal absorption. Also Moss et al. (2002) provide a 
good historical overview and parameter appraisal, and add a thorough discussion of the 
limitations the available database impose on QSPR development. Bouwman et al. (2008, 
2005) evaluated over 30 QSPRs for their usefulness in regulatory risk assessment by 
assessing them against the OECD QSAR validation principles and tested the predictive 
quality of the QSPRs that fulfilled the OECD criteria against an external validation set of 
EDETOX and in-house TNO data. Mitragotri et al. (2011) presented a more succinct overview 
 
Figure 1-3 Flynn dataset as published by USEPA (2004) 
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of QSPRs, but also reported more recent developments and addressed the entire field of in 
silico models for skin permeation. External validation is the ultimate test of the quality of a 
QSAR (Cronin and Schultz, 2003), and besides Bouwman et al. (2008, 2005) also Lian et al. 
(2008) and Korinth et al. (2012) attempted such a validation, the former on five QSPRs using 
a dataset collected from public literature and the latter on 3 QSPRs using measured in vitro 
data of a varied set of 11 chemicals, generated in the same test system with the same 
protocol by one laboratory. 
Table 1-1 lists the algorithms of the global QSPRs for aqueous solutions reviewed in the 
publications mentioned in the previous paragraph. The majority of these QSPRs relate 
permeation to the octanol-water partition coefficient (KOW) and molecular weight (MW), 
indicating the importance of these physio-chemical properties in the permeation process. 
However, also hydrogen bonding, characterised by a number of different molecular 
descriptions, may play an important role (Geinoz et al., 2004; Moss and Cronin, 2002). Also 
additional descriptors may be needed to fully predict skin permeation. As a matter of fact, 
when Degim et al. (2003) tried to develop a neural network predicting the permeation 
constants in the Wilschut database (Wilschut et al., 1995), they could not find a significant 
solution based on MW and log KOW alone, but when using the sum of the charges on the 
atoms in the molecule as an additional parameter, obtained excellent results. This is also 
illustrated by the bad performance of log KOW and MW based QSPRs with external validation 
sets. All QSPRs predicting kp tested by Bouwman et al. (2008, 2005) and Korinth et al. (2012) 
showed a correlation R2 of less than 0.3 with the external validation set, although their 
datasets fell within the application domain of these QSPRs with respect to the input 
parameters (data not shown). The external validation by Lian et al. (2008) showed a much 
better performance of this type of QSPRs, but this was probably mainly due to the great 
overlap between the chemicals in their validation set and the training sets of the respective 
tested QSPRs: Seventy-five chemicals of the Flynn dataset published by USEPA (2004) are 
present among the 124 chemicals of the Lian et al. dataset. The Flynn database is most 
often used to derive the training set of QSPRs (Geinoz et al., 2004). When the correlations of 
the predictions of the log KOW and MW QSPRs evaluated by Lian et al. are calculated for the 
Bouwman et al. dataset, they all had a R2<0.3 (unpublished results). 
The QSPRs listed in using other molecular descriptors than log KOW and MW, were dismissed 
for regulatory use by Bouwman et al. (2008), since they were considered not easily available 
to regulatory risk assessors. Chen et al. (2013) evaluated two QSPRs, one based on log KOW 
and MW (Potts and Guy, 1992), one on solvatochromic parameters and three mechanistic 
brick-and-mortar models (see also section 1.1.4.6.3) against a dataset of hydrophilic 
molecules (defined as having a log KOW <0.5). The QSPR models did not perform well 
(R2<0.5), while the mechanistic models appeared to do reasonably well (highest R2 = 0.60). 
However, for a number of molecules multiple values were present in the dataset (e.g. 16 
values for water), giving more weight to these molecules in the analysis. When the 
correlations based on average log kp values were calculated, also the performance of the 
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brick-and-mortar models was below par (highest R2 = 0.48) (unpublished results). In view of 
the bad result of the QSPRs in external validation sets or the difficult access to the necessary 
molecular descriptors, their use in a regulatory setting is not feasible.  
Another complicating factor for these QSPRs that are mainly derived by multiple linear 
regression, is that the relation between log kp or Jmax and at least some of the descriptors 
used is not always linear, e.g. Zhang et al. (2009) observed that Jmax showed a more or less 
parabolic relationship with log KOW for similar sized permeants, Magee (1998) (cited in Moss 
et al., 2002) demonstrated that hydrogen bonding is more important in the most 
hydrophobic group of chemicals and Moss et al. (2011) showed that the relation between 
measured kp-values and important properties determining permeation is non-linear. 
New developments in QSPR development include neural network, nearest neighbour and 
Gaussian process models. These novel models are able to predict non-linear processes, and 
Gaussian process models have been shown to perform better than selected QSPRs (see 
Moss et al., 2011) as have fuzzy models and artificial neural networks (Russell and Guy, 
2009). However, they yet have to prove their practical value (Mitragotri et al., 2011).  
Little work has been done to include vehicle effects in QSPR predictions (Karadzovska et al., 
2013), most of it by Riviere and co-workers (see a.o. Ghafourian et al., 2010a, 2010b; Guth 
et al., 2014; Riviere and Brooks, 2005; Riviere et al., 2014; Samaras et al., 2012). Many of the 
QSPRs were based on Abraham descriptors with the addition of a mixture factor, a 
composite of descriptors like polarizability, refractive index and Henry’s law constant. Each 
of these QSPRs was based on a small training set of less than 20 molecules, and all showed 
quite different mixture factors (Guth et al., 2014; Riviere and Brooks, 2005; Riviere et al., 
2014). So it seems a global QSPR for vehicle effects is not within reach. Karadzovska et al. 
(2013) have published a recent overview on QSPR work on dermal absorption from different 
vehicles. 
 
 
 
Chapter 1 Introduction 
page 26 
 
Ta
bl
e 
1-
1 
Li
st
 o
f g
lo
ba
l Q
SP
Rs
 fo
r a
qu
eo
us
 so
lu
tio
ns
. 
Pr
ed
ic
te
d 
pa
ra
m
et
er
 
M
od
el
 
In
pu
t p
ar
am
et
er
s 
Re
fe
re
nc
e 
k p
 
lo
g 
k p
 =
 –
2.
3 
+ 
0.
65
2l
og
 K
O
W
 –
 0
.0
06
03
M
W
 –
  0
.6
23
AB
SQ
on
 –
 0
.3
13
Ss
ss
CH
 
AB
SQ
on
, K
O
W
, M
W
, S
ss
sC
H 
Pa
te
l e
t a
l. 
(2
00
2)
 
k p
 
lo
g 
k p
 =
 -0
.6
2
6∑
C
a 
– 
2
3
.8
∑
(Q
+)
/α
 –
 0
.2
8
9
 S
ss
sC
H
 –
 0
.0
35
7S
ss
sO
H
 –
 0
.4
82
I B 
+0
.4
05
B
R +
 0
.8
34
  
B R
, h
yd
ro
ge
n 
bo
nd
 
de
sc
rip
to
r (
∑
C
a)
, I
B, 
∑
(Q
+)
/α
, S
ss
sO
H
 
De
ar
de
n 
et
 a
l. 
(2
00
0)
 
k p
 
lo
g 
k p
 =
 –
2.
72
4 
– 
0.
00
26
4M
W
 ×
 c
ha
rg
e 
+ 
0.
59
lo
g 
K O
W
  
ch
ar
ge
, K
O
W
, M
W
 
Pu
gh
 e
t a
l. 
(2
00
0)
 
k p
 
lo
g 
k p
 =
 –
0.
07
(lo
g 
K O
W
)2
 +
 0
.8
4l
og
 K
O
W
 –
 0
.2
7H
b 
– 
1.
84
lo
gM
W
 +
 0
.8
33
7 
Hb
, K
O
W
, M
W
 
Li
en
 a
nd
 G
ao
 (1
99
5)
 
k p
 
If 
-1
.3
8 
≤
 lo
g 
K O
W
 ≤
 1
.9
6
: 
lo
g 
k p
 =
 0
.7
9 
lo
g 
K O
W
 –
 0
.0
37
1M
R 
– 
2.
26
 
If
 1
.5
3 
≤ 
lo
g 
K O
W
 ≤
 2
.9
7
: 
lo
g 
k p
 =
 1
.0
5 
lo
g 
K O
W
 –
 0
.0
25
9M
R 
– 
3.
24
 
If
 2
.5
 ≤
 lo
g 
K O
W
 ≤
 5
.4
9:
  
lo
g 
k p
 =
 0
.9
5 
lo
g 
K O
W
 –
 0
.0
37
M
R 
– 
0.
10
7H
BA
 –
 2
.9
2 
hy
dr
og
en
 b
on
d 
de
sc
rip
to
r 
(H
BA
), 
K O
W
, M
W
, M
R 
M
ag
ee
 (1
99
8)
 (c
ite
d 
by
 
G
aj
ew
sk
a 
et
 a
l.,
 2
01
4 
in
 
su
pp
le
m
en
ta
l m
at
er
ia
l) 
k p
 
lo
g 
k p
 =
 −
 1
.3
6
(3
.5
4
H
B
D
 –
 0
.3
7)
 –
 3
.3
9 
hy
dr
og
en
 b
on
d 
de
sc
rip
to
r 
(H
BD
) 
Ta
ya
r e
t a
l. 
(1
99
1)
 (c
ite
d 
by
 
G
ei
no
z e
t a
l.,
 2
00
4)
 
k p
 
lo
g 
k p
 =
 0
.4
4R
2 -
 0
.4
9π
2H
 -1
.4
8Σ
α
2H
 - 
3.
44
Σβ
2H
+
 1
.9
4V
x -
 1
.5
7 
Hy
dr
og
en
 b
on
d 
de
sc
rip
to
rs
 
( ∑
𝛼𝛼
2𝐻𝐻
, ∑
𝛽𝛽
2𝐻𝐻
), 
R 2
, V
x 
Ab
ra
ha
m
 a
nd
 M
ar
tin
s (
20
04
) 
(p
re
vi
ou
s v
er
si
on
s r
ep
or
te
d 
in
 A
br
ah
am
 e
t a
l. 
(1
99
9,
 
19
97
, 1
99
5)
) 
k p
 
lo
g 
k p
 =
 0
.0
25
6M
V 
– 
1.
72
HD
 –
 3
.9
3H
A 
– 
1.
29
 
hy
dr
og
en
 b
on
d 
de
sc
rip
to
rs
 
(H
A,
 H
D)
, M
V 
Po
tt
s a
nd
 G
uy
 (1
99
5)
 
k p
 
lo
g 
k p
 =
  –
 0
.6
VE
H
 –
 0
.0
14
0M
R 
– 
0.
15
7H
BA
 –
 0
.2
9H
BD
 –
 0
.1
40
 
hy
dr
og
en
 b
on
d 
de
sc
rip
to
rs
 
(H
BA
, H
BD
), 
M
R,
 V
EH
 
Ho
st
yn
ek
 a
nd
 M
ag
ee
 (1
99
7)
 
(c
ite
d 
by
 G
ei
no
z e
t a
l.,
 2
00
4)
 
k p
 
k p
 =
 0
.1
 
K O
W
0.
75
12
0 
+
 K
O
W
0.
75
  
K O
W
 
Br
ow
n 
an
d 
Ro
ss
i (
19
89
) 
k p
 
lo
g 
k p
 =
 0
.8
20
lo
g 
K O
W
 –
 0
.0
09
3M
V 
– 
2.
36
 –
 0
.0
03
9M
pt
 
K O
W
, M
pt
, M
V 
Ba
rr
at
t (
19
95
) 
k p
 
lo
g 
k p
 =
 0
.8
30
lo
g 
K O
W
 –
 0
.0
11
9M
V 
– 
2.
31
 
K O
W
, M
V 
G
ei
no
z e
t a
l. 
(2
00
4)
 
 
 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 27 
 
 T
ab
le
 1
-1
 (c
on
tin
ue
d)
 
Pr
ed
ic
te
d 
pa
ra
m
et
er
 
M
od
el
 
In
pu
t p
ar
am
et
er
s 
Re
fe
re
nc
e 
k p
 
k p
 =
 
k li
p
1+
 k
lip
 ×
  
M
W
2.
6
 
lo
g 
k li
p =
 −
 2
.3
2 
+0
.5
7
4l
o
g 
K O
W
 –
 0
.0
05
M
W
 
K O
W
, M
W
 
Cl
ee
k 
an
d 
Bu
ng
e 
(1
99
3)
 
J m
ax
 
J m
ax
=
C s
at
1
5
  
0.
03
8
 +
 0
.1
5
3
K O
W
  
e−
0
.0
1
6
M
W
  
K O
W
, M
W
 
Fi
se
ro
va
-B
er
ge
ro
va
 e
t a
l. 
(1
99
0)
 
k p
 
If 
M
W
 <
 1
50
 a
nd
 lo
g 
K O
W
 <
 0
.5
: 
lo
g 
k p
 =
 −
3
 
If 
M
W
 <
 1
50
 a
nd
 lo
g 
K O
W
 >
 3
: 
lo
g 
k p
 =
 −
0
.5
 
If
 M
W
 <
 1
50
 a
n
d
 0
.5
 ≤
 lo
g 
K O
W
 ≤
 3
: l
og
 k
p =
 lo
g 
K O
W
 −
 3
.5
 
If 
M
W
 >
 1
50
 a
nd
 lo
g 
K O
W
 <
 0
.5
: 
lo
g 
k p
 =
 −
5
 
If 
M
W
 >
 1
50
 a
nd
 lo
g 
K O
W
 >
 3
.5
: 
lo
g 
k p
 =
 −
1
.5
 
If
 M
W
 >
 1
50
 a
n
d
 0
.5
 ≤
 lo
g 
K O
W
 ≤
 3
: l
og
 k
p =
 lo
g 
K O
W
 −
 5
.5
 
K O
W
, M
W
 
Fl
yn
n 
(1
99
0)
 (c
ite
d 
in
 G
ei
no
z 
et
 a
l.,
 2
00
4)
  
k p
 
lo
g 
k p
 =
 0
.5
35
6l
og
 K
O
W
 –
 0
.0
05
22
7M
W
 –
 2
.5
6 
K O
W
, M
W
 
Fu
jiw
ar
a 
et
 a
l. 
(2
00
3)
 
k p
 
lo
g 
k p
 =
 0
.9
3l
og
 K
O
W
 +
 0
.0
13
M
W
 –
 2
.1
1 
K O
W
, M
W
 
G
ei
no
z e
t a
l. 
(2
00
4)
 
k p
 
lo
g 
k p
 =
 0
.8
lo
g 
K O
W
 +
 0
.0
10
8M
W
 –
 2
.3
5 
K O
W
, M
W
 
G
ei
no
z e
t a
l. 
(2
00
4)
 (b
as
ed
 o
n 
a 
su
bs
et
 
(n
=2
1)
 o
f t
he
 F
ly
nn
 d
at
ab
as
e,
 se
le
ct
ed
 b
y 
El
 T
ay
ar
 e
t a
l.,
 1
99
1)
 
k p
 
k p
 =
 M
W
−
2
.4
0
4
 ×
  
−
5∙
10
−
6 +
 
0.
0
0
25
−
0
.0
89
 +
 0
.3
93
 
K O
W
  
K O
W
, M
W
 
M
cK
on
e 
an
d 
Ho
w
d 
(1
99
2)
 (c
ite
d 
by
 
G
aj
ew
sk
a 
et
 a
l.,
 2
01
4 
in
 su
pp
le
m
en
ta
l 
m
at
er
ia
l) 
k p
 
lo
g 
k p
 =
 0
.7
lo
g 
K O
W
 –
 0
.0
72
2M
W
⅔
 −
 1
.6
9
18
 
K O
W
, M
W
 
M
itr
ag
ot
ri 
(2
00
2)
 (c
ite
d 
by
 L
ia
n 
et
 a
l.,
 
20
08
) 
k p
 
lo
g 
k p
 =
 0
.7
66
lo
g 
K O
W
 –
 0
.0
10
M
W
 –
 2
.2
81
 
lo
g 
k p
 =
 0
.8
12
lo
g 
K O
W
 –
 0
.0
4L
M
V 
– 
0.
23
0
ST
W
 −
 2
.0
64
 
K O
W
, M
W
 
K O
W
, L
M
V,
 S
TW
 
M
oo
dy
 a
nd
 M
ac
Ph
er
so
n 
(2
00
3)
 
Th
e 
be
st
 fi
tt
in
g 
m
od
el
 is
 sh
ow
n 
an
d 
th
e 
m
od
el
 w
ith
 th
e 
ea
sie
st
 to
 o
bt
ai
n 
pa
ra
m
et
er
s  
k p
 
lo
g 
k p
 =
 0
.7
4l
og
 K
O
W
 –
 0
.0
09
1M
W
 –
 2
.3
9 
K O
W
, M
W
 
M
os
s a
nd
 C
ro
ni
n 
(2
00
2)
* 
(p
re
vi
ou
s v
er
si
on
 
pu
bl
ish
ed
 b
y 
Cr
on
in
 e
t a
l.,
 1
99
9)
 
* 
Th
e 
au
th
or
s e
rr
on
eo
us
ly
 re
po
rt
ed
 th
e 
un
it 
of
 th
e 
k p
 p
re
di
ct
ed
 b
y 
th
is 
al
go
rit
hm
 to
 b
e 
cm
/s
 in
st
ea
d 
of
 c
m
/h
. 
 
 
 
Chapter 1 Introduction 
page 28 
 
Ta
bl
e 
1-
1 
(c
on
tin
ue
d)
 
Pr
ed
ic
te
d 
pa
ra
m
et
er
 
M
od
el
 
In
pu
t p
ar
am
et
er
s 
Re
fe
re
nc
e 
k p
 
lo
g 
k p
 =
 0
.7
1l
og
 K
O
W
 –
 0
.0
06
1M
W
 –
 2
.7
 
lo
g 
k p
 =
 0
.7
4l
og
 K
O
W
 –
 0
.0
06
M
W
 –
 2
.8
 
lo
g 
k p
 =
 0
.7
2l
og
 K
O
W
 –
 0
.0
05
9M
W
 –
 2
.8
 
K O
W
, M
W
 
Po
tt
s a
nd
 G
uy
 (1
99
2)
 
G
uy
 a
nd
 P
ot
ts
 (1
99
2)
 
G
ei
no
z e
t a
l. 
(2
00
4)
 
k p
 
lo
g 
k p
SC
-in
te
rc
el
lu
la
r =
 0
.7
31
8l
og
 K
O
W
 –
 0
.0
06
83
2M
W
 –
 2
.5
9 
lo
g 
k p
SC
-tr
an
sc
el
lu
la
r =
 –
1.
36
1l
og
 M
W
 –
 1
.3
67
 
k p
 =
 k
pS
C-
in
te
rc
el
lu
la
r +
 k
pS
C-
tr
an
sc
el
lu
la
r 
K O
W
, M
W
 
te
n 
Be
rg
e 
(2
00
9)
 
k p
 
lo
g 
k p
 =
 0
.6
6l
og
 K
O
W
 –
 0
.0
05
6M
W
 –
 2
.8
0 
K O
W
, M
W
 
U
SE
PA
 (
U
SE
PA
, 
20
04
, 
cu
rr
en
tly
 u
se
d 
in
 
th
e 
DE
RM
W
IN
 
sk
in
 
ab
so
rp
tio
n 
es
tim
at
io
n 
so
ft
w
ar
e)
 
k p
 
lo
g 
k p
 =
 0
.5
14
lo
g 
K O
W
 –
 0
.0
05
0M
W
 –
 2
.4
4 
lo
g 
k p
 =
 0
.5
2l
og
 K
O
W
 –
 1
.5
8M
W
/T
 –
 2
.4
1
 
K O
W
, M
W
 
K O
W
, M
W
, T
 
Ve
cc
hi
a 
an
d 
Bu
ng
e 
(2
00
2b
) 
k p
 
lo
g 
k p
 =
 0
.6
88
lo
g 
K O
W
 +
 0
.1
81
 
M
W
 –
 1
.5
26
 
K O
W
, M
W
 
W
ils
ch
ut
 e
t a
l. 
(1
99
5)
 (c
ite
d 
by
 G
aj
ew
sk
a 
et
 a
l.,
 2
01
4 
in
 su
pp
le
m
en
ta
l m
at
er
ia
l) 
k p
 
k p
ol
 =
 1
∙1
0-
10
 
M
W
k a
q 
= 
2.
5
 
M
W
 
k p
= 
 
1
k l
ip
+ 
k p
ol
 +
 
1 k a
q 
-1
 
lo
g 
k li
p =
 0
.6
20
lo
g 
K O
W
 −
 0
.1
59
 
M
W
 –
 1
.2
86
 
K O
W
, M
W
 
W
ils
ch
ut
 e
t a
l. 
(1
99
5)
 
J m
ax
 
lo
g 
J m
ax
 =
 –
0.
01
41
M
W
 –
 4
.5
2 
M
W
 
M
ag
nu
ss
on
 e
t a
l. 
(2
00
4)
 
k p
 
lo
g 
k p
 =
 0
.0
20
8l
og
 V
e –
 0
.7
23
N
 –
 2
.6
9 
N
, V
e 
Bu
ch
w
al
d 
an
d 
Bo
do
r (
20
01
) 
Th
e 
un
it 
fo
r 
al
l m
od
el
s 
fo
r 
k p
 is
 c
m
/h
. I
n 
ca
se
 t
he
 o
rig
in
al
 m
od
el
s 
ha
d 
cm
/s
 a
s 
un
it,
 lo
g 
36
00
 (
=3
.5
6)
 h
as
 b
ee
n 
ad
de
d 
to
 t
he
 e
qu
at
io
n(
s)
 f
or
 lo
g 
k p
 m
od
el
s 
an
d 
th
e 
eq
ua
tio
ns
 fo
r  k
p h
av
e 
be
en
 m
ul
tip
lie
d 
w
ith
 3
60
0.
 T
he
 u
ni
t f
or
 J m
ax
 o
f F
ise
ro
va
-B
er
ge
ro
va
 is
 m
g/
(c
m
2 ∙h
) a
nd
 fo
r M
ag
nu
ss
on
 m
ol
/(
cm
2 ∙h
). 
  
 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 29 
Ta
bl
e 
1-
1 
Le
ge
nd
  
AB
SQ
on
 =
 is
 
th
e 
su
m
 
of
 
ab
so
lu
te
 
ch
ar
ge
s 
on
 
ox
yg
en
 an
d 
ni
tro
ge
n 
at
om
s 
B R
 
= N
um
be
r o
f r
ot
ab
le
 b
on
ds
 
cb
 
= t
he
 n
um
be
r o
f c
ar
bo
ns
 n
ot
 in
vo
lve
d 
in
 a
 
C=
 O
 b
on
d 
ch
ar
ge
 
= t
he
 s
um
 o
f 
th
e 
ab
so
lu
te
 v
al
ue
s 
of
 t
he
 
pa
rti
al 
ch
ar
ge
s 
(c
al
cu
lat
io
n 
m
et
ho
d 
de
sc
rib
ed
 in
 P
ug
h 
et
 a
l. (
20
00
)) 
C s
at
 
= C
on
ce
nt
ra
tio
n 
in
 w
at
er
 a
t 
sa
tu
ra
tio
n 
(e
xp
re
ss
ed
 in
 m
g/
cm
3 ) 
HA
 
= H
yd
ro
ge
n 
bo
nd
 ac
ce
pt
or
 ac
tiv
ity
 
Hb
 
= n
um
be
r o
f h
yd
ro
ge
ns
 
HB
A 
= h
yd
ro
ge
n 
bo
nd
 ac
ce
pt
or
s 
HB
D 
= h
yd
ro
ge
n 
bo
nd
 d
on
or
s 
HD
 
= H
yd
ro
ge
n 
bo
nd
 d
on
or
 ac
tiv
ity
 
 
I B 
= 
Ba
lab
an
 in
de
x 
LM
V 
= L
iq
ui
d 
M
ol
ar
 V
ol
um
e 
lo
g K
OW
 =
 o
ct
an
ol
-w
at
er
 p
ar
tit
io
n 
co
ef
fic
ie
nt
 
M
pt
 
= m
el
tin
g p
oi
nt
 
M
R 
= m
ol
ec
ul
ar
 re
fra
ct
ivi
ty
 
M
V 
= 
m
ol
ar
 vo
lu
m
e 
 
M
W
 
= 
m
ol
ec
ul
ar
 w
ei
gh
t 
N 
= 
Nu
m
be
r 
of
 
af
fe
ct
ed
 
hy
dr
og
en
 
bo
nd
s, 
ca
lcu
lat
ed
 b
y 
su
m
m
in
g 
th
e 
nu
m
be
r 
of
 N
 
an
d 
O 
at
om
s 
(a
lip
ha
tic
 t
wi
ce
, 
ar
om
at
ic 
on
ce
) (
Bo
do
r a
nd
 B
uc
hw
ald
 1
99
7)
 
π 2H
 
= 
So
lu
te
 d
ip
ol
ar
ity
/p
ol
ar
iza
bi
lit
y 
R 2
 
= 
Ex
ce
ss
 m
ol
ar
 re
fra
ct
io
n 
∑α
2H  
= 
Ef
fe
ct
ive
/o
ve
ra
ll h
yd
ro
ge
n 
bo
nd
 ac
id
ity
 
∑β
2H  
= 
Ef
fe
ct
ive
/o
ve
ra
ll h
yd
ro
ge
n 
bo
nd
 b
as
ici
ty
 
 
∑C
a 
= H
YB
OT
-P
LU
S 
H-
bo
nd
 a
cc
ep
to
r 
fre
e 
en
er
gy
 
fa
ct
or
 
∑(
Q+
)/α
 =
 H
YB
OT
-P
LU
S p
os
iti
ve
 ch
ar
ge
 p
er
 u
ni
t v
ol
um
e 
Ss
ss
CH
 
= t
he
 s
um
 o
f 
E-
st
at
e 
in
di
ce
s 
fo
r 
all
 m
et
hy
l 
gr
ou
ps
/E
le
ct
ro
to
po
lo
gic
al
 
at
om
-ty
pe
 
in
de
x 
fo
r s
in
gly
 b
on
de
d 
CH
 
Ss
ss
OH
 =
 El
ec
tro
to
po
lo
gic
al 
at
om
-ty
pe
 in
de
x 
fo
r s
in
gly
 
bo
nd
ed
 O
H 
ST
W
 
= S
ur
fa
ce
 T
en
sio
n 
in
 W
at
er
  
V e
 
= V
an
 d
er
 W
aa
ls 
ef
fe
ct
ive
 m
ol
ec
ul
ar
 v
ol
um
es
, 
ca
lcu
lat
ed
 a
cc
or
di
ng
 to
 B
uc
hw
ald
 a
nd
 B
od
or
 
(1
99
8)
 
VE
H 
= v
eh
icl
e 
ty
pe
 (
fo
r 
ac
et
on
e 
VE
H=
1 
an
d 
fo
r 
et
ha
no
l V
EH
=2
) 
Vx
 
= M
cG
ow
an
 ch
ar
ac
te
ris
tic
 vo
lu
m
e 
 
 
 
 
 
Chapter 1 Introduction 
page 30 
1.1.4.6.3 Mathematical skin models 
The QSPRs described in the previous section merely predict a constant (kp or Jmax) of the skin 
permeation process. In order to calculate actual amounts of permeant crossing the skin 
under relevant exposure conditions, a mathematical model is needed. The following 
overview is mainly based on two recent reviews of mathematical modelling of dermal 
absorption by Anissimov et al. (2013) and Mitragotri et al. (2011). 
The most simple model is to only consider the stratum corneum, being the major barrier for 
dermal absorption in most cases (section 1.1.3), and assume it is a (pseudo-)homogeneous 
compartment. In that case, the fundamental mathematical relationship is, based on Fick’s 
first law (see a.o. Anissimov et al., 2013; Mitragotri et al., 2011; Russell and Guy, 2009): 
At infinite dose and under ideal sink conditions (meaning that permeant concentration at 
the other side of the skin can be considered 0, because any permeant molecule that has 
crossed is rapidly removed), transport across the skin can be calculated using a non-
differential version of Equation 1-1 from section 1.1.3 (Anissimov et al., 2013): 
When finite dose conditions need to be considered, steady state will not be reached, and 
the differential Equation 1-1 needs to be solved to calculate skin permeation, yielding: 
Mt = M0 ×	1 − ekp/Vveh× A × (ttlag) Equation 1-4 Finite dose dermal permeation 
in which  
M(0) = mass load on the membrane at time t=0, and 
Vveh = volume of the vehicle the permeant is dissolved in (expressed in cm3) 
kp,SC = KSC/veh x DSC/LSC  Equation 1-2 Permeation constant fraction of partitioning, diffusivity and 
diffusion path 
in which 
kp,SC  = permeation constant in cm/h  
KSC/veh  = vehicle/stratum corneum partition coefficient (unitless) 
DSC  = diffusivity of the penetrant in the stratum corneum in cm2/h 
LSC  = length of the diffusion pathway through the stratum corneum in cm 
Mt=	C × kp × A × (t − tlag) Equation 1-3 Infinite dose dermal permeation 
in which  
M(t) = mass that has crossed the membrane at time t, 
C = the concentration of the substance in the vehicle in mg/cm3,  
kp = permeation constant of the stratum corneum in cm/h (which can be considered 
identical to the overall kp of the skin when the stratum corneum is the principal 
barrier for the permeant, which is the case for comparatively hydrophilic 
molecules),  
A = is the exposed in skin area in cm2, 
t = exposure time (expressed in hours) , and 
tlag = lag time (expressed in hours) = time needed to establish the steady state  
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A more elaborate description of the use of this equation to estimate dermal absorption is 
given in chapter 6. 
The chemical-specific parameters kp and tlag needed to use these equations can be either 
measured or predicted based on properties of the chemical. Since tlag = LSC2 /6DSC and kp is 
given by Equation 1-2, LSC needs to be known to be able to use Equation 1-3 or Equation 1-4 
to predict dermal permeation based on the properties of the permeant: kp can be predicted 
using an adequate QSPR, for water KSC/veh can be approximated by KOW, and DSC can be 
calculated once LSC is known. For hydrophilic molecules that mainly follow the transcellular 
pathway, LSC is approximately equal to the thickness of the stratum corneum (Mitragotri et 
al., 2011), which can be measured. However, for lipophilic molecules, which mainly follow 
the tortuous intercellular pathway, it is not. Of course, when lag time is negligible compared 
to exposure time, one only has to rely on the predicted kp, as lag time can assumed to be 0. 
Also when the stratum corneum is not the rate limiting barrier, Equation 1-3 or Equation 1-4 
may be used. Instead of representing the stratum corneum, the parameters can be 
considered values averaged over the different skin compartments (Anissimov et al., 2013). 
When the concentration of permeant at various depths in the stratum corneum needs to be 
taken into account, e.g. when using in vivo tape stripping to calculate diffusivity and the 
permeation constant (section 1.1.4.1), solutions to the second order differential equation 
constituting Fick’s second law need to be found (see a.o Anissimov et al., 2013): 
∂C(x,t)
∂t
= DSC
∂2C(x,t)
∂2x
 Equation 1-5 Fick's second law 
Various mathematically complex solutions to this differential equation have been 
elaborated, the description of which is outside the scope of this overview. For this, the 
reader may consult the excellent reviews of Mitragotri et al. (2011) and Anissimov et al. 
(2013). 
More complex models of the skin mainly concern the stratum corneum, being often the 
rate-limiting barrier. Most of these models try to describe the structure of the stratum 
corneum more accurately as a so called “brick-and-mortar” model, in which the mortar 
represents the lipids and the bricks the corneocytes (Anissimov et al., 2013; Mitragotri et al., 
2011). The simplest one only describes permeation through the lipid phase of the stratum 
corneum (intercellular pathway), others also consider the transcellular pathway through the 
corneocytes and the most complex ones subdivide the corneocytes (intercellular pathway) 
in protein fraction and a water fraction, allowing to take stratum corneum hydration into 
account (Mitragotri et al., 2011). Although receiving less attention, also viable epidermis and 
avascular and vascular dermis have been modelled (Anissimov et al., 2013). Every 
compartment added to the skin model implies an increase in parameters to describe 
partitioning between the different compartments and diffusion across them, and increases 
the mathematical complexity of the models and thereby the data needs of the models in 
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order determine the various chemical-specific and skin specific parameters (Anissimov et al., 
2013; Mitragotri et al., 2011). This means that, in general, the usability of the more complex 
models in regulatory risk assessment will be limited, due to lack of data to populate the 
models with the necessary parameters. Furthermore, specialist numerical skills are required 
to use complex models (Anissimov et al., 2013), which will hamper acceptance by regulatory 
risk assessors, who are by nature generalists. The latter objection is mitigated by the 
versatile and complex skin model called the Finite Dose Skin Permeation Model (FDSP) made 
available on the internet3 by the US Centers for Disease Control and Prevention (CDC). It 
includes the stratum corneum (a brick-and-mortar model including hydration as a variable 
parameter), the viable epidermis and the dermis, and also takes into account the volatility of 
the permeant. The most recent description is provided by Dancik et al. (2013), and in 
chapter 7 its use as alternative for our model described in chapter 6 is assessed. 
1.1.4.6.4 Physiology Based Pharmacokinetic (PBPK) models with a skin compartment 
When evaluating systemic effects of permeants, it may be of importance to establish not 
only how much will pass the skin into the systemic circulation, but also what the fate of the 
permeant will be when it is distributed by circulation to other organs. This can be modelled 
with so called PBPK models, in silico models consisting of compartments representing 
different organs or groups of organs of an organism (e.g. rat, human), linked by circulating 
blood. Depending on the aim of a specific model, compartments are added, separated, 
subdivided or lumped. Transport of chemicals between the compartments and blood are 
modelled as perfusion or diffusion limited processes, dependent on chemical-specific blood-
tissue partitioning coefficients and the physiological characteristics of the compartment. For 
some compartments (e.g. liver, kidney) metabolism may be modelled as well. By adding a 
skin compartment to this type of models, absorption, distribution, metabolism and 
excretion of chemicals entering the body via the skin can be modelled as well (Anissimov et 
al., 2013). As these models are even more complex than the complex mathematical skin 
models and often require a great number of chemical specific parameters, they are even 
more difficult to use in regulatory risk assessment. Therefore, they are not further discussed 
here. 
1.1.4.7 Selection of the most appropriate method for the purpose of risk assessment. 
When using in vivo methods, the degree of dermal penetration and of systemic absorption 
of the permeant can be determined. The principal asset of in vivo studies in relation to in 
vitro studies is that they use skin that possesses its full metabolic and physiological 
competence. In vivo studies in humans are the gold standard for regulatory risk assessment. 
The principal set-back of using laboratory animals is that their skin permeability, 
metabolism, distribution and excretion may differ from those of humans.  
                                                     
3 http://www.cdc.gov/niosh/topics/skin/finiteSkinPermCalc.html 
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The barrier characteristics of the stratum corneum are mostly unaltered after excision of a 
piece of skin from the body. Therefore, data from in vitro skin absorption tests correlate 
well with in vivo studies performed with the identical permeants (certainly for hydrophilic 
compounds) (Godin and Touitou, 2007; Jakasa and Kezic, 2008). In vitro tests are a suitable 
alternative for in vivo studies and also present some advantages over in vivo experiments, 
amongst others a saving in animals, costs and time, better reproducibility of results, and the 
possibility to test a wider range of different exposure parameters. Therefore, for regulatory 
risk assessment the use of in vitro dermal absorption studies with human skin is to be 
preferred, a conclusion also drawn by the WHO task group on environmental health criteria 
for dermal absorption (WHO, 2006). When metabolism is expected to be of importance, 
viable skin should be used. In that case, since the logistics of obtaining viable human skin are 
rather complicated, animal skin, e.g. rat skin, may be the best alternative. 
Ideally, permeant application conditions in the in vitro test would be identical to those of 
the human exposure scenario’s to be evaluated. Alternatively, especially when many 
different exposure conditions need to be evaluated, one could decide to only test an infinite 
dose to determine kp and lag time and calculate absorption for different exposure 
conditions using a mathematical model with these parameters and the specific exposure 
parameters as input (chapter 6). 
1.1.5 Factors influencing absorption 
The many factors that may influence the rate and extent of dermal absorption can be 
divided in three main categories: 
1. Physicochemical properties of the permeant and its vehicle 
2. Properties and condition of the exposed skin 
3. Exposure conditions 
1.1.5.1 Physicochemical properties of the permeant and its vehicle 
Since, in general, dermal absorption is a passive process involving diffusion down a 
concentration gradient and partitioning over lipophilic (e.g. stratum corneum) and 
hydrophilic (e.g. viable epidermis) media the octanol/water partition coefficient (log KOW) 
and molecular size are among the most important chemical properties governing the rate 
and extent of dermal absorption (EFSA, 2011; WHO, 2006) (see also section 1.1.4.6.2). 
Molecular weight can be a proxy for molecular size, but only with confidence within a 
homologous series (EFSA, 2011). 
The process described in section 1.1.3 refers to permeants diffusing across the skin from a 
solvent. However, chemicals may also come in contact with the skin in different physical 
states, e.g. solid, vapour, neat liquid.  
Since diffusion is driven by random thermal movement, direct absorption of solids will be 
restricted, since in solid state the movement of molecules is restricted to oscillations. 
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Diffusion of entire particles across the skin is unlikely as well, since Watkinson et al. (2013) 
calculated, using two QSPRs for dermal absorption, that even nanoparticles are too big to 
diffuse in measurable amounts across the skin. Consequently, solid permeants first need to 
dissolve in a vehicle before they are able to penetrate into the stratum corneum (Heylings 
and Esdaile, 2008). The finer the solid particles, the more readily they may dissolve in e.g. 
moisture on the skin, to subsequently penetrate into the stratum corneum (Heylings and 
Esdaile, 2008). Still one would expect absorption to be less when permeants are in the solid 
state. Indeed, pesticides from solid formulations tend to be absorbed to a lower degree 
than pesticides from liquid formulations (Aggarwal et al., 2015, 2014), although it cannot be 
excluded this is due to the properties of the pesticides since the authors did not control for 
that confounder. Romonchuk et al. (2006) found that the flux from pure powder (grains of 
approx. 50 µm) was over ten times slower than that from saturated solutions of 
4-cyanophenol and methylparaben. However, the authors did not expect this as according 
to them the thermodynamic activity of the pure powder and the saturated solutions are the 
same and they did observe equal fluxes for both physical states when using an artificial 
membrane. Concluding, although the theoretical explanation is not clear, absorption from 
powders as opposed to from solutions seems to be slower. 
On the other hand, permeants in the vapour phase have the maximum freedom of 
movement, but the amount of molecules near the skin surface will be much lower than will 
be the case for a solute in solvent. Therefore it may be expected that absorption from the 
vapour phase will be slow and negligible compared to absorption via the respiratory route, 
which occurs at an epithelial surface designed to take up molecules instead of being 
designed as a barrier. Still for some substances, dermal absorption from vapours may be an 
important contributor to the total uptake. For example, Weschler and Nazaroff (2014) 
collected measured values for the contribution of dermal uptake to the total uptake (via the 
dermal and respiratory routes) in humans for 19 volatile organic substances. For ten of 
them, dermal uptake contributed 20% or more to the total body burden, for some 
(2-butoxyethanol, aniline and 2-methoxyethanol) the contribution of dermal uptake was 
even higher than that of respiratory uptake. For the others, the contribution of dermal 
uptake was 7% or less. 
A special case are the permeants that are present on the skin as neat liquids. One could 
expect that skin permeation of such a liquid (if miscible with the solvent, e.g. water), would 
simply increase with concentration from diluted to neat permeant, following Equation 1-1. 
More strictly formulated, neat kp is expected to be equal to the aqueous kp multiplied with 
the proportion of water solubility and density in the neat state, based on thermodynamic 
considerations (Frasch et al., 2007). Indeed, a mixture of butoxyethanol and water does 
show this behaviour at higher dilutions of butoxyethanol, but in the mid region of dilutions 
the flux becomes constant and it decreases when the mixture approaches neat 
butoxyethanol (Bunge et al., 2012). Based on the comparison between the permeation of 
butoxyethanol through rat skin in vitro and an artificial membrane (silicone), decreasing skin 
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hydration at higher concentrations of butoxyethanol is likely the cause of this phenomenon 
as skin hydration is an important factor in its permeability for hydrophilic compounds 
(Bunge et al., 2012). The same behaviour has been observed for other glycol ethers, and 
ethanol (Bunge et al., 2012). Also for a number of liquid compounds not miscible with 
water, neat application did not reflect the results obtained with saturated aqueous 
solutions. For example diethylphthalate’s flux across hairless guinea pig skin in vitro was 
twice as high from a saturated solution compared to the neat form, while for 
dichloroethylene it was approx. 5 times lower (Frasch et al., 2007). This is probably related 
to vehicle effects like (de)hydration (ethanol/water) or delipidisation (organic solvents) 
(Frasch et al., 2007). 
Of course, solubility is also an important factor for chemicals that are lodged on the skin 
dispersed or dissolved in a vehicle (solvent(s) and possibly other ingredients). When 
dissolved, the ionisation state of a molecule is of influence, since ionised molecules have 
lower absorption than the corresponding non-ionised forms, the permeability coefficient 
being lower by 1-2 orders of magnitude (EFSA, 2011). Consequently, also the pH of the 
vehicle, as well as the pKa of the permeant will influence the rate of absorptions, since these 
values will largely determine the ionisation state of acids and bases. For ionisable 
substances log KOW should be substituted by log Dow, which is the distribution coefficient or 
apparent partition coefficient, and is given by the following formula (Mälkiä et al., 2004): 
DOW=
[HA]oct+[A-]oct 
[HA]water+[A-]water
 
Equation 1-6 Partitioning coefficient ionogenic molecules 
Also volatility of the permeant will be an important factor in dermal absorption as 
substances rapidly evaporating from the skin will be absorbed to a lesser extent than 
substances that do not readily evaporate. The relative importance of evaporation will be 
determined by the ratio between the rates of evaporation and penetration (see e.g. Kasting 
and Saiyasombati, 2001). 
Protein binding properties of permeants will also influence their absorption rate, as binding 
to structural proteins in the skin may retard absorption and binding with carrier proteins 
may enhance it (Holmgaard et al., 2014). However, the importance of the latter has never 
been demonstrated (section 1.1.3). 
Other vehicle related factors that influence dermal absorption are (EFSA, 2011; WHO, 2006): 
• Solvent drag, an absorbable solvent takes a dissolved lipophilic substance with it. 
• Lipophilicity/hydrophilicity: Partitioning of the permeant between the stratum corneum 
and vehicle depends on its lipophilicity/hydrophilicity and that of the vehicle.  
• Presence of irritants and/or sensitizers may cause significant skin irritation and therefore 
increased skin permeability. 
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• Presence of surfactants like quaternary ammonium compounds may alter the barrier 
properties of the stratum corneum and/or produce an irritant reaction that could 
increase dermal absorption (chapters 3 to 5).  
• Volatility, when a solvent rapidly evaporates, the permeant, when not very volatile as 
well, will be deposited as a solid on the skin, a form in which it will less readily cross the 
skin. 
• Presence of compounds that directly interact with stratum corneum lipids or proteins, 
which may enhance or retard permeation. E.g., a protein cross-linker like glutaraldehyde 
may decrease the permeability of the stratum corneum (chapter 5). 
1.1.5.2 Properties and condition of the exposed skin 
The main barrier to absorption of chemicals is the stratum corneum (EFSA, 2011; WHO, 
2006). Hair follicle and sweat and sebaceous gland density may influence dermal absorption, 
as these appendages provide a short-cut through the epidermis (section 1.1.2). 
Consequently, there are differences in dermal absorption between anatomical sites and 
species. In humans, the hierarchy of absorption at different anatomical sites is: scrotum > 
forehead > torso and arms > palms and soles of feet (EFSA, 2011). The permeability of pig 
and monkey skin is comparable to human skin, while the skin of rats, guinea-pigs, and 
rabbits is more permeable (WHO, 2006). In a comparative study with different chemicals, 
dermal absorption decreased in this sequence: rabbit > rat > pig > human (Bartek et al. 
(1972, cited in WHO, 2006)). Also the EDETOX in vitro dermal absorption data show as a 
general tendency higher kp values for animal skins (Figure 1-4). Remarkably, the values for 
snake skin, based on a limited data set, seem to be quite close to the human values, as are 
those of pig and minipig. 
There are no systematic data on age-related differences in dermal absorption, but, based on 
incidental data, there are minor differences in skin absorption due to age, limited to certain 
skin areas (e.g. facial and back skin) (EFSA, 2011). 
In principle, blood and lymph flow may influence absorption as the magnitude of the flow 
rate will determine how fast the permeated molecule is removed from the skin into the 
systemic circulation keeping the concentration gradient over the skin as large as possible. 
However, this is principally of interest for small, moderately lipophilic chemicals, as their 
removal from the skin by the blood flow is rate limiting for their systemic absorption (WHO, 
2006). 
Sweating and skin hydration may increase dermal absorption, but less than 2 fold (EFSA, 
2011). So sweating and skin hydration appear to be of minor importance in skin absorption. 
Diffusion rates increase with temperature and therefore skin temperature will influence 
absorption (WHO, 2006). Temperature may also change the crystalline structure of the lipids 
in the stratum corneum, which can provoke higher permeability (WHO, 2006). Vecchia and 
Bunge (2002a) found a positive correlation between temperature and kp in the Flynn dermal 
 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 37 
absorption database. Further QSPR analysis, however, indicated the influence of absolute 
temperature on the absorption process was weak: adding absolute temperature to a QSPR, 
based on an amplified Flynn database and containing just MW and log KOW, only increased 
the explained variability in log kp from 55.1 to 56.4% (Vecchia and Bunge, 2002b). 
Furthermore, under in vivo conditions, ambient temperature influences the blood flow to 
the skin, which starts to increase from a temperature of approx. 24 oC (Guyton, 1991), thus 
potentially modifying absorption (see above). 
Skin lesions caused by mechanical damage or disease may reduce the barrier function of the 
skin and increase its permeability. Mechanical lesions by either tape stripping or abrasion 
cause up to over a 100-fold increase of absorption, but this occurs only when the lesions 
reach the dermis (EFSA, 2011). In people suffering from atopic dermatitis, psoriasis or 
eczema skin permeability increased, sometimes even in not affected regions of the skin 
(Kezic and Nielsen, 2009). Based on an evaluation of the few in vitro studies available in 
public literature, the increase in absorption through damaged or diseased skin is modest 
when compared to intact skin and affects mainly the absorption of hydrophilic molecules 
(Gattu and Maibach, 2010).  
The skin possesses xenobiotic metabolising enzymes. Both phase I and phase II enzymes are 
present in the viable epidermis and in the dermis, be it, in general, in lower activities than in 
the metabolising organ par excellence, the liver (see e.g. Oesch et al., 2014, who give an 
overview of skin metabolizing capacity). For example, cultured skin cells and viable skin 
preparations in diffusion experiments are able to hydrolyse butoxyethanol to butoxyacetic 
acid and parabens to p-hydroxybenzoic acid (Williams, 2008). There is anecdotal evidence 
for the influence of skin metabolism on dermal absorption. In some experiments with 
 
Figure 1-4 Comparison of human and animal kp values, measured in vitro (data from the EDETOX project 
(http://edetox.ncl.ac.uk/)) 
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mouse skin induction of cutaneous xenobiotic metabolizing enzymes increased the 
permeation of benzo[a]pyrene 2- to 3-fold (Kao et al., 1985, cited in WHO, 2006). However, 
metabolism may not be relevant if the stratum corneum is the rate limiting factor in 
percutaneous absorption. On the other hand, if the viable tissue is rate limiting, which may 
well be the case for lipophilic compounds, turnover to a more polar compound may increase 
permeation, e.g. in vitro absorption experiments with human and rat skin and esters of the 
pesticide fluroxypyr showed that the parent compound could only be detected in the 
stratum corneum, while only the metabolite could be detected in the viable skin and in the 
receptor fluid (equivalent to systemic absorption in vivo) (Hewitt et al., 2000). This suggests 
that the esterase activity present in the viable skin may enhance absorption of these esters, 
although this should be confirmed by comparing it with a condition in which the esterase 
activity is inhibited (e.g. by using non-viable skin preparations). Also Beydon et al. (2014) 
when studying the absorption of phenoxyacid ester herbicides in viable rat and human skin 
in vitro only found the free esters in the receptor fluid. Still, the PPR Panel of EFSA considers 
that skin metabolism will not alter the calculated absorption significantly as the 
metabolically active cells are situated below the stratum corneum and therefore the main 
barrier to absorption has to be passed before any metabolism can occur (EFSA, 2011). 
The outer layers of the stratum corneum are continuously removed by a process called 
desquamation (section 1.1.2). Therefore, chemicals present in the stratum corneum may be 
removed, and will no longer be available for systemic absorption. This will mostly be of 
importance for very lipophilic substances or substances that in another way remain 
associated with the stratum corneum (reservoir formation, see section 1.1.4.2). This is, 
amongst others, the case for DDAC (chapter 5) 
1.1.5.3 Exposure conditions 
Two distinct dosing regimens can be discerned: infinite and finite dose (Figure 1-5). At 
infinite dose, the amount of substance applied per unit skin area (dermal load) is so high 
that no appreciable dose depletion takes place, and the absorption rate is practically 
constant. How high the dermal load should be to reach infinite dose conditions will, 
amongst others, depend on the permeability of the chemical (the lower the permeability, 
the lower the dermal load necessary to reach infinite dose). Under these conditions, relative 
absorption is a meaningless number as increasing the load will not increase the absorption 
rate.  
Under finite conditions, the applied dose will markedly change resulting in a decreasing 
absorption rate over time. In this case, absorption is usually expressed as a percentage of 
the dermal loading. Since this relative absorption will increase with time (Figure 1-5), it is 
important that the exposure conditions reflect the in-use situation with respect to these 
parameters. So if many different exposure conditions are to be evaluated for a certain 
compound, many different in vitro tests are needed or an in silico model capable of 
predicting absorption under these different exposure conditions (chapter 6). 
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When exposed, skin may be bare or covered with (protective) clothing. When skin is 
covered in such a way that evaporation from the skin is completely prevented, it is said to 
be occluded. An example of an occluding piece of clothing are latex surgical gloves. When 
the skin is covered by a fabric merely limiting evaporation from the skin, without completely 
preventing it, e.g. a cotton shirt, it is said to be semi-occluded. The effects of occlusion of 
the exposed skin, may be related to temperature and humidity, as occlusion may increase 
the hydration of the stratum corneum from 5-15% to as much as 50%, and may increase its 
temperature from 32 to as much as 37 ˚C (Bucks and Maibach, 2002). Bucks & Maibach 
(2002) have reviewed occlusion and in vivo penetration and demonstrated that there is an 
apparent trend of increased absorption due to occlusion with increasing permeant 
lipophilicity. Occlusion may cause up to 9-fold increases in absorption (EFSA, 2011). 
As increased skin temperature and hydration may increase absorption (section 1.1.5.2), also 
raised ambient temperature and humidity conditions can be expected to augment 
absorption rates. However, the limited data available, which concern dermal absorption of 
vapours, show only a ca. 1.3-fold increase when ambient temperature was raised from 20 to 
30 ˚C, while an increase in ambient relative humidity from 59 to 65% caused a somewhat 
higher increase, which however was not statistically significant (Jones et al., 2003). For the 
moment, the impact of these two parameters seems limited, but more data are needed to 
draw more definitive conclusions. 
 Objectives and outline of this thesis 1.2
1.2.1 Objective 
Given the possible importance of the dermal exposure route, the aim of this thesis is to 
characterise the role of dermal loading (the amount of chemical applied per cm2 skin), of 
 
Figure 1-5 Relative cumulative absorption and flux under finite and (nearly) infinite dose conditions 
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irritative/corrosive potential, of frequency of exposure and of the vehicle used in dermal 
absorption and subsequent risk assessment in more detail, using in vitro models for dermal 
absorption and literature data whenever possible. 
1.2.2 Outline 
Chapter 1 presents an overview of the importance of dermal absorption in toxicological risk 
assessment, the factors influencing its rate and the in silico, in vitro as well as in vivo models 
currently available to measure and predict it. Many factors influence the rate of dermal 
absorption of a substance. In this thesis, four of these, dermal loading (chapters 3 and 6), 
irritative/corrosive potential (chapters 3 and 4), frequency of exposure (chapters 3, 4 and 5) 
and the vehicle used (chapter 6), were investigated in more detail. 
Chapter 2 aims to investigate the relationship between relative dermal absorption and 
dermal loading (Buist et al., 2009). It discusses the fallacy of the present common practice in 
regulatory toxicological risk assessment to ignore the impact of dermal loading on dermal 
absorption. Dermal loading is defined as the amount of substance per unit area of exposed 
skin. To illustrate the importance of dermal loading for dermal risk assessment, in chapter 2 
an inventory is made of all dermal absorption data publicly available at the time of 
investigation including also a number of (anonymised) TNO data. The data are analysed with 
respect to the relation between relative dermal absorption and dermal loading. 
Furthermore the relevance of the results of this analysis for the estimation of dermal 
absorption under realistic exposure conditions in the framework of regulatory risk 
assessment is discussed. 
In order to investigate the possible influence of the frequency of exposure, chapter 3 aims 
to investigate the influence of single and repeated dermal exposure to biocidal active 
substances on in vitro skin permeability, based on public literature. This investigation has 
been performed on the basis of data available in public literature on dermal absorption of 
biocides. Also the potential influence of irritative and/or corrosive properties of biocides is 
discussed. Taking into account the results of this literature based evaluation, a proposal for 
addressing this issue via experimental research is formulated.  
Chapter 4 (Buist et al., 2005) aims to investigate the influence of single and repeated dermal 
exposure to biocidal active substances on in vitro skin permeability, using an experimental 
approach, based on the proposal formulated in chapter 3. The biocidal active substances 
were selected based on an inventory of biocidal products admitted on the market in the 
Netherlands, including their composition with respect to active substances (biocidal active 
substances) and their use categories (e.g. rodenticides, preservatives, disinfectants).  
The biocidal active substances selected for this study were alkyldimethylbenzylammonium 
chloride (ADBAC), boric acid, deltamethrin, dimethyldidecylammonium chloride (DDAC), 
formaldehyde, permethrin, piperonyl butoxide, sodium bromide, and tebuconazole. Using 
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these model compounds the influence of single and repeated exposure on skin permeability 
using in vitro dermal absorption experiments was investigated. Also the potential role of 
irritative and/or corrosive properties of biocides is analysed. 
Chapter 5 aims to determine the permeability coefficient (kp) of the biocidal active 
substance DDAC, to investigate its skin permeation at a finite dose more representative of 
normal worker and consumer exposure and to probe the influence of various commercial 
biocidal formulations on its absorption (Buist et al., 2007). The chapter zooms in on the 
consequences of skin barrier effects of single and repeated exposure for dermal absorption 
of a corrosive quaternary ammonium compound and biocidal active substance, DDAC. The 
influence of the use of different vehicles (dissolution media) on the dermatokinetics of 
DDAC was characterised using in vitro dermal absorption experiments.  
Chapter 6 aims to develop and test a simple model to predict finite dose dermal absorption 
from infinite dose data (kp and lag time) and the stratum corneum/water partition 
coefficient (KSC,W) (Buist et al., 2010). A simple mathematical model to predict finite dose 
dermal absorption from infinite dose data, which takes into account different exposure 
conditions with respect to dermal loading, concentration, exposed skin surface and 
exposure duration is developed. To test the model, a series of in vitro dermal absorption 
experiments was performed under both infinite and finite dose conditions using acetic acid, 
benzoic acid, bis(2-ethylhexyl)phthalate, butoxyethanol, cortisone, decanol, diazinone, 2,4-
dichlorophenol, ethacrynic acid, linolenic acid, octylparaben, oleic acid, propylparaben, 
salicylic acid and testosterone.  
Chapter 7 summarises the results obtained in this thesis and discusses how the parameters 
investigated affect dermal absorption. It also indicates how to best estimate dermal 
absorption under realistic exposure conditions for use in regulatory risk assessment, using a 
limited amount of experimental data. The chapter also presents future perspectives for the 
role and implementation of dermal absorption in regulatory risk assessment and the 
possibility to use alternative in vitro and/or in silico testing strategies. 
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 Abstract 2.1
Quantification of skin absorption is an essential step in reducing the uncertainty of dermal 
risk assessment. Data from literature indicate that the relative dermal absorption of 
substances is dependent on dermal loading. Therefore, an internal exposure calculated with 
absorption data determined at a dermal loading not comparable to the actual loading may 
lead to a wrong assessment of the actual health risk. To investigate the relationship 
between dermal loading and relative absorption in a quantitative manner, 138 dermal 
publicly available absorption experiments with 98 substances were evaluated (87 in vitro, 51 
in vivo; molecular weight between 40 and 950, log KOW between -5 and 13), with dermal 
loading ranging mostly between 0.001 and 10 mg/cm2. In 87 experiments (63%) an inverse 
relationship was observed between relative dermal absorption and dermal loading, with an 
average decrease of factor 33 ± 69. Known skin irritating and volatile substances less 
frequently showed an inverse relationship between dermal loading and relative absorption. 
 Introduction 2.2
The dermal route is the primary route of occupational exposure for most pesticides 
(Benford et al., 1999; Wolfe, 1976) and biocides (EU, 2002). Despite the relatively high 
dermal exposure in occupational settings, regulation for pesticides has evolved from 
concern regarding consumers and the oral route of exposure, both in the United States and 
in Europe (EU, 1991, 1994; USEPA, 2008). As a consequence, studies requested for 
 
Figure 2-1 Effect on risk assessment of choosing unrealistic dermal loading, when there is an inverse 
relationship between loading and relative absorption. 
In this case the consequence of choosing an excessively high dermal loading from a dermal absorption 
study is depicted. 
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registration purposes emphasise the oral route and low-level daily exposure (Krieger and 
Ross, 1993). Until recently the importance of dermal exposure has not been so clear for 
industrial chemicals. However, the results of the EU RISKOFDERM-project indicate that also 
for this category of chemicals dermal exposure may be substantial (see a.o. Marquart et al., 
2006), while toxicity studies available for risk assessment in the EU are mainly conducted via 
the oral route. Since systemic toxicity is dependent on the internal dose (or better, the 
internal concentration profile) some means must be provided to relate the bioavailability 
upon occupational dermal exposure to the (orally) absorbed dose in the toxicity study. This 
explains why dermal absorption studies may be requested for registration of pesticides (EU, 
1991, 1994; USEPA, 2008) and biocides (EU, 1998). The risk assessment approach for 
pesticides and biocides in the EU differs from that for industrial chemicals. However, as in 
both regulatory frameworks oral toxicity data are often used to estimate dermal risks, oral-
to-dermal route extrapolation is needed and an estimate of dermal absorption may be 
useful. 
Dermal absorption estimates are generally derived from in vivo or in vitro dermal absorption 
studies, in which one or more concentrations are tested for relative dermal absorption. In 
rare cases, human internal exposure is estimated via biomonitoring techniques, eliminating 
the need for dermal absorption estimates to transform external exposure values into 
internal ones (van de Sandt et al., 2007). In absence of (reliable) experimental data, default 
values for dermal absorption may be applied (EU, 2003) or sometimes QSPRs (van de Sandt 
et al., 2007). 
Some data in public literature indicate that relative dermal absorption of specific substances 
decreases with increasing dermal loading (i.e., amount of substance per unit area of skin) 
(e.g., Brewster et al., 1989; Bunge, 2005; Wester and Maibach, 1976). An internal dose, 
therefore, when calculated without taking into account differences in relative absorption 
between the dermal loading applied in the animal study and the one workers are exposed 
to, may underestimate or overestimate the actual worker risk (Figure 2-1). 
So far no substantiation has been presented with respect to the relative incidence of this 
inverse relationship nor has the practical relevance for worker risk assessment been probed 
in detail. In the present paper, we investigate the relevance of this phenomenon, by making 
an inventory and data analysis of existing dermal absorption studies reporting the relation 
between relative dermal absorption and dermal loading of specific substances. 
 Materials and methods 2.3
Public literature was screened for dermal absorption studies in which different dermal 
loadings or concentrations had been tested. Online databases, such as Toxline and Medline 
were used. In addition, in order to increase the potential number of suitable data, 
information provided in (drafts of) Risk Assessment Reports, prepared under Council 
Regulation EEC No. 793/93 on Existing Substances, including data from direct and indirect 
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references therein, was used. The searches were concluded in 2005. Most studies retrieved 
presented systemically absorbed doses or both systemically and potentially absorbed doses, 
a few studies presented only potentially absorbed doses or did not specify how absorption 
was defined. In contrast to the systemically absorbed dose, the potentially absorbed dose 
also includes that part of the dose which is present in the dosed skin site (after washing) at 
the end of the experiment. For in vivo studies the systemically absorbed dose equals the 
dose or dose equivalents recovered from excreta and all tissues (except the treated skin) 
over the total experimental period (usually between 1 and 7 days), while for in vitro studies 
it equals the recovery from the receptor fluid (usually over a period of 24 h). In order to 
obtain a homogeneous database, we selected only those studies which presented at least 
information on systemic absorption. 
The relationships between relative absorption and dermal loading for all substances and 
experiments encountered were classified into two categories: inverse relationship between 
relative absorption and dermal loading and no inverse relationship between relative 
absorption and dermal loading, based on the following statistical analysis: before testing for 
differences between levels of dermal loading, missing standard deviations (SD) were 
imputed. Coefficients of variation (CV) were determined for each experiment for which an 
SD was available. Missing SDs were imputed as mean times the median CV value. A two-
sided Dunnett’s test (Dunnett, 1955) was used to test between levels of dermal loading, 
using the lowest dermal loading as reference. Per experiment, SDs were used to calculate a 
pooled SD. A t-statistic was calculated as (dermal loading i − dermal loading 1)/ SDpooled × 
 1/𝑛𝑛𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑑𝑑𝑙𝑙𝑑𝑑𝑑𝑑𝑙𝑙𝑙𝑙𝑙𝑙 1 + 1/𝑛𝑛𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑑𝑑𝑙𝑙𝑑𝑑𝑑𝑑𝑙𝑙𝑙𝑙𝑙𝑙 𝑙𝑙 .The degrees of freedom for the test was equal 
to N - k, where N is the total number of available observations and k is the number of 
dermal loading groups including the reference dermal loading. 
A continuously decreasing p-value with increasing dermal loading indicates an inverse 
relation between dermal loading and absorption. In case of significant p-values compared to 
the reference dermal loading, but a non-continuous decrease in p-values, consecutive 
dermal loadings were also tested. If in that case no statistically significant differences 
between these consecutive dermal loadings were found, the relation between dermal 
loading and absorption was also indicated as inverse. 
For the analysis of the data also an “absorption decrease factor” was defined, i.e., the 
relative dermal absorption at low dermal loading divided by the relative dermal absorption 
at high dermal loading. 
 Results 2.4
The literature search produced more than 40 publications and other documents with a total 
of 138 dermal absorption experiments from which for a specific substance the relationship 
between relative dermal absorption and dermal loading could be established. Most 
experiments were performed in vitro (87), but also many in vivo studies are present in the 
 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 55 
assembled database (51). The methods used to compute in vivo systemic dermal absorption 
were diverse, e.g., based on excreta only, on excreta and tissues or by comparing urinary 
excretion after intravenous and dermal application (see Annex describing the database, 
published on the internet site of this journal). In vitro ‘‘systemic” dermal absorption figures 
were always based on the dose recovered from the receptor fluid at the end of the 
experiment. In 130 cases methods comparable to those described by OECD guidelines 427 
and 428 (OECD, 2004a, b) were used and in eight cases they were not comparable or not 
described in sufficient detail. Whether or not OECD comparable methods were used, did not 
influence the relation found between dermal loading and relative absorption (analysis not 
shown). In approximately half of the cases the rat was the investigated species, and in one 
third of the cases human skin was exposed, while in the remainder of the studies pig, guinea 
pig, mouse or monkey skin was used. The species investigated did not significantly influence 
the nature of the relationship observed (data not shown). The average exposure time in the 
experiments was 22 h, while, on average, absorption was measured over a period of 41 h. 
The most frequent combinations of exposure time and sampling time were (in hours): 8/8 (n 
= 25), 8/24 (n = 12) and 24/24 (n = 37). In 65 of the 138 experiments, the exposure time was 
between 4 and 10 h, which constitutes a realistic worker exposure period, 60 had exposures 
times ≥24 h, and for 13 experiments exposure duration was not (clearly) indicated. The 
experiments with shorter (4-10 h) and longer (24 h and more) exposures did not differ 
significantly in the nature of the relationship between relative absorption and dermal 
loading (data not shown). Therefore, the results of all experiments with different exposure 
times were analysed together. Some experiments were performed under non-occlusive 
conditions (n = 54), some under semi-occlusive conditions (n = 46) and some under occlusive 
conditions (n = 27). For some experiments it was not clear under which condition of 
occlusion they were performed (n = 11). As the state of occlusion did not influence the 
relation between relative absorption and dermal loading (data not shown), these results 
 
Figure 2-2 Relation between dermal loading range factor and change in relative absorption with 
dermal loading. 
Dermal loading range factor = high dermal loading divided by low dermal loading. 
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were lumped together as well. The MW of the 98 substances investigated ranged between 
40 and 950, while their log KOW ranged between -5 and 13. 
Of the 138 cases, 87 (63%) show an inverse relationship between relative dermal absorption 
and dermal loading (see Table 2-2). Within a 100-fold increase in dermal loading, relative 
absorption may decrease up to 100-fold (e.g., for nonylphenol ethoxylates in humans 
(Monteiro Riviere et al., 2000)). For 10-fold or higher increases in dermal loading, the 
average decrease was a factor 42 ± 76 when an inverse relationship was present. The 
relative number of inverse relationships and the decrease factor tended to increase with 
increasing width of the dermal loading ranges investigated (see Table 2-2 (page 64) and 
Figure 2-2). Differences between dermal loading range classes were statistically significant 
(see Table 2-3A). Most dermal loading ranges tested were between 0.001 and 10 mg/cm2 
(see Annex describing the database, published on the internet site of this journal). Worker 
exposure for a diverse number of typical cases of hand exposure to industrial chemicals 
ranged from 0.0014 to 4.8 mg/cm2 (Marquart et al., 2006), while for non-agricultural 
pesticides a typical case value of 4.8 mg/cm2 and a reasonable worst case value of 
14 mg/cm2 are mentioned in the Technical Guidance Document on Risk Assessment (EU, 
2003). Therefore, the cases reported here seem to cover a range of exposures relevant for 
workers. The relative number of inverse relationships for substances with log KOW > 1 was 
73%, while for substances with log KOW ≤1 it was 30% (see Table 2-3B, page 64). 
The 29 volatile substances (VP > 0.01 Pa)4 tested showed significantly less cases of inverse 
proportionality than non-volatiles (see Table 2-3D), irrespective of state of occlusion. Skin 
irritants less often showed inverse proportionality between dermal loading and relative 
absorption (see Table 2-3C). 
Particularly for pesticides vehicle effects may influence relative absorption at different skin 
loadings as field concentrations are often obtained by diluting a concentrate with water, 
changing the composition of the vehicle. Comparison between substances dissolved in 
water (mainly non-pesticides) and substances dissolved in aqueous dilutions of formulants 
(pesticides) seems to confirm this: pesticides showed a significantly larger proportion of 
inverse relationships compared to substances dissolved in water (see Table 2-3E). However, 
the width of the dermal loading ranges investigated may be a confounding factor, as the 
pesticides were studied over much larger dermal loading ranges and the proportion of 
inverse relationships increases with the width of the dermal loading range (see Table 2-3B). 
                                                     
4 As defined in the EU Technical Guidance Document on Risk Assessment (EU, 2003). 
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Table 2-2  Relation between relative absorption and dermal loading. 
Relation  
Total 
Dermal loading range factor examined Dermal loading 
range factor 
(median) >1-10 >10-100 >100-1000 >1000 
Not inverse Number 51 21 23 6 1 16 
 Decrease 
factor ± SD 3.5 ± 17 1.3 ±0.8 1.0± 0.5 21 ± 50 0.7  
Inverse Number 87 18 31 33 5 100 
 Decrease 
factor ± SD 33 ± 69 4.4 ± 3.0 25 ± 31 40 ± 64 149 ± 203  
Total cases Number 138 39 54 39 6 83 
Decrease factor = relative absorption at low dermal loading divided by relative absorption at high dermal 
loading.  Dermal loading range factor = high dermal loading divided by low dermal loading. 
 
Table 2-3 Correlation between some parameters and the nature of the relationship relative 
absorption/dermal loading.  
A. Influence extent of dermal loading range on nature of relationship relative absorption/dermal loading. 
Relation Dermal loading range factor (=high dermal loading/low dermal loading) Total 
≤10 >10-100 >100-1000 >1000 
Not inverse 21 23 6 1 51 
Inverse 18 31 33 5 87 
Total 39 54 39 6 138 
p-value χ2: 0. 002 (null hypothesis = no difference between dermal loading range factor classes). 
B. Influence log KOW on nature of relationship 
relative absorption/dermal loading. 
 C. Influence skin irritancy class on nature of relationship 
relative absorption/dermal loading. 
Relation Log P Total 
 
Relation Skin irritant Total 
≤1 >1-3 >3-5 >5  No Yes 
Not 
inverse 19 8 17 4 48 
 
Not inverse 3 25 28 
Inverse 8 23 49 7 87  Inverse 15 21 36 
Total 27 31 66 11 135  Total 18 46 64 
p-Value χ2: <0. 0001 (null hypothesis = no 
difference between log KOW classes). 
 p-Value χ2: 0.001 (null hypothesis = no difference between 
skin irritancy classes). Note: Skin irritation class of the 
investigated substances was looked up in on-line 
databases (CTB, NTP, EPA, ATSDR) and in RTECS on CD-
ROM). 
D. Influence volatility of test substance on 
nature relationship relative absorption/ 
dermal loading. 
 E Influence pesticide formulant on nature relationship 
relative absorption/dermal loading. 
Relation 
Vapour pressure 
Total 
 
Relation 
Number Dermal loading factor (mean ± SD (median)) 
>0.01 Pa <0.01 Pa 
 
Water Water + formulant Total Water 
Water + 
formulant 
Not 
inverse 18 16 34 
 
Not inverse 12 9 21 38 ±43 (23) 
165 ± 251 
(20) 
Inverse 11 33 44 
 
Inverse 7 43 50 12 ±13 (6) 
525 ± 896 
(175) 
Total 29 49 78 
 
Total 19 52 71 28 ± 37 (6) 
463 ± 831 
(129) 
p-Value χ2: 0.01 (null hypothesis = no difference 
between volatility classes). 
 
 p-Value χ2: <0.001 (null hypothesis = no difference 
between the two vehicle classes). 
Dermal loading factor = high loading divide by low 
loading. 
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 Discussion and conclusions 2.5
2.5.1 Relation between dermal loading and relative absorption 
The experiments reviewed here provide a strong indication that in a majority of cases an 
inverse relationship exists between relative dermal absorption and dermal loading. Relative 
absorption may vary by more than a factor 100 within a dermal loading range that is 
relevant for occupational risk assessment. For the cases of inverse relationships reported 
here, relative absorption decreased on average with a factor 33 ± 69, when comparing low 
and high dermal loading (ranging from 0.009 µg/cm2 to 400 mg/cm2). A likely explanation of 
this relationship is saturation of the absorption capacity of the skin by the increasing dermal 
loading. When this capacity is saturated, the absorption rate will no longer proportionally 
increase with dermal loading, and thus the relative amount absorbed will decrease. 
Especially for poorly water-soluble substances, the very slow rate of dissolution in the water 
film on the skin or its rapid saturation may be the cause of levelling off of relative absorption 
in higher dermal loading ranges. 
Although the majority of substances show an inversely proportional relationship between 
dermal loading and relative absorption, many do not. One explanation for this observation 
may be the dermal loading range, which in most experiments only covered one or two 
orders of magnitude: it may have been chosen in such a way that the penetration process 
was not yet saturated or not yet limited by the rate of dissolution into the dermal water 
film. Our results indeed show an increasing proportion of inverse relationships with wider 
dermal loading ranges (see Table 2-3A). Also skin irritating or corrosive properties of a 
substance may mask an inverse relationship, as rising concentrations of such a substance 
may decreasing the barrier function of the skin, increasing the permeability of the skin. Our 
results support this notion, as more than 80% of the proven non-irritants in our analysis 
show an inverse relationship while only 56% of the irritants exhibit this relationship (see 
Table 2-3C). Furthermore, volatile substances may not exhibit a clear inverse relationship 
between dermal loading and relative dermal absorption, because evaporation may rapidly 
reduce applied doses, thus preventing, e.g., saturation of the absorption process. This is 
corroborated by our observation that volatile substances showed relatively fewer cases of 
inverse relations between dermal loading and relative absorption than non-volatiles (see 
Table 2-3D). 
2.5.2 Consequences for risk assessment 
Underestimating the relative dermal absorption for the worker will lead to an 
underestimate of the internal exposure, which will in turn lead to an underestimation of the 
risk involved. Conversely, overestimating the dermal absorption for the worker will lead to 
an overestimation of the risk. Within a 100-fold range of exposure relative dermal 
absorption may vary up to a factor 100, therefore, as a consequence of the wrong choice of 
dermal loading, the risk index may be under- or over-estimated by the same factor. 
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In dermal exposure assessment often models are used which report their results 
in mg/person/day, without specifying the exposed area. If the underarms, hands and legs 
were exposed, the contaminated skin area would be ca. 8500 cm2, while exposure of the 
hands only involves an area of 720 cm2 (Paustenbach, 2000). Dermal exposure of 30 mg/day 
amounts to a dermal loading of 3.5 µg/cm2 for arm, hand and leg exposure and to 42 
µg/cm2 for hands only. For e.g., 2,6-di-tert-butyl-4-nitrophenol these dermal loadings would 
mean a ca. eight times lower internal exposure for hands only (see Table 2-1) and therefore 
a lower risk than for the same absolute exposure to arms, hands and legs combined. 
In European Risk Assessment Reports or pesticide monographs frequently only one value for 
relative dermal absorption is presented, often without specifying the dermal loading at 
which it was determined. For an appropriate evaluation, as illustrated by the example 
above, it is recommended to include the relevant data on dermal absorption studies in 
European Risk Assessment Reports and pesticide monographs, i.e., tested dermal loadings 
(expressed as μg/cm2) with the corresponding relative absorption percentages. 
Furthermore, the tested dermal loadings should be similar to the actual human dermal 
loadings. In case of a (forcibly unnoticed) discrepancy in dermal loading between dermal 
absorption study and human exposure, relying on a single value may lead to a wrong 
estimate of internal exposure and therefore of risk. 
 Conclusions 2.6
Based on the data obtained, an inverse relationship between relative absorption and dermal 
loading exists for many chemical substances. Therefore, an internal exposure calculated 
with absorption data determined at a dermal loading not comparable to the actual loading 
may lead to a wrong assessment of the actual health risk. Some substances may exhibit 
deviating dermal absorption behaviour, likely caused by local toxicodynamic effects such as 
irritation or because of their volatility. 
In order to prevent unsafe or overly conservative outcomes of risk assessments, the dermal 
loading dependency of relative dermal absorption should be taken into account. When 
using experimentally derived dermal absorption data, estimates determined at a dermal 
loading closest to that of the exposure of interest have to be used. Moreover, the inverse 
relation does stress the importance of examining, in dermal absorption studies, dermal 
loadings relevant for both human exposure and dermal toxicity studies. 
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Appendix A. Supplementary data 
Supplementary data associated with this chapter can be found, in the online version of the 
paper, at doi:10.1016/ j.yrtph.2009.04.002. 
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3 The influence of repeated exposure to biocides on 
the skin barrier: A literature study 
This chapter is largely based on TNO rapport V 5491 “Dermal absorption after repeated 
exposure to biocides. A discussion paper and research proposal” by H.E. Buist, J.G.M. 
Bessems, J.J. van de Sandt, F. Schurz, C. de Heer, published on November 19th, 2003. 
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 Abstract 3.1
Differences between absorption after single and repeated dermal exposure were 
investigated based on a literature scan, which demonstrated that the effect of repeated 
exposure does not show a unique trend. However, an increase in daily absorption was 
frequently observed upon repeated daily exposure. The little information available on 
possible differences between single and repeated exposure was mostly related to 
pharmaceuticals. However, consumers and workers may be repeatedly exposed to other 
type of chemicals, like disinfectants and cleaning products, which often contain biocidal 
active substances that may decrease the barrier function of the skin, especially after 
repeated exposure. These biocidal products, therefore, may present a safety risk that is not 
covered by the present risk assessment practice. Consequently, it was decided to investigate 
the importance of this issue for biocide safety evaluation. As the present literature search 
revealed that hardly any data on absorption upon repeated dermal exposure to biocides are 
available, it was concluded that data need to be generated by testing. 
To cover the entire range of biocidal products in such future testing, a representative series 
of biocidal substances needs to be tested, making in vitro testing of dermal absorption the 
preferred choice over in vivo testing. Based on an inventory made it appeared that the 16 
product types represented among the biocidal products authorised in the Netherlands could 
be clustered into 6 more or less homogeneous categories based on similarity in active 
substances. Thus it can be concluded that the required in vitro testing can be limited to 
testing a representative congener from each of these 6 categories. 
 Introduction 3.2
The skin is a relevant route of internal exposure for workers and consumers (see  1.1.1). 
However, toxicity studies submitted within the European regulatory frameworks mostly 
concern the oral route of administration. This often implies that oral-to-dermal route 
extrapolation needs to be performed in order to compare dermal exposure to limit values 
derived from oral toxicity studies (ECB, 2003): this route-to-route extrapolation should 
ideally be based on internal exposure, which is calculated by correcting the measured or 
modelled external exposure values for the percentage absorption of the evaluated 
substance via the respective routes. Dermal absorption of the evaluated substances, 
commonly expressed as percentage of the applied dose, is usually determined through in 
vivo or in vitro dermal absorption studies executed according to globally accepted guidelines 
(OECD, 2004a and b; ECB, 2003). In the EU, default dermal absorption values of 100% or 
10% (depending on the MW and log KOW of the permeant) are used in case of oral-to-dermal 
route extrapolation, as a worst-case approach when data are not available (see 
section  1.1.4.6.1). 
The OECD guidelines on in vivo or in vitro dermal absorption studies are not explicit on 
whether single or repeated exposure should be investigated (OECD, 2004a and b). Common 
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practice is that dermal absorption studies submitted within the EU regulatory frameworks 
are restricted to single exposure (ECB, 2003). Occupational dermal exposure is generally 
repeated in nature: e.g. disinfectant exposure in workers performing the daily disinfection 
of slaughterhouses (Preller & Schipper, 1999), metal working fluid exposure in metal 
workers (van Wendel de Joode, 2005), polycyclic aromatic compound exposure in asphalt 
pavement workers (McClean, 2012), exposure to floor and bathroom cleaning products in 
hospital cleaners (Bello, 2009). Also consumer dermal exposure, e.g. to cosmetics or 
household cleaning products, may be repeated in nature (WHO, 2013). Therefore, 
differences in absorption between single and repeated dermal exposure could be an issue in 
toxicological risk assessment.  
In the present study the issue of repeated dermal exposure was investigated by scanning 
public literature (section  3.3.1). Based on this literature study, the possible differences 
between absorption after single and repeated dermal exposure and their potential causes 
are discussed. As few relevant data were found, an experimental approach to determine the 
importance of these differences in toxicological risk assessment was considered necessary. 
Chemically reactive substances are most likely to influence the barrier function of the skin 
(see section  1.1.5.1) and thus dermal absorption. Repeated exposure may aggravate these 
effects. In view of their function, many biocides are such reactive substances (see e.g. 
SCENIHR, 2009) and biocides are often repeatedly applied (e.g. disinfectants). Therefore, it 
was decided to use biocides as the model compounds to investigate the effects of repeated 
exposure on dermal absorption, since they represent worst case compounds. To select 
relevant and representative active substances used in biocides, an inventory was made of 
the biocides authorised in the Netherlands, their composition, molecular weights, log KOW’s 
and skin irritating properties of their active substances (section 3.4.2). Hierarchic clustering 
provided insight into the subcategories that could be defined within the group of biocides 
providing a basis for definition of priorities for future experimental testing. 
 Methods 3.3
3.3.1 Literature scan on dermal absorption after repeated exposure 
A search of the Medline database on CD-ROM was performed, covering the period 1966 to 
July 2003. The following key words were used: “skin” AND “absorption” AND (“repeated 
dose” OR “repeated exposure” OR “repeated”). Relevant references were collected and 
analysed. In 2015, the search performed in 2003 was updated to include references up to 
August 2015, in order to check whether additional references providing new insights could 
be gained from recent literature. 
3.3.2 Inventory of biocides admitted in the Netherlands 
An inventory of biocidal products authorised on the market in the Netherlands in 2003, their 
composition with respect to active substances and their area(s) of application was provided 
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by the Dutch Board for the Authorisation of Plant Protection Products and Biocides (CTGB), 
and also obtained from their web-site (http://www.ctgb.org/). Both datasets were 
combined to yield a complete inventory. The different biocide product types were grouped 
on the basis of the degree of overlap between the active substances used in the biocidal 
products of these product types, using the hierarchical clustering algorithm with city block 
as distant measure from the MATLAB software release 13 of The Mathworks Inc. 
The CAS numbers of the active substances used in biocides were obtained using the on-line 
ChemFinder search engine (http://www.chemfinder.com/). The molar weights and log KOW’s 
were picked from the on-line SRC Interactive PhysProp Database (http://esc.syrres.com/ 
interKOW/physdemo.htm). When no experimental log KOW was found in this database, the 
SRC’s on-line Interactive Log KOW (KowWin) estimation software was used to calculate log 
KOW (http://esc.syrres.com/interKow/Kowdemo.htm). The skin irritating properties of the 
active substances were collected from European chemical Substances Information System 
(ESIS) at that time provided on-line by the European Chemicals Bureau (http://ecb.jrc.it/)5 
and the on-line HSDB and Toxline databases accessed through TOXNET, portal provided by 
the US National Library of Medicine (http://toxnet.nlm. nih.gov/). 
 Results 3.4
The literature search performed in 2003 produced approximately 180 references, of which 
57 seemed relevant for the issue at hand based on title and, if available, abstract. For fifty-
two of these 57 references the full papers could be obtained for detailed evaluation, of 
which 27 indeed concerned the issue of absorption after repeated dermal exposure. Most 
substances reported in these references were dermally applied pharmaceuticals. One 
pesticide (malathion) was addressed, and no biocide. Nearly all references described in vivo 
studies (rats, mice, man). Most exposures investigated lasted up to 24 hours per day, and 
the substances were mostly applied daily, with a varying number of total applications. The 
vehicles in which the permeants were applied ranged from simple solvents, such as ethanol 
and DMSO, to creams and gels (see Table  3-1 to Table  3-3). Also the state of occlusion varied 
between studies. 
The retrieved studies revealed some differences between the results of dermal absorption 
after single and repeated exposure. The clearest effect was the increase in daily absorption 
often observed when exposure was repeated each day (see Table 3-1 and Figure 3-1). This 
observation is based on experiments with 12-13 different chemicals. Blood concentrations 
showed a similar tendency, although, in general, the fold-change was lower and not always 
statistically significant (see Table 3-2 and Figure 3-2). Only 6-7 different substances with 
data on blood concentrations after single and repeated dermal exposure were retrieved 
from public literature. Very few studies on skin permeability were located: Roberts and 
                                                     
5 Nowadays provided on-line by ECHA at http://echa.europa.eu/information-on-chemicals/ 
 cl-inventory-database. 
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Harlock (1978) found that salicylic acid may increase or decrease skin permeability, 
depending on the pattern of repeated exposure, while Campbell et al. (2002) did not find 
any influence of repeated exposure to lidocaine on skin permeability. A remarkable result 
was obtained by Vänttinen and Moravcova (2001): when repeating dermal exposure to two 
phytoestrogens after one and subsequently after five months, excretion of these chemicals 
and their final metabolites was lower after each repetition (a factor 10 or more). This big 
decrease in absorption is probably not related to changes in skin permeability, but rather to 
induction of metabolic changes, since baseline excretion of these compounds (measured 
one day before repetition of the exposure) had declined to the same degree. 
An updated literature search performed in 2015 yielded 34 additional potentially relevant 
papers, of which only 14 contained information relevant to the issue at hand. Repeated 
exposure to benzophenone-3 (Gonzalez, et al. 2006), to butyl paraben (Janjua, et al. 2008) 
and N,N-dimethylformamide (Chang, et al. 2005) led to increased daily absorption 
compared to single exposure, as measured by urinary excretion. In four different studies on 
tacrolimus absorption during treatment of atopic dermatitis with a skin ointment containing 
this medicine, two also showed increases in daily absorption upon repeated exposure: 
Reitamo et al. (2009) found an increase in the plasma AUC0-24 after 14 days of repeated 
exposure and Undre et al. (2009) observed that blood concentrations of tacrolimus were 
twice as high on day 14 of repeated exposure than on day 1. Plasma concentrations of 
tacrolimus were low: Undre et al. (2009) demonstrated that tacrolimus concentrations in 
the skin were more than 700 times higher than in blood. Furthermore, absorption tended to 
reduce with increased skin healing (Rubins, et al. 2005). These observations may explain 
 
Figure 3-1 Dermal absorption after single and repeated daily dermal dosing 
Data from studies with daily exposures, listed in Table  3-1. Daily dermal absorption after repeated exposure 
was divided by that after a single dose to obtain the ratio. Note that nearly all values are > 1 indicating 
increased absorption after repeated exposure as compared to single dose exposure. 
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why the other two studies (Harper, et al. 2005, Rubins, et al. 2005) did not find any increase 
in tacrolimus absorption upon repetition of exposure. Repeated dermal exposure of rats to 
progesterone led to a decrease in trough plasma concentrations6 with one formulation 
(“F10”) and no change with another (Progestelle®) (Matsui, et al. 2015). 
Three studies concerned dermal drug delivery systems (a gel, a patch and a transdermal 
delivery system called Buprederm™) designed to maintain a steady state plasma 
concentration. The drugs investigated were oxybutynin (Dmochowski, et al. 2011), 
scopolamine (Nachum, et al. 2006) and buprenorphine (Park, et al. 2008). Repeated expo-
sure (or continuous exposure with slow release) indeed produced a more or less stable 
plasma concentration of the drug or its active metabolite.  
In short, these more recent papers confirmed the results of the previous investigation that 
there exists a tendency of increased daily absorption after repeated dermal exposure. New 
data on skin permeability after repeated dermal exposure were not found. Furthermore, 
relevant and consistent data remained scarce, making it difficult to draw general 
conclusions and to gain real insight in the importance of including the effects of repeated 
dermal exposure in toxicological risk assessment. In a next step it was therefore decided to 
investigate this issue via an experimental approach focused on biocides. In order to prepare 
a well-balanced research plan, an inventory of biocides authorised in the Netherlands was 
made and their active substances characterised with respect to a number of properties 
influencing dermal absorption. 
                                                     
6 Through plasma concentrations are the dips in the plasma concentration time curves. 
 
Figure 3-2 Blood (whole blood, plasma or serum) concentrations or AUC after single and repeated daily 
dermal dosing 
Data from studies with daily exposures, listed in Table  3-2. AUC or blood concentration after repeated 
exposure was divided by the same parameter after single dose to obtain the ratio. Note that nearly all 
values are > 1 indicating increased absorption after repeated exposure as compared to single dose 
exposure. 
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Distance between clusters (arbitrary units) 
Figure 3-3 Clustering of areas of application of biocidal products 
PT02 = Private area and public health area disinfectants and other biocidal products; PT03 = Veterinary 
hygiene biocidal products; PT04 = Food and feed area disinfectants; PT08 = Wood preservatives; PT10 = 
Masonry preservatives; PT11 = Preservatives for liquid-cooling and processing systems; PT12 = Slimicides; 
PT14 = Rodenticides; PT18 = Arthropodicides 
In October 2003, 714 biocides were authorised in the Netherlands, covering 16 of the 23 
biocidal product types defined by the EU Biocidal Products Directive (BPD) 98/8/EC (EU, 
1998) (see Table ‎4-1). Quite a number of biocidal products were used in more than one area 
of application, on average the 714 different biocidal products were authorised under more 
than two biocidal product types. There is also a certain measure of overlap between 
biocides with regard to the active substances present, even when used in different areas of 
application. Thus the product types can be clustered on basis of the degree of overlap in 
their active substances. Figure 3-3 depicts the results of clustering of biocidal product types, 
using the hierarchical clustering algorithm with city block as distant measure from the 
MATLAB. This clustering revealed that biocides used as disinfectants across various product 
types (PT02-04) are quite alike, while also slimicides and preservatives for liquid cooling and 
processing systems (PT11-12) are chemically closely related. The arthropodicides (PT18) are 
unlike all other biocidal products. 
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A total of 100 active substances were represented in the 714 authorised biocidal products. 
The top 20 compounds are listed in Table  3-4, along with some of their characteristics. Of 
the 714 authorised biocidal products 452 contain only one active substance, 152 contain 
two, 43 three and 6 four active substances. The 20 most frequent pairs of active substances 
are listed in Table  3-5. The top 3 contains lye, an acid and oxidising agents. The fourth 
ranked pair consists of the known sensitizers 2-methyl-4-isothiazolin-3-one and 5-chloro-2-
methyl-4-isothiazoIin-3-one (see http://echa.europa.eu/information-on-chemicals), while 
ranks 5 to 7 contain aldehydes and surfactants. Approximately 60% of the biocidal 
substances with skin irritation data are classified as skin irritants (see Table 3-6). 
MW and log KOW 
Molecular weight and log KOW are important determinants for the ability of chemicals to 
penetrate the skin barrier (De Heer et al., 1999; ECB, 2003). Therefore, these properties are 
important to consider when selecting representative biocidal active substances for the 
experiments to be planned. Most biocidal active substances are expected to exhibit high 
dermal absorption since their MW is lower than 500, while only few are expected to exhibit 
low dermal absorption, having a MW >500 and a log KOW >4 or <-1 (see section  1.1.4.6.1). 
Figure  3-4 depicts the log KOW and MW distribution for biocidal active substances. 
Table 3-4 Top twenty biocidal active substances and some of their characteristics 
Rank Name CAS No. MW Log KOW 
Skin 
irritant? 
Number of 
products 
1 didecyldimethylammoniumchloride 7173-51-5 362 4.7 Yes 166 
2 sodium hypochlorite 10022-70-5 74 ? Yes 64 
3 hydrogen peroxide 7722-84-1 34 -1.6 Yes 46 
4 potassium hydroxide 1310-58-3 56 ? Yes 39 
5 glutaraldehyde 111-30-8 100 -0.2 Yes 41 
6 alkyldimethylbenzylammoniumchloride 63449-41-2 372 ? Yes 42 
7 peracetic acid 79-21-0 76 -1.1 Yes 33 
8 sodium dichloro-isocyanurate 2893-78-9 220 -0.06 Doubtful 30 
9 sodium hydroxide 1310-73-2 40 -3.9 Yes 25 
10 2-methyl-4-isothiazolin-3-one 2682-20-4 115 ? Yes 23 
11 5-chloro-2-methyl-4-isothiazolin-3-one 26172-55-4 150 -0.3 Yes 23 
12 formaldehyde 50-00-0 30 0.4 Yes 23 
13 l-bromo-3-chloro-5,5-dimethyl- hydantoine 16079-88-2 241 -0.9 ? 20 
14 deltamethrin 52918-63-5 505 6.2 No 18 
15 piperonyl butoxide 51-03-6 338 4.8 Yes 17 
16 diethyl-m-toluamide 134-62-3 191 2.2 Yes 17 
17 pyrethrins 121-29-9 372 4.3 No 15 
18 2,2 dibromo-3-nitrilopropionamide 10222-01-2 242 0.8 Yes 15 
19 difenacoum 56073-07-5 445 7.6 ? 15 
20 copper(I)oxide 1317-39-1 143 ? ? 15 
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In general, preservatives and disinfectants tend to be small, hydrophilic molecules, while 
rodenticides and arthropodicides tend to be larger and more lipophilic (see Figure  3-2). 
Wood preservatives are an exception to this rule, having an intermediate position between 
these two groups. 
Table 3-5 The twenty most frequent pairs of active substances in registered biocidal products containing 
two or more active substances 
Rank Pair Number of products 
1 potassium hydroxide and sodium hypochlorite 42 
2 peracetic acid and hydrogen peroxide 34 
3 sodium hypochlorite and sodium hydroxide 25 
4 2-methyl-4-isothiazolin-3-one and 5-chloro-2-methyl-4-isothiazoIin-3-one 23 
5 didecyldimethylammoniumchloride and formaldehyde 22 
6 didecyldimethylammoniumchloride and glutaraldehyde 22 
7 formaldehyde and glutaraldehyde 20 
8 piperonyl butoxide and pyrethrins 14 
9 alkyldimethylbenzylammoniumchloride and didecyldimethylammoniumchloride 10 
10 1-bromo-3-chloro-5,5-dimethylhydantoine and l,3-dichloro-5-ethyl-5-methyl hydantoine 7 
11 alkyldimethylbenzylammoniumchloride and glutaraldehyde 7 
12 diurone and copper(I)oxide 6 
13 carbendazim and thiram 5 
14 carbendazim and ziram 5 
15 copper(l)oxide and zinc oxide 5 
16 potassium hydroxide and sodium hydroxide 5 
17 ziram and thiram 5 
18 1,3-dichloro-5-ethyl-5-methylhydantoine and l-3-dichloro-5,5- dimethylhydantoine 
4 
19 fenoxycarb and piperonyl butoxide 4 
20 permethrin and fenoxycarb 4 
 
Table 3-6 Classification of biocidal active substances with respect to skin irritation 
 
Classification Number 
% of biocidal active substances with 
skin irritation data 
 
 Skin irritant 43 59  
 Doubtful 7 9.6  
 Non skin irritant 23 32  
 No skin irritation data found 30 n/a  
 Total investigated 103   
 Discussion and conclusions 3.5
The scan of public literature demonstrated no clear trend in the effects of repeated dermal 
exposure on absorption. This is probably caused by differences in the chemical nature of the 
permeants, as well as the variety of exposure conditions and vehicles used. However, one 
effect was frequently observed: an increase in daily absorption when exposure was 
repeated daily. This implies that single exposure dermal absorption experiments often used 
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in regulatory settings may underestimate daily absorption of chemicals when repeatedly 
applied, e.g. daily.  
The results of the inventory of the biocides authorised in the Netherlands confirmed their 
possible impact on the skin barrier, since many of them were reactive chemicals like lye, 
acids, aldehydes, peroxides and/or have corrosive, irritant or skins sensitising properties. 
This warrants experimental research into the effect of repeated exposure to biocides on the 
skin barrier, since the usual single exposure dermal absorption experiments may not suffice 
to adequately record the possible impact and literature data on this issue are lacking.  
To cover the entire range of biocidal products, a representative series of biocidal substances 
needs to be investigated. Aspects to be included are the different functions biocides may 
have, their corrosive and/or irritating properties and their physicochemical properties like 
log KOW and MW. In order to achieve a representative overview, many biocides would need 
to be tested, making in vitro testing of dermal absorption the preferred choice over in vivo 
testing, as the former costs less time and money. Results of the present inventory revealed 
that the 16 product types represented among the biocidal products authorised in the 
Netherlands could be clustered into 6 more or less homogeneous categories based on 
 
Figure 3-4 Distribution of log KOW and MW of biocidal active substances 
The hashed areas contain the chemicals with a low (default) dermal absorption and the uniformly grey area 
the ones with a high (default) absorption, based on the rule of thumb that dermal absorption of substances 
with a log KOW <-1 or >4 and a MW >500 is 10% and that of all other substances 100%. 
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similarity in active substances. Thus it is concluded that the required in vitro testing can be 
limited to testing a representative congener from each category. 
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 Abstract 4.1
The dermal route of exposure is important in worker exposure to biocidal products. Many 
biocidal active substances which are used on a daily basis may decrease the barrier function 
of the skin to a larger extent than current risk assessment practice addresses, due to 
possible skin effects of repeated exposure. The influence of repeated and single exposure to 
representative biocidal active substances on the skin barrier was investigated in vitro. The 
biocidal active substances selected were alkyldimethylbenzylammonium chloride (ADBAC), 
boric acid, deltamethrin, dimethyldidecylammonium chloride (DDAC), formaldehyde, 
permethrin, piperonyl butoxide, sodium bromide, and tebuconazole. Of these nine 
compounds, only the quaternary ammonium chlorides ADBAC and DDAC had a clear and 
consistent influence on skin permeability of the marker compounds tritiated water and 
[14C]propoxur. For these compounds, repeated exposure increased skin permeability more 
than single exposure. At high concentrations the difference between single and repeated 
exposure was quantitatively significant: repeated exposure to 300 mg/L ADBAC increased 
skin permeability two to threefold in comparison to single exposure. Therefore, single and 
repeated exposure to specific biocidal products may significantly increase skin permeability, 
especially when used undiluted. 
 Introduction 4.2
The dermal route of exposure is important in worker exposure to biocidal products (TNsG, 
2002). For a number of biocidal product types, professional operators are likely to be 
exposed five days a week for extended periods of time (TNsG, 2002), e.g., in 
slaughterhouses which are disinfected daily (HeRy et al., 1999). Many biocidal active 
substances are classified as “corrosive” or “skin irritants” by the EU or, if EU classification is 
lacking, are listed in public literature as “skin irritants”. In October 2003, 714 biocidal 
products were admitted in the Netherlands, covering 16 of the 23 biocidal product types 
defined by the EU Biocidal Products Directive (BPD) 98/8/EC (EU, 1998) (see Table 4-1). The 
total number of active substances represented in the 714 admitted biocidal products is 100. 
More than one third of these products contain two or more biocidal active substances. Of 
the biocidal active substances used in disinfectants registered in the Netherlands (EU 
Product Types (PT) 02-05) 50% are classified as “corrosive” by the EU and 7% as “skin 
irritant,” while another 25% is listed in public literature as “skin irritant” (data not shown). 
Disinfectants represent by far the highest number of registered biocidal products in the 
Netherlands. 
Corrosive or skin irritating substances are able to damage the barrier function of the skin, 
thereby potentially increasing the systemic exposure to these substances. Repeated 
exposure may increase the inflicted skin damage, thereby further augmenting systemic 
exposure. 
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In toxicological risk assessment, dermal absorption of the evaluated substance (e.g., a 
biocide) is usually determined through in vivo or in vitro dermal absorption studies executed 
according to OECD or EPA guidelines (ECB, 2003; EPA, 1998; OECD, 2004a; OECD, 2004b). 
Common practice is that dermal absorption studies submitted within the EU regulatory 
frameworks are restricted to single exposures (ECB, 2003). Therefore, possible differences in 
absorption between single and repeated dermal exposure are not taken into account, which 
may lead to underestimation of toxicological risks. 
Since many biocidal active substances are used on a daily basis, they have the potential to 
affect the barrier function of the skin to a larger extent than current risk assessment 
practice addresses. A survey of public literature revealed that the public literature contains 
limited information on the influence of biocidal active substances on skin permeability (see 
chapter 3). Furthermore, information on repeated exposure appears to be restricted to 
chemicals which are not representative of biocidal products. In this paper, experimental 
research on the influence of single and repeated dermal exposure to biocidal active 
substances on in vitro skin permeability is reported. Nine biocidal substances were selected 
for the experiments, based on pre-set criteria. 
  
Table 4-1 Distribution of the biocidal products registered in The Netherlands over the different product 
types 
Product type EU-code 
Number 
of 
products 
 Product type EU-code 
Number 
of 
products 
Private area and public health area 
disinfectants and other biocidal 
products 
PT02 297 
 
Masonry preservatives PT10 100 
Veterinary hygiene biocidal products PT03 208 
 Preservatives for liquid-cooling 
and processing systems PT11 184 
Food and feed area disinfectants PT04 433  Slimicides PT12 124 
Drinking water disinfectants PT05 5  Metalworking-fluid preservatives PT13 10 
In-can preservatives PT06 4  Rodenticides PT14 37 
Film preservatives PT07 1  Repellents and attractants PT19 18 
Wood preservatives PT08 58 
 Insecticides, acaricides, and 
products to control other 
arthropods (“arthropodicides”) 
PT18 162 
Fibre, leather, rubber, and 
polymerised materials preservatives PT09 1 
 
Antifouling products PT21 52 
A considerable number of biocidal products are registered under two or more product types 
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 Materials and methods 4.3
4.3.1 Selection of biocidal active substances 
The biocidal active substances were selected based on an inventory of biocidal products 
admitted on the market in the Netherlands, including their composition with respect to 
active substances (biocidal active substances) and their area(s) of application. The molar 
weights and octanol water partition coefficients (log KOW) were retrieved from the on-line 
SRC Interactive PhysProp Database (http://esc.syrres.com/interKOW/physdemo.htm). If no 
experimental log KOW was available in this database, the SRC’s on-line Interactive log KOW 
(KowWin) estimation software was used to calculate log KOW7. The present EU-classification 
(EU, 2004) of the biocidal active substances with respect to skin irritating properties was 
retrieved from the European Chemical Substances Information System provided on-line by 
the European Chemicals Bureau8. Non-classification by the EU does not necessarily imply a 
biocidal active substance has been tested negatively: it may simply mean it was not tested 
for that particular characteristic. Therefore, if the biocidal active substance was not 
classified as “corrosive” or “skin irritating” by the EU or was not listed, data from the on-line 
HSDB and Toxline databases, accessed through TOXNET9, were used to judge the skin 
irritation potential. 
The following criteria have been applied in order to select biocidal active substances 
representative of the biocidal products admitted in the Netherlands for testing: 
1. The selection should reflect the variety in molecular weights and log KOW values among 
biocidal active substances. 
2. The selected active substances should be quantitatively important, as measured by the 
number of products and product types they are part of. 
3. Inorganic and organic molecules should be represented. 
4. Both skin irritants and non-irritants should be represented. 
5. The selected substances should occur in combination with other active substances (since 
one active substance may influence the skin absorption of another active substance in 
the product). 
Based on these criteria, initially eight substances were selected for the in vitro assays. Table 
4-2 lists the selected substances and their selection parameter values, based on which they 
were considered fairly representative of the biocidal active substances admitted on the 
Dutch market. As the preliminary results indicated that alkyldimethylbenzylammonium 
chloride (ADBAC) was the only substance showing a clear difference in skin permeability 
between single and repeated exposure, its structural analogue didecyldimethylammonium 
chloride (DDAC) was later added. Its characteristics are quite similar to those of ADBAC, and 
                                                     
7 http://esc.syrres.com/interKOW/KOWdemo.htm) 
8 http://ecb.jrc.it/ 
9 http://toxnet.nlm.nih.gov/ 
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it is represented in even more biocidal products (166). Ten products consist of a 
combination of ADBAC and DDAC.  
4.3.2 In vitro skin permeability assay 
The assay was performed in static diffusion cells using cryopreserved human abdominal 
skin, as previously described by van de Sandt et al. (1993, 2000). The skin originated from 
seven female donors, aged 31-57 years (average 39). The dermis was partly removed using 
forceps and scissors, and the average skin thickness was 0.702 ± 0.062 mm. The receptor 
fluid (total volume 1.2 mL) consisted of a physiological salt solution (0.9% NaCl w/v) 
containing 0.01% sodium azide. The skin preparations were exposed to 10 μL/cm2 of a 
solution of the selected biocidal active substance for 4h (single exposure, starting 48 h after 
onset of the experiment) or for 3 times 4h (repeated exposure, starting at 0, 24, and 48 h, 
respectively). If applicable, the ethanol solvent was evaporated under N2, immediately after 
application. Each biocidal active substance was tested at 3-4 concentrations, representing 
the range of concentrations in which the biocide can be present in the products and in the 
prescribed application dilutions. The specifications, concentrations, and solvents used are 
listed in Table 4-3. The experimental design is illustrated in Figure 4-1 
Each exposure period was finished by washing off the test substance using 4 cotton swabs 
humidified with a 3% Teepol solution and subsequently drying the skin preparations using 2 
dry cotton swabs. The same washing procedure was applied to the control skins. In the 
repeated as well as in the single exposure experiments all skins were washed three times, in 
order to control for a possible effect of the washing procedure on skin permeability. For 
each biocide/concentration combination, the single and multiple dosing experiments were 
 
Table 4-3 Test substance concentrations applied 
Test substance (purity, %w/w) Supplier 
Concentrations 
applied (mg/ml) Vehicle 
ADBAC (not specified)a Sigma 300, 50, 1 Water 
Boric acid (>99%) Aldrich 50, 25, 10 Water 
DDACb (ca. 50% 2-propanol-water 
solution) 
Merck 100, 25, 2.5, 
0.005 
7.4% 2-propanol in 
water 
Deltamethrin (99%) Supelco 3, 1, 0.2 Ethanol 
Formaldehyde (36.5-38% aqueous 
solution) 
Sigma 30, 5, 0.2 Water 
Permethrin (94.4%) Riedel de Haan 10, 1, 0.1 Ethanol 
Piperonyl butoxide (tech. 90%) Aldrich 30, 10, 1 Ethanol 
Sodium bromide (minimum 99.5%) Sigma 500, 1, 0.003 Water 
Tebuconazole (99.4%) Riedel de Haan 10, 5, 1 1% carboxymethyl-
cellulose 
a Alkyldimethylbenzylammonium chloride; the alkyl group is predominantly n-C12H25, but the product also 
contained C14 and C16 homologues. It passed the Sigma quality control with respect to impurities. 
b Didecyldimethylammonium chloride.  
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always performed with skin from the same donor. The proper control experiments were 
performed in parallel with every individual experiment. 
Prior to the start of the experiment, integrity of the skin preparations was assessed by 
determining the permeability coefficient (kp) of tritiated water, as described by van de Sandt 
et al. (1993, 2000), using a cut-off value of 4.0 x 10-3 cm/h. Alongside with tritiated water, 
[14C]propoxur, a pesticide with MW 209, log KOW 1.5, was used as marker of skin 
permeability. At the end of the last exposure period, 500 μL of a mix of [3H]H2O (Perkin 
Elmer Life Sciences, purity not indicated, ca. 37 kBq/mL) and ca. 31 mM [14C]propoxur (TNO-
Prins Maurits Laboratory, Rijswijk, the Netherlands, purity >99%,40.7 MBq/mL) was applied 
to the skin preparations. During the following 3h, 200 μL samples of receptor fluid were 
collected every hour and assayed for 3H- and 14C-radioactivity by liquid scintillation counting 
in a Wallac Pharmacia scintillation counter. Directly after each sampling the original volume 
of the receptor fluid was restored by adding 200 μL fresh receptor fluid to each well. The 
amount of radiolabelled marker molecules that had penetrated the skin was plotted against 
time. For [3H]H2O the penetration rate was calculated by linear regression analysis over 3h. 
Since for [14C]propoxur no steady state was reached, the maximum penetration rate was 
calculated over the last hour of marker exposure. The permeability constant (kp, expressed 
in cm/h) for [3H]H2O and the apparent kp for [14C]propoxur of the treated and control skins 
were calculated by dividing the maximum penetration rate (μg/cm2/h) by the applied 
concentration (μg/cm3). 
Skin permeability may vary considerably between donors or due to differences in solvents. 
In order to control for these variables, relative (apparent) kp values were calculated by 
dividing the (apparent) kp of an exposed skin by the (apparent) kp of its control skin. These 
relative (apparent) kp values were used to measure the effects of biocidal active substances 
on the skin barrier function. Each exposure condition was performed in quadruplicate. 
Occasionally, outlying relative (apparent) kp values which differed more than 3 standard 
 
Figure 4-1 Experimental design.  
I, single exposure; II, multiple exposure; III, vehicle control (ethanol, 1% carboxymethylcellulose, 7.4% 2-
propanol in water); IV, vehicle control (water); and V, control without washing. 
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deviations from the mean of the other three repeat values, were excluded from the results. 
To detect treatment effects as such, comparisons were made for absolute kp values for each 
substance and for each treatment level and the pertaining control. The assumption was 
made that the samples were from a normal distribution and the following procedure was 
applied: 
1. First it was tested whether a substance had a statistically significant effect on the cell 
membrane per se by means of t tests between treatments and the pertaining control. 
The homogeneity of variances was tested and a pooled or a separate variance t test was 
applied. 
2. Relative kp values were analysed separately for tritiated water and propoxur, using a two-
way ANOVA with factors Group (different concentrations) and Application 
(single/repeated). If either one or two factors or the interaction yielded a significant 
effect (p < 0.05), post hoc t tests were applied between single-repeated application for 
each concentration level. 
3. If variances in relative kp values were not homogeneous (according to Levine’s test for 
equality of variances), Brown-Forsythe two-way ANOVA was applied instead, followed by, 
if the ANOVA was significant (p < 0.05), separate variance post hoc t tests. 
4. Linear trend tests (orthogonal contrasts) were applied to relative kp values across 
increasing concentrations for every substance, separately for the single and repeated 
factor. 
Power analysis showed that a two-fold increase or decrease in tritiated water permeability, 
on average, can be detected with sufficient confidence (with a power of 91 ± 17% for 
differences between control and exposed groups, and of 91 ± 13% for differences between 
single and repeated exposure). Changes in propoxur permeability could only be detected 
with sufficient power from threefold increases or decreases upwards (power 92 ± 13% for 
differences between control and exposed groups and of 89 ± 18% for differences between 
single and repeated exposure). Therefore, the test procedure is sensitive enough to detect 
small, but relevant differences in permeability for tritiated water. 
 Results 4.4
Nine biocidal active substances were tested for their effect on skin barrier function. Only the 
quaternary ammonium chlorides ADBAC and DDAC had a clear and consistent influence on 
skin permeability as measured with propoxur and tritiated water. After single exposure to 
ADBAC, skin permeability increased most at a concentration of 50 mg/L: approximately 
twofold (Table 4-4 and Figure 4-2). Single exposure to DDAC caused the highest increase in 
permeability at 100 mg/L, being ca. three to fourfold (Table 4-4 and Figure 4-3). After 
repeated exposure, the maximum increase in skin permeability after ADBAC exposure was 
observed at a concentration of 300 mg/L and was ca. three to fourfold, while for DDAC this 
was ca. four to fivefold at a concentration of 100 mg/L. Except for tritiated water 
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permeability after single exposure to ADBAC (p = 0.10 in linear trend test), permeability 
increased linearly with increasing concentration (p < 0.05). The observation that repeated 
Table 4-4 Skin permeability for 3H2O and [
14C]propoxur after single and repeated exposure to a number of 
biocidal active substances 
Biocide 
Concen-
tration 
( mg/L) 
Relative (apparent) kp (% of control ± SD)  Ratio repeated/single 
(±SD)a 
3H2O  
 [14C]propoxur  
3H2O [
14C]Propoxur 
Single Repeated  Single Repeated  
Boric acid 10 116 ± 28 87 ± 31  82 ± 40 77 ± 17  0.8 ± 0.3 0.9 ± 0.5 
 25 96 ± 26 112 ± 31  94 ± 27 91 ± 19  1.2 ± 0.5 1.0 ± 0.3 
 50 101 ± 30 108 ± 22  81 ± 43 105 ± 40  1.1 ± 0.4 1.3 ± 0.8 
Sodium bromide 0.003 123 ± 50 94 ± 36  117 ± 25 102 ± 44  0.8 ± 0.4 0.9 ± 0.4 
 1 83 ± 26 133 ± 51  96 ± 32 101 ± 55  1.6 ± 0.8 1.1 ± 0.7 
 500 106 ± 35 113 ± 48  107 ± 38 156 ± 95  1.1 ± 0.6 1.5 ± 1.0 
ADBAC 1 91 ± 16 89 ± 13  43 ± 12 60 ± 17  1.0 ± 0.2 1.4 ± 0.6 
 50 188 ± 36 228 ± 23  242 ± 68 360 ± 46  1.2 ± 0.3 1.5 ± 0.5 
 300 123 ± 19 410 ± 151  155 ± 42 364 ± 32  3.3 ± 1.3 2.3 ± 0.7 
DDAC 0.005 108 ± 13 113 ± 40  165 ± 6 115 ± 20  1.0 ± 0.4 0.7 ± 0.1 
 2.5 141 ± 25 161 ± 30  278 ± 66 279 ± 94  1.1 ± 0.3 1.0 ± 0.4 
 25 274 ± 49 254 ± 14  238 ± 15 300 ± 23  0.9 ± 0.2 1.3 ± 0.1 
 100 312 ± 28 438 ± 39  435 ± 24 512 ± 21  1.4 ± 0.2 1.2 ± 0.1 
Formaldehyde 0.2 82 ± 13 67 ± 5  63 ± 44 58 ± 14  0.8 ± 0.1 0.9 ± 0.7 
 5 88 ± 10 108 ± 24  82 ± 35 88 ± 55  1.2 ± 0.3 1.1 ± 0.8 
 30 84 ± 19 76 ± 14  87 ± 29 172 ± 131  0.9 ± 0.3 2.0 ± 1.7 
Piperonyl 
butoxide 
1 101 ± 30 88 ± 14  70 ± 23 64 ± 18  0.9 ± 0.3 0.9 ± 0.4 
10 99 ± 19 84 ± 6  103 ± 6 91 ± 11  0.8 ± 0.2 0.9 ± 0.1 
30 84 ± 16 97 ± 12  54 ± 46 88 ± 18  1.2 ± 0.3 1.6 ± 1.4 
Deltamethrin 0.2 100 ± 48 72 ± 13  108 ± 50 85 ± 17  0.7 ± 0.4 0.8 ± 0.4 
 1 98 ± 17 107 ± 14  154 ± 12 99 ± 5  1.1 ± 0.2 0.6 ± 0.1 
 3 122 ± 37 98 ± 18  72 ± 7 61 ± 11  0.8 ± 0.3 0.9 ± 0.2 
Permethrin 0.1 74 ± 20 84 ± 45  81 ± 50 93 ± 31  1.1 ± 0.7 1.1 ± 0.8 
 1 73 ± 6 92 ± 13  66 ± 5 155 ± 18  1.3 ± 0.2 2.3 ± 0.3 
 10 150 ± 32 107 ± 17  82 ± 32 94 ± 35  0.7 ± 0.2 1.1 ± 0.6 
Tebuconazole 1 106 ± 29 89 ± 10  76 ± 5 72 ± 9  0.8 ± 0.2 0.9 ± 0.1 
 5 91 ± 16 129 ± 53  90 ± 20 149 ± 94  1.4 ± 0.6 1.7 ± 1.1 
 10 98 ± 8 94 ± 16  114 ± 36 93 ± 17  1.0 ± 0.2 0.8 ± 0.3 
SD = standard deviation. 
Italicised values indicate statistically significant difference (p ≤0.05) between experimental and control group. 
Bold printed values indicate a statistically significant difference (p ≤0.05) between single and multiple 
exposure. 
 a Relative (apparent) kp after repeated exposure divided by relative (apparent) kp after single exposure. 
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exposure to quaternary ammonium chlorides increased skin permeability more than single 
exposure was especially clear at high concentrations: repeated exposure to 300 mg/L 
ADBAC increased skin permeability two to threefold more than after single exposure. 
Formaldehyde had a tendency for reducing skin permeability, especially after repeated 
exposure. However, the effect was only in very few cases statistically significant, and did not 
exhibit a clear dose relationship (Table 4-4): it did not show a statistically significant linear 
trend. Statistically significant effects on permeability of piperonyl butoxide, deltamethrin, 
and permethrin were few and often contradictory. Most likely these effects are chance 
findings. 
In the control groups (groups III and IV in Figure 4-1), the kp for tritiated water increased 
from a mean of 1.6 ± 0.8 cm/h x 10-3 before onset of the experiments to a mean of 2.6 ± 1.0 
cm/h x 10-3 at the end of the experiment (55 h later). On average the kp increased twofold 
(see Table 4-5). The control skin preparations that were not subjected to the washing 
procedure (group V in Figure 4-1) had virtually the same kp for tritiated water as the 
corresponding control group that was subjected to the washing procedure (Figure 4-4). The 
Effect of ADBAC on 3H2O penetration Effect of ADBAC on [
14C]-propoxur penetration 
  
Figure 4-2 Influence of ADBAC on skin permeability.  
* Statistically different from single exposure at corresponding concentration (p- value ≤0.05). 
Effect of DDAC on 3H2O penetration Effect of DDAC on [
14C]-propoxur penetration 
  
Figure 4-3 Influence of DDAC on skin permeability.  
* Statistically different from single exposure at corresponding concentration (p- value ≤0.05). 
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apparent kp for propoxur for the non-washed group was approximately two times lower as 
for the washed control group. However, the difference was not statistically significant (p-
value 0.11). 
 Discussion and conclusions 4.5
4.5.1 Characteristics of the test system 
Over prolonged periods of time, the barrier function of the skin preparations may 
deteriorate in a diffusion cell when using a simple physiologic saline receptor fluid. In order 
to determine whether the quality of the skin preparations remained intact during the 
experimental period (55 h), we measured the permeation of tritiated water in non-exposed 
control groups (groups III and IV). We observed a twofold increased permeability, which 
indicates that the barrier was slightly reduced. Apart from deterioration, the increased 
hydration of the skin due to the humid incubation conditions may have contributed to this 
increase. In addition, most outliers removed from the calculations (see Section 4.2) were 
only deviant for one of the markers (tritiated water or [14C]propoxur), not for both markers. 
Therefore, we conclude that the quality of the skin preparations was sufficient to obtain 
reliable data. 
The washing procedure is another factor that may influence skin permeability in our test 
system (Bucks et al., 1985). However, the kp values for tritiated water were very similar 
between skin preparations which were not subjected to the washing procedure (group V) 
and those which were washed 3 times (group IV). Although propoxur permeability was in 
some cases slightly higher in the washed group, we conclude that the washing procedure 
had only a very limited effect on the skin permeability in our experiments. 
 
 
 
Figure 4-4 Influence of washing procedure on skin permeability. 
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4.5.2 Influence of biocide exposure on skin permeability 
Of the nine biocidal active substances tested, only the quaternary ammonium chlorides 
ADBAC and DDAC clearly and consistently changed skin permeability for the two marker 
molecules, both after single and repeated exposure. These quaternary ammonium chlorides 
increased skin permeability up to six fold, probably due to structural changes induced by 
these compounds. ADBAC was proven to cause an increase of eosinophilic staining, nuclear 
condensation, cellular swelling, and separation between dermis and epidermis in in vitro 
human skin organ cultures, at concentrations of 10 and 50 mg/mL (van de Sandt and Rutten, 
1995). All these changes were dose-related. Likewise in a dose-related fashion, epidermal 
cell proliferation was significantly inhibited, MTT conversion was decreased and pro- 
inflammatory hydroxyl fatty acids were released. These changes indicate that ADBAC causes 
structural and functional damage to cultured human skin at a concentration (50 mg/mL) 
provoking increased permeability, both to tritiated water and propoxur, in the experiment 
reported in the present manuscript. This property is probably linked to the amphipathic, 
soap-like character of these molecules. Soap is reported to increase permeability of guinea 
pig skin (Bucks et al., 1985). Furthermore, it has been suggested that high water and lipid 
solubility enhances the corrosive character of quaternary ammonium compounds (Lin and 
Hemming, 1996). Another explanation may be the skin irritant properties; both investigated 
quaternary ammonium chlorides are classified as “corrosive” by the EU (EU, 2004). 
However, also formaldehyde is classified “corrosive”, but did not increase permeability in 
our experiments. This may be a reflection of a different underlying molecular mechanism. 
Quaternary ammonium chlorides are surfactants and therefore solubilisers, while 
formaldehyde is a chemical cross-linker (Heck and Casanova-Schmitz, 1984) which may very 
well have a different effect on skin structure and barrier function. 
Both DDAC and ADBAC considerably increased in vitro skin permeability after single 
application of relatively low concentrations. This suggests that quaternary ammonium 
chlorides probably enhance their own dermal uptake and that of other biocidal active 
Table 4-5 Control skin permeability for 3H2O at the start and the end of the experiments 
Control group # Vehicle kp (cm/h x 10
-3) at 0 h kp (cm/h x 10
-3) at 55 h Ratio 55/0 h 
1 None 0.8 ± 0.2 2.3 ± 0.2 2.8 ± 0.6 
2 None 2.7 ± 0.8 4.5 ± 1.2 1.7 ± 0.5 
3 Ethanol 1.8 ± 1.0 2.9 ± 0.2 2.0 ± 1.1 
4 Ethanol 2.2 ± 0.5 3.2 ± 0.5 1.5 ± 0.3 
5 None 0.9 ± 0.3 1.7 ± 0.04 2.1 ± 1.0 
6 1% CMC 1.7 ± 0.5 2.7 ± 0.5 1.7 ± 0.5 
7 Ethanol 1.6 ± 1.0 2.4 ± 1.0 1.6 ± 0.3 
8 7.4% 2-propanol in water 1.1 ± 0.6 1.6 ± 0.3 1.9 ± 1.1 
9 None 0.9 ± 0.4 2.1 ± 0.9 2.3 ± 0.3 
Mean ± SD  1.6 ± 0.8 2.6 ± 1.0 2.0 ± 0.7 
SD = standard deviation. 
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substances, when products with multiple active substances or a combination of different 
products are used. At these low concentrations, no difference in permeability effects was 
observed between single and repeated exposure. In contrast, a relatively high concentration 
of ADBAC (300 mg/L) and DDAC (100 mg/L) induced a further increase of skin permeability 
after repeated exposure. Therefore, repeated exposure can be a quantitatively important 
issue, especially during the task of mixing and/or loading of undiluted products containing 
quaternary ammonium chlorides. It should be noted, however, that in our in vitro 
experimental setting, daily exposure can be simulated for a maximum of 3 days, while 
operator exposure to biocidal active substances may take place 5 times a week for periods 
covering several months on a row. Therefore, we should not exclude that also at low 
concentrations of quaternary ammonium chlorides repeated exposure may be a significant 
factor. 
Based on the results, we conclude that repeated exposure may be a quantitatively 
important issue for some specific biocidal products. The risks of the use of quaternary 
ammonium chlorides may be underestimated when the skin permeability enhancing 
properties are not taken into account, especially during repeated mixing and/or loading of 
undiluted products.  
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 Abstract 5.1
The in vitro dermal absorption kinetics of didecyldimethylammonium chloride (DDAC) was 
studied after single and multiple exposure. In addition, the influence of biocidal 
formulations on the absorption of DDAC was investigated. Following dermal exposure to 
DDAC in aqueous solution, less than 0.5% of the applied dose reached the receptor fluid 
after 48 h. The apparent permeability coefficient (kp) was 5 ± 1 cm/h x 10-6 for 
concentrations <12.5 mg/mL, and 12 ± 3 cm/h x 10-6 for concentrations ≥12.5 mg/mL, 
suggesting that DDAC decreases the skin barrier function. DDAC distributed readily into the 
stratum corneum, but the dermis appeared to be the main barrier for DDAC penetration. 
Multiple dosing of DDAC increased its flux across the skin, when applied in high 
concentrations (>11 mg/mL). However, the amount of DDAC reaching the receptor fluid 
remained low (<1% over a 48 h period). Selected biocidal formulations tended to reduce 
DDAC skin absorption. The degree of reduction appeared to be correlated to the amount of 
aldehydes present. Based on the comparison of the distribution of DDAC in full-thickness 
skin and epidermal membranes, we conclude that approximately one- third of the DDAC 
measured in the full-thickness membranes resides in the dermis. As a reasonable worst case 
assumption, this fraction could be considered systemically available when estimating the 
daily systemic body burden of DDAC. 
 Introduction 5.2
The quaternary ammonium chlorides alkyldimethylbenzylammonium chloride (ADBAC) and 
didecyldimethylammonium chloride (DDAC) have been shown to reduce the skin barrier 
function in vitro (Buist et al., 2005). Both compounds clearly and consistently increased the 
skin permeability of the marker compounds [3H-]water and [14C-]propoxur after single 
application of relatively low concentrations. These results suggest that quaternary 
ammonium chlorides may also enhance their own dermal uptake. A survey of the biocidal 
products on the market in The Netherlands revealed that of the 714 products admitted on 
the market at that time, 42 contained ADBAC and 166 contained DDAC. The biocidal 
products that contain these quaternary ammonium chlorides are disinfectants and 
preservatives. Especially when used in disinfectants, the probability of workers and consum-
ers being exposed via the dermal route is high. Relatively little is known about the systemic 
toxicity of quaternary ammonium chlorides, but the acute oral LD50 of DDAC in rats 
(84 mg/kg bw/d, BIBRA, 1990), would lead to the classification “toxic” according to EU 
criteria. Systemic effects (reduced urinary excretion of potassium and chloride) were 
observed at single oral doses of 10-50 mg/kg bw. The LD50 of ADBAC in rats is higher than 
that of DDAC: 234-525 mg/kg bw, and an oral administration of 250 mg/kg bw led to severe 
congestion of liver and kidneys (Xue et al., 2004). According to EU criteria ADBAC would be 
classified as ‘harmful’. In view of its frequent use as a disinfectant, its potential systemic 
toxicity and because of its effects on skin permeability, the absorption kinetics of DDAC was 
studied after multiple and single exposure. We used an in vitro model to conduct our 
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research, as it allowed us to conduct many more experiments than would have been the 
case with an in vivo model or, even more so, with human volunteers. Properly conducted in 
vitro measurements can be used to predict in vivo absorption (see a.o. the recent WHO 
monograph on dermal absorption (WHO, 2006) and the evaluation by Hakkert et al. (2005)). 
In order to determine the permeability coefficient (kp) of DDAC, the initial experiments were 
performed using a high volume of exposure (313 μL/cm2) in order to approach the infinite 
dose conditions. Further experiments were executed using a low volume of exposure (10 
μL/cm2), which is more representative of normal worker and consumer exposure (finite 
dose). As absorption may be considerably influenced by the nature of the vehicle (Hakkert 
et al., 2005), the influence of various commercial biocidal formulations on DDAC absorption 
was investigated as well. 
 Materials and methods 5.3
5.3.1 In vitro experiments 
The in vitro skin penetration assays were performed in static diffusion cells using 
cryopreserved human abdominal skin, as previously described by van de Sandt et al. (1993, 
2000). The skin originated from four female donors, aged 28-60 years (average 43). The 
dermis was partly removed using forceps and scissors, attaining an average skin thickness of 
0.565 ± 0.064 mm. Most experiments were executed with these full-thickness skin 
preparations. The receptor fluid (total volume 1.2 mL) consisted of a physiological salt 
solution (0.9% NaCl w/v) containing 0.01% sodium azide and 3% BSA. Some experiments 
were executed using epidermal membranes instead of full-thickness skin. They were 
prepared by incubating skin overnight in a 2 M NaBr solution in saline, after which the 
epidermis was peeled off the dermis using forceps. 
In the high volume experiments, the skin preparations were exposed to 313 μL/cm2 of DDAC 
in 7.4% 2-propanol in water for 48 h at concentrations of 0.5, 2.5, 12.5 and 50 mg DDAC/mL. 
In the low volume experiments, the skin preparations were exposed to 10 μL/cm2 of DDAC 
in 7.4% 2-propanol in water or formulation for 4 h (single exposure) or for three times 4 h 
(repeated exposure, starting at 0, 24 and 48 h).The DDAC concentrations applied were 
50 mg/ mL (Roloxid 50 formulation), 27.5 mg/ mL (Bakta Steril) and 11 mg/ mL (MS 
Macrodes), respectively. These formulations were compared to equivalent solutions of 
DDAC in 7.4% 2-propanol in water. The experimental designs are illustrated in Figure 5-1. 
Each exposure period was finished by washing off the test substance using four cotton 
swabs humidified with a 3% Teepol solution and subsequently drying the skin preparations 
using two dry cotton swabs. In the repeated as well as in the single low volume experiments 
all skin preparations were washed three times, in order to control for a possible effect of the 
washing procedure on skin permeability. Each experiment was performed with skin from 
one donor. Most experiments were performed each with skin from a different donor. 
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Prior to the start of the experiment, integrity of the skin preparations was assessed by 
determining the permeability coefficient (kp) of tritiated water, as described by van de Sandt 
et al. (1993, 2000). Only skin preparations with a kp of less than 3.0 x 10-3 cm/h for tritiated 
water were used in the subsequent experiments. 
After the start of (the first) exposure, 500 μL samples of receptor fluid were collected at 
regular intervals and assayed for 14C-radioactivity by liquid scintillation counting in a Wallac 
Pharmacia scintillation counter. Directly after each sampling the original volume of the 
receptor fluid was restored by adding 500 μL fresh receptor fluid to each well. The amount 
of [14C]-DDAC that had penetrated the skin was plotted against time and the penetration 
rate was calculated by linear regression analysis. At the end of each experiment, the 
recovery was determined by measurement of radioactivity in the cotton swabs fraction 
(cotton swabs were extracted with ethanol and a subfraction was counted for radioactivity) 
and the skin membrane fraction (skin membranes were dissolved in 1.5 M KOH in 20% 
ethanol and a subfraction was counted for radioactivity). In some experiments the skin 
preparations were tape-stripped seven times using D-squame (Monoderm, Monaco). Each 
first tape strip was collected and counted separately. Subsequent tape strips were pooled in 
groups of three. Radioactivity in the tape strip fractions was determined by direct addition 
of scintillation fluid. 
[14C]-DDAC (labelled at the methyl-groups, s.a. 2.15 GBq/mmol, radiochemical purity >99%) 
was purchased from Amersham, England. Unlabelled DDAC (50% solution in 2-
propanol/water (2:3)) was purchased from Merck KgaA, Darmstadt, Germany. The 
commercially available biocides Bakta Steril, Roloxid 50 and MS Macrodes were obtained 
from Fisher Emergo B.V. Landsmeer, Netherlands. 
 
Figure 5-1 Experimental design.  
(I) High volume exposure full-thickness skin. (II) Single low volume exposure full-thickness skin and epidermal 
membrane. (III) Repeated low volume exposure full-thickness skin. (IV) Single low volume exposure DDAC in 
water or formulation (full-thickness skin). (V) Repeated low volume exposure DDAC in water or formulation 
(full-thickness skin). 
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5.3.2 Statistics 
Statistical calculations were executed using MS Excel version 2003. First equality of 
variances was tested using the FTEST function to calculate the F (folded) statistic. If the two-
tailed probability of a greater F-value was >0.05, equality of variances was assumed, and the 
null hypothesis of no differences between groups was tested using the unpaired 
homoscedastic TTEST function. If the probability was ≤0.05, inequality of variances was 
assumed, and the null hypothesis was tested using the heteroscedastic TTEST function. As 
the groups were relatively small (usually n = 4), normal distribution was assumed and not 
further tested. 
Table 5-1 Statistical analysis of the differences between kp-values determined at different concentrations of 
DDAC, using the χ2-test 
p-values of χ2 -test  
 Concentration DDAC 
( mg/mL) 
0.5 2.5 12.5 
 
 50 0.014a 0.005a 0.258 
12.5 0.0009a 0.005a  
2.5 0.11   
a Statistically significant difference between kp-values of the two corresponding concentrations (p < 0.05); 
number of replicates is 4. 
 Results 5.4
The high volume experiments (design I, Figure 5-1) with DDAC showed that the kp-value 
increased with increasing concentration (see Figure 5-2). Cumulative penetration of DDAC 
showed almost linear kinetics between 28 and 48h after application for the two lower 
concentrations, while for the two higher concentrations tested the absorption rate 
increased with time (see Figure 5-3). Based on this observation and on the statistical 
analysis of the data (see Table 5-1), two categories of DDAC concentrations could be 
discerned with respect to kp-values: for concentrations <12.5 mg/ mL the kp was 5 ± 1 cm/h 
x 10-6, while for concentrations ≥12.5 mg/ mL it was 12 ± 3 cm/h x 10-6. 
In the experiments in which the kp-values were determined, the cumulative absorption in 
the receptor fluid remained very low and never exceeded 0.1% of the administered dose, 48 
h after the start of exposure (see Table 5-2). A far greater fraction remained associated with 
the skin (tape strips and membrane). The relative size of this fraction increased with 
decreasing DDAC concentration, ranging from ca. 4% at 50 mg/ mL to ca. 40% at 0.5 mg/mL. 
The contribution of the stratum corneum (adhered to tape strips) relative to the rest of the 
skin increased with decreasing concentration, from ca. one ninth of the total radiolabel 
associated with skin at 50 mg/ mL to more than one fourth at 0.5 mg/mL.  
In the low volume experiments (design II, Figure 5-1), mimicking realistic worker exposure 
conditions, DDAC was washed off the skin preparation after four hours of exposure, using 
cotton swabs. After exposure to 50 mg/ mL DDAC, a larger fraction of the applied dose was 
recovered from the receptor fluid when epidermal membranes were used (ca. 5%) instead 
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of full-thickness skin (ca. 0.5%), 66 h after start of exposure (Table 5-4). Interestingly, the 
amount of the applied dose recovered from the skin was lower for epidermal membranes 
(ca. 14% for epidermal membranes and ca. 18% for full-thickness skin), resulting in a total 
absorption of ca. 19% for both test systems. 
Repeated exposure to low volumes of 50 mg/ mL DDAC (design III, see Figure 5-1) did not 
tend to increase the absolute amount of DDAC initially present in the stratum corneum10 
after the first exposure (ca. 20 µg), while the amount of DDAC in the rest of the skin layers 
clearly increased with time from ca. 15 µg to ca. 70 µg (see Figure 5-4). However, the 
increase after the third exposure was considerably less (ca. 10 µg) than after the second 
exposure (ca. 35 µg). A similar saturation of the stratum corneum was observed when full-
thickness skin preparations exposed to a low volume of 50 mg/mL DDAC in Roloxid 50 or  
                                                     
10 Represented by the radiolabel recovered from tape strips 2-7; tape strip 1 is assumed to represent DDAC 
not removed from the skin by swabbing. 
  
Figure 5-2 Permeability of human skin for DDAC in 
relation to its concentration (high 
volume application). 
 
Figure 5-3 Cumulative relative absorption of DDAC 
after continuous exposure to various 
concentrations dissolved in 
water/propanol (313 µL/cm2). 
 
Table 5-2 Distribution of radiolabel in skin preparations after 48 h of exposure to DDAC solution 
(313 µL/cm2) 
Amounts in percentage of administered dose (± SD) 
 DDAC concentration ( mg/mL)  
50 12.5 2.5 0.5 
Receptor 0.05 ± 0.01 0.08 ± 0.02a 0.05 ± 0.01 0.04 ± 0.00 
Membrane 3.9 ± 0.6a 8.5 ± 1.1a 13.0 ± 3.2a 28.8 ± 5.7a 
Tape strips 0.5 ± 0.2 1.3 ± 0.3 3.1 ± 0.6a 11.4 ± 3.1a 
Swabs 88.8 ± 2.2 86.6 ± 1.3 80.4 ± 3.0a 47.5 ± 3.8a 
Recovery 93.2 ± 2.6 96.5 ± 0.1 96.5 ± 0.4 87.7 ± 0.9a 
a Statistically significantly different from all other concentrations (p < 0.05). Number of replicates is 4. 
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water/propanol were compared: although the amount absorbed from water/propanol into 
the entire skin was three times higher, the amount present in the stratum corneum was 
virtually the same (data not shown). 
When skin preparations were exposed to DDAC in commercial formulations (Roloxid 50, 
Bakta Steril, MS Macrodes: see Table 5-3; designs IV and V, Figure 5-1), the behaviour of 
DDAC was similar to the behaviour of unformulated DDAC: a skin reservoir was built up and 
relatively little DDAC eventually reached the receptor fluid. There were no statistically 
significant differences in skin reservoir built up between skin preparations that received 
multiple and single exposures (see Table 5-6), although penetration rates of DDAC tended to 
be higher when preceded by two daily 4h-exposures (see Table 5-5). However, the tested 
formulations clearly reduced the amount of DDAC built up in the skin as well as DDAC 
penetration rates, compared to when water/propanol was used as a vehicle (see Table 5-6 
and Table 5-5). The more formaldehyde and glutaraldehyde the formulations contained, the 
greater the reduction of the skin reservoir and of the penetration rate. It was also 
remarkable that the skin preparations exposed to the formulation containing the highest 
concentration of formaldehyde and glutaraldehyde were more difficult to solubilise before 
being assayed for radio-activity than the other exposed skin preparations. 
Table 5-3 Overview of the active ingredients of the tested formulations 
Formulation Concentration ( mg/mL) 
In-use dilution factorsa 
DDAC ADBAC Formaldehyde Glutaraldehyde 
Bakta Steril 27.5 — — — 50x, 100x 
Roloxid 50 100 — 32 80 30x, 60x, 100x, 200x, 300x 
MS Macrodes 11 30 196 106 50x, 67x 
a According to the official Instructions for Use published by the Dutch Board for the Authorisation of 
Pesticides (http://www.ctb-wageningen.nl/). 
  Discussion and conclusions 5.5
We studied the dermatokinetics of DDAC in order to determine to which extent this 
frequently used biocide may pass the barrier of the skin into systemic circulation. Our 
results show that DDAC poorly penetrates human skin in vitro. Following exposure 
conditions relevant for workers and consumers (10μL/cm2, 0.5-50 mg/mL), only less than 
Table 5-4 Distribution of radiolabel in full-thickness skin preparations and epidermal membranes after 4-h 
exposure to DDAC solution (10 µL/cm2, 50 mg/mL) 
 Full-thickness skin Epidermal membrane 
Receptor 0.3 ± 0.0a 5.3 ± 0.7 
Membranes 18.4 ± 2.1a 13.9 ± 1.5 
Swabs 75.0 ± 3.9a 69.3 ± 2.3 
Recovery 93.8 ± 4.3 88.5 ± 3.1 
The data are expressed as % of the applied dose (means ± SD), 62 h after the exposure period of 4 h (n = 4). 
a Statistically significant difference between epidermal membrane and full-thickness skin (p < 0.05). 
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0.5% of the applied dose passed the full-thickness skin preparation and reached the 
receptor fluid. In an experiment in which we applied a high volume of DDAC, the per-
meability constant kp of DDAC appeared not to be independent of the concentration 
applied, as it was ca. two times higher at high concentrations (≥12.5 mg/mL) than at low 
concentrations. This finding is in line with our earlier study, in which we observed that DDAC 
increased the skin absorption of two marker molecules (Buist et al., 2005). It can be 
hypothesized that DDAC damages the stratum corneum by solubilisation since its structural 
analogue ADBAC has been shown to effectively extract cholesterol from the stratum 
corneum (Aki and Kawasaki, 2004). ADBAC also affected the viability of human skin organ 
cultures, as was observed by a series of histopathological changes (van de Sandt and Rutten, 
1995) using exposure conditions similar to those employed in the present experiments. 
Therefore, the higher skin permeability constant of DDAC measured after exposure to high 
concentrations is likely to be due to the damage inflicted by this surfactant to the barrier 
function of the skin thus violating one of the conditions for Fick’s law to be applicable, that 
is that the substance applied should not interfere with the skin’s permeability. 
DDAC diffused readily into the stratum corneum, as at high concentrations of DDAC this skin 
layer was already saturated after the first of three exposure periods. The underlying part of 
the skin appeared to be more resistant to DDAC penetration than the stratum corneum, as it 
was only (nearly) saturated after the second exposure period. This is in line with the high log 
 
Figure 5-4 Distribution of radiolabel in full-thickness skin preparations during multiple exposure to DDAC 
solution (10 µL/cm2, 50 mg/mL), at different times after the start of the experiment. 
Skin preparations were three times exposed to [14C]-DDAC for the following periods after the start of the 
experiment: t = 0-4, 24-28 and 48-52 h 
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KOW of DDAC of 4.7, indicating high lipophilicity. Furthermore, the structurally related 
alkyldimethylbenzylammonium chloride (ADBAC) has been demonstrated to possess high 
affinity for the stratum corneum lipids ceramide and cholesterol, while its affinity for 
defatted stratum corneum was much less (Aki and Kawasaki, 2004). In line with these 
properties of DDAC, the dermis appeared to be the main barrier for DDAC penetration, as 
removal of this skin compartment resulted in a ca. 10-fold increase of DDAC penetration 
into the receptor fluid after a single exposure to a low volume of 50 mg/ mL DDAC. 
In previous experiments, DDAC exposure decreased the barrier function of the skin, as 
measured by the penetration of marker molecules (tritiated water and propoxur) (Buist et 
al., 2005). Multiple dosing of relatively high concentrations increased this effect. In the 
present experiments, multiple dermal dosing of DDAC in commercial formulations increased 
its flux across the skin compared to single dosing, when applied in relatively high 
concentrations (>11 mg/mL). However, the flux differences between single and multiple 
dosing were relatively limited and not always statistically significant. It should be noted that 
these differences may in fact be somewhat greater than observed in this study, as 
radiolabelled DDAC was only applied after the second of the repeated exposures, and 
dilution of the radiolabelled DDAC with the previously applied non-labelled DDAC may have 
led to an underestimation of the amount penetrated after multiple exposure. In previous 
experiments tritiated water penetration was also slightly increased after triple exposure to 
100 mg/ mL DDAC, as compared to a single exposure (Buist et al., 2005). Taken together, it 
can be concluded that the total amount DDAC reaching the receptor fluid was low (less than 
0.5% over 48 h) and repeated exposure did not affect this in a quantitatively significant 
fashion, relative to one single exposure. 
Table 5-5 Influence of various formulations on the distribution of DDAC after single and multiple exposure 
Formulation 
DDAC 
conc. 
( mg/mL) 
Aldehyde 
conc. (M) 
Exposure 
(10 
µL/cm2) 
DDAC in receptor fluid  DDAC in membrane 
(% 
dose ± SD) 
Formulation/ 
water 
(fraction ± SD)a 
 
(% 
dose ± SD) 
Formulation/ 
water 
(fraction ± SD)a 
 
Roloxid 50 50 0.9 Multiple 0.16 ± 0.10 0.16 ± 0.12  8.7 ± 2.8 0.53 ± 0.3 
Roloxid 50 50 0.9 Single 0.10 ± 0.04 0.13 ± 0.06  7.1 ± 2.7d 0.32 ± 0.16c 
Bakta Steril 27.5 0.0 Multiple 0.79 ± 0.22b 0.81 ± 0.48  15.3 ± 1.0d 0.76 ± 0.17 
Bakta Steril 27.5 0.0 Single 0.47 ± 0.10b 1.28 ± 0.38  12.4 ± 2.4e 0.68 ± 0.26 
MS 
Macrodes 11 7.6 Multiple 0.03 ± 0.00 0.03 ± 0.01
c  4.2 ± 1.6 0.11 ± 0.05c 
MS 
Macrodes 11 7.6 Single 0.05 ± 0.02 0.05 ± 0.03
c  4.8 ± 1.9 0.11 ± 0.05c 
Number of replicates was 4, unless indicated otherwise. Each exposure lasted 4h. Single exposures were 
executed with radiolabelled DDAC. The first two exposures of the multiple exposure regime were executed 
with unlabelled DDAC and the last with radiolabelled. 
a Calculated by dividing % dose recovered with formulation by % dose recovered with the corresponding 
water control group. 
b Statistically significant difference between multiple and single exposure (p < 0.05) 
c Statistically significantly different from water control group (p < 0.05).  
d Two replicates in control group.  
e Three replicates in control group. 
 
 
 
 
Chapter 5 Dermatokinetics of didecyldimethylammonium chloride and the influence of some commercial 
biocidal formulations on its dermal absorption in vitro 
page 120 
It is well known that the nature of the vehicle in which a substance is applied to the skin 
may alter the rate at which it is absorbed, either accelerating it or slowing it down. The 
magnitude of the vehicle effect needs to be taken into account in the risk assessment of 
substances. In our study, we showed that several selected commercial formulations tended 
to reduce skin penetration of DDAC. This was most pronounced with the formulation MS 
Macrodes, which contains the highest concentration of formaldehyde (196 mg/mL) and 
glutaraldehyde (106 mg/mL), and reduced the flux of DDAC across the skin by 95%. The 
reduction caused by Bakta Steril, the only tested formulation not containing any aldehydes, 
was smallest and did not reach statistical significance. In our previous experiments, 
formaldehyde exhibited a tendency to decrease skin permeability for tritiated water and 
propoxur, when tested up to concentrations of 30 mg/ mL (Buist et al., 2005). The results 
obtained in the present study confirm this early finding. A possible explanation of this 
phenomenon is the ability of formaldehyde and glutaraldehyde to cross-link proteins (Usha 
and Ramasami, 2005). Cross-linking of proteins in the epidermis, such as keratins, could turn 
the skin less permeable. This is corroborated by our observation that skin preparations 
exposed to MS Macrodes were more resistant to solubilising than those exposed to one of 
the other formulations. 
Although DDAC increased skin permeability, it is unlikely that this would lead to a 
considerable increase of its systemic availability. DDAC remains closely linked to the stratum 
corneum and even more than 40 h after termination of exposure to DDAC in commercial 
formulations, the cumulative dose present in the receptor fluid did not exceed 1% of the 
applied dose. Furthermore, repeated exposure did not lead to a quantitatively significant 
increase of DDAC in the receptor fluid. It is likely that DDAC ultimately will be lost from the 
Table 5-6 Influence of various formulations on the DDAC flux through skin preparations during single and 
multiple exposure 
Vehicle n DDAC conc. ( mg/mL) 
Exposure  
(10 µL/cm2) Flux (µg/cm
2/h) Relative flux formula/water  (fraction ± SD)a 
Roloxid 50 4 50 Multiple 0.083 ± 0.045 0.20 ± 0.13c 
Roloxid 50 4 50 Single 0.043 ± 0.018 0.12 ± 0.07d 
Bakta Steril 4 27.5 Multiple 0.13 ± 0.03b 0.49 ± 0.26d 
Bakta Steril 4 27.5 Single 0.08 ± 0.02b 0.95 ± 0.35e 
MS Macrodes 4 11 Multiple 0.002 ± 0.001 0.03 ± 0.01c 
MS Macrodes 4 11 Single 0.003 ± 0.001 0.05 ± 0.02c 
Number of replicates was 4, unless indicated otherwise. Each exposure lasted 4 h. Single exposures were 
executed with radiolabelled DDAC. The first two exposures of the multiple exposure regime were executed 
with unlabelled DDAC and the last with radiolabelled. 
a Calculated by dividing the flux measured with formulation by the flux measured with the corresponding 
water control group containing the same concentration of DDAC. 
b Statistically significant difference between multiple and single exposure (p < 0.05).  
c Statistically significantly different from water control group (p < 0.05).  
d Two replicates in control group.  
e Three replicates in control group. 
 
 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 121 
stratum corneum by desquamation. The DDAC fraction associated with the dermis may not 
be lost and could become systemically available via the local microcirculation. However, its 
release into systemic circulation is expected to be slow and, consequently, its contribution 
to the daily systemic body burden would be low. Based on the comparison of the 
distribution of DDAC over receptor fluid and skin preparation between full-thickness skin 
and epidermal membranes after 4 h of low volume exposure, we conclude that 
approximately one-third of the DDAC measured in the full-thickness membranes resides in 
the dermis. As a reasonable worst case assumption, this fraction could be considered 
systemically available when estimating the daily systemic body burden of DDAC. 
Consequently, when using the in vitro absorption data determined with epidermal 
membranes (not containing any dermis), the fraction of DDAC present in the membrane 
does not need to be taken into account when estimating the daily systemic body burden. 
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 Abstract 6.1
Most QSPRs for dermal absorption predict the permeability coefficient, kp, of a molecule, 
which is valid for infinite dose conditions. In practice, dermal exposure mostly occurs under 
finite dose conditions. Therefore, a simple model to predict finite dose dermal absorption 
from infinite dose data (kp and lag time) and the stratum corneum/water partition 
coefficient (KSC,W) was developed. To test the model, a series of in vitro dermal absorption 
experiments was performed under both infinite and finite dose conditions using acetic acid, 
benzoic acid, bis(2-ethylhexyl)phthalate, butoxyethanol, cortisone, decanol, diazinone, 2,4-
dichlorophenol, ethacrynic acid, linolenic acid, octylparaben, oleic acid, propylparaben, 
salicylic acid and testosterone. For six substances, the predicted relative dermal absorption 
was not statistically different from the measured value. For all other substances, measured 
absorption was overpredicted by the model, but most of the overpredictions were still 
below the European default absorption value. In conclusion, our finite dose prediction 
model provides a useful and cost-effective estimate of dermal absorption, to be used in risk 
assessment for non-volatile substances dissolved in water at non-irritating concentrations. 
 Introduction 6.2
Dermal absorption data are needed in toxicological risk assessment of chemical substances 
in order to estimate internal dose after dermal exposure to these chemicals. This internal 
dose can then be compared to an internal limit value for systemic effects to assess the 
safety of the dermal exposure (see a.o. the EU technical guidance on risk assessment: EU, 
2004). Dermal absorption can be estimated using in vivo or in vitro studies with humans or 
animals, which need to be conducted under conditions mimicking those expected to occur 
 Infinite dose Finite dose 
Flux 
 
  
Cumulative 
penetration 
 
  
Figure 6-1 Comparison of infinite and finite dose dermal penetration 
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during the exposure(s) to be evaluated for toxicological risk (EU, 2004). When no 
experimental data are available, European regulatory authorities assume 100% dermal 
absorption unless the chemical possesses a molecular weight >500 and a log KOW smaller 
than -1 or higher than 4, in which case 10% absorption is assumed (EU, 2004). In our 
experience, most molecules evaluated in regulatory risk assessment are assumed to be 
totally absorbed, when applying this rule. 
At the end of the year 2006, the EU parliament accepted new legislation on the registration 
of chemicals, known under the acronym REACH11. REACH entered into force on 1st June 
2007. Based upon it, over 50,000 existing chemicals will need to be evaluated for 
environmental and health safety under the conditions they are manufactured, used and 
                                                     
11 Registration, Evaluation Authorisation and restriction of CHemicals. 
 
Table 6-1 Test compounds and concentrations. 
Test compound 
Final concentrations (radioactivity in MBq 
mL-1) 
Experiments on concentration dependence 
of kp 
Finite dose prediction 
experiments 
[14C]Acetic acid 95.8; 21.0; 4.66; 0.82; 0.26 mg mL-1  
(0.22; 0.25; 0.25; 0.25; 0.14) 
100 mg mL-1 (0.45) 
[14C]Benzoic acid -- 33 mg mL-1 (0.19) 
[14C]Bis(2-ethylhexyl)phthalate  2.47 µg mL-1 (0.0027) 
[14C]Butoxyethanol 451.5; 90.3; 18.1; 3.61; 1.01 mg mL-1  
(0.16; 0.17; 0.050; 0.010; 0.0028) 
451 mg mL-1 (0.020) 
[14C]Cortisone -- 195 µg mL-1 (0.0035) (infinite 
dose) 
22.2 µg mL-1 (0.13) (finite dose) 
[14C]Decanol 0.74; 0.142; 0.0265; 0.00416 mg mL-1  
(0.0016; 0.021; 0.029 ; 0.014) 
2.5 mg mL-1 (0.024) 
[14C]Diazinone -- 16.95 µg mL-1 (0.11) 
114C]2,4-Dichlorophenol 383; 50.8; 2.67; 0.52 µg mL-1  
(0.087 ; 0.027; 0.0047; 0.0025) 
370 µg mL-1 (0.029) 
[14C]Ethacrynic acid -- 11.1 µg mL-1 (0.020) 
[14C]Linolenic acid -- 10.84 µg mL-1 (0.073) 
[14C]0ctylparaben 104; 19; 3.13; 0.101 µg mL-1  
(0.029; 0.024 ; 0.024; 0.00076) 
89 µg mL-1 (0.046) 
[14C]Oleic acid -- 10.81 µg mL-1 (0.072) 
[14C]Propylparaben 503; 104; 21.2; 4.92; 0.99 µg mL-1  
(0.032; 0.031; 0.032; 0.031; 0.0075) 
502 µg mL-1 (0.041) 
[14C]Salicylic acid -- 361 µg mL-1 (0.014) 
[14C]Testosterone 21.0; 8.03; 5.79; 1.74; 0.61 µg mL-1  
(0.13; 0.052; 0.037 ; 0.011; 0.0039) 
25.6 µg mL-1 (0.16) 
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discarded. All substances should be evaluated by the end of 2017. For many chemicals, data 
on dermal absorption under many different exposure conditions will need to be generated. 
To save time and money, a simple in silico method, not automatically leading to a default of 
100% absorption, would be advantageous. Extensive overviews of available in silico 
methods have been published recently (WHO, 2006; Bouwman et al., 2008). Most QSPRs 
calculate the permeability coefficient, kp, of a molecule, which is a measure of the skin 
permeability of a molecule under steady state conditions. Steady state is reached after a 
certain lag time, which amongst others depends on the nature of the molecule. The kp is 
usually expressed in cm/h, and from it the flux of solute over the skin under steady state 
conditions can be calculated for so called infinite dose conditions, i.e., when the 
concentration of the solution applied to the skin does not change (appreciably) over time. In 
practice, however, dermal exposure will mostly occur under finite instead of infinite dose 
conditions, meaning the concentration of the solute in solution on the skin will clearly 
change over time. Under these conditions, the flux of the substance across the skin will 
decrease with time as the solution on the skin is depleted of its solute (see Figure 6-1). Using 
kp values and initial concentrations to calculate absorption would thus lead to 
overestimation. Therefore, we developed a simple model to predict finite dose absorption 
from infinite dose data (kp and lag time). In order to test this finite dose absorption 
prediction model, a series of in vitro dermal absorption experiments was performed with 15 
different substances, both under infinite and finite dose conditions. 
 Materials and methods 6.3
6.3.1 In vitro dermal absorption experiments 
The in vitro skin absorption assays were executed according to standard protocols used in 
our laboratory to perform in vitro dermal absorption studies according to OECD test 
guideline 428 (OECD, 2004). The assays were performed in static diffusion cells using 
cryopreserved human abdominal skin (exposed area 0.64 cm2), as previously described by 
van de Sandt et al. (1993, 2000). The skin originated from nine female donors, aged 29-53 
years (average 39 ± 7.4). Epidermal membranes were used, which were prepared by 
incubating skin overnight in 2 M NaBr solution in saline, after which the epidermis was 
peeled from the dermis using forceps. The receptor fluid (total volume 1.2 mL) consisted of 
a physiological salt solution (0.9% NaCl w/v) containing 0.01% sodium azide and 6% 
polyoxyethylene (20) oleyl ether, the latter having been added to ensure also lipophilic test 
substances would be readily soluble in it. Prior to the start of the experiment, integrity of 
the epidermal membranes was assessed by determining the permeability coefficient (kp) of 
tritiated water, as described by van de Sandt et al. (1993, 2000). Epidermal membranes with 
a kp for tritiated water of less than 3.0 x 10-3 cm/h were used in the subsequent 
experiments. 
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The epidermal membranes were exposed to 780 μL (the maximum volume the donor cells 
of our system can accommodate) or 16 μL aqueous dose solution/cm2, representing infinite 
and finite dose experiments12, respectively. 
For the absorption experiments in which kp was assessed over a broad range of test 
concentrations for seven substances, the aim was to test 5x a 1:5 dilution of the test 
compounds. For a number of substances, the highest test concentrations were selected 
based on maximum solubility in water, which was determined experimentally before 
preparation of the solutions (octylparaben, propylparaben, testosterone, 2,4-dichlorophenol 
and decanol). As the flux is determined by the concentration of the substance and its kp, it is 
not useful to test beyond maximum water solubility. For the other compounds solubility was 
not a limiting factor. Butoxyethanol and ethylene glycol were tested at a maximum 
concentration of 50% (v/ v) (corresponding to, respectively, ca. 470 and ca. 530 mg mL-1). 
Acetic acid was tested at a lower maximum concentrations of 100 mg mL-1, as this 
compound is known to have corrosive potential. According to EU classification, 10% acetic 
acid constitutes the lower limit for classification as “irritating”. This means a series of 
concentrations was used up to the point where, according to EU classification, irritancy 
starts. In the absorption experiments it was shown that the kp is relatively constant over a 
broad range of test concentrations. Therefore, test concentration selection for the other 
experiments was less critical. The test concentrations of the different test compounds are 
presented in Table 6-1. All concentrations chosen were below the maximum solubility of the 
test substance in water. All test solutions were prepared using a [14C]- radiolabel. Depending 
                                                     
12 For very slowly penetrating substances even 16 μl/cm2 may constitute an infinite dose. However, as the 
results for our experiments show, this was not the case for our test substances. 
  
Figure 6-2 Exemplary plot of cumulative penetration 
versus time. 
 
Figure 6-3 Concentration of substances in the donor 
cell relative to the total amount present 
the stratum corneum and the donor cell 
at steady state as a function of log KOW. 
The relative concentration was calculated using Eq. 
(3) and QSARs for KSC,W:
 ABRA, the QSAR of Abraham 
et al. (1995); MW. the QSAR for KSC,W of Hui et al. 
(1995) for the MW indicated. 
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on the specific activity of the radiolabel and the desired test concentration, the radiolabel 
was mixed with unlabelled test compound. The dose compartments were occluded using a 
glass coverslip fixed to the rim of the donor cell with Vaseline, in order to avoid evaporation. 
In all experiments, the epidermal membranes (3-4 per test group) were exposed to the dose 
solutions for the whole experimental period. The duration of the finite dose experiments 
was set to 8 h to represent one working day. The infinite dose experiments were much 
longer in duration (48-51 h), in order to make sure linear steady state penetration would be 
observed (during which kp can be measured, see Figure 6-2), even for substances with a long 
lag time. These long exposures usually did not affect the skin barrier, as steady state 
penetration was normally maintained throughout this period. If towards the end of this 
period penetration rates did change, only the linear portion of the time versus cumulative 
penetration curve was used to measure kp. 
After the start of exposure, 500 μL samples of receptor fluid were collected at regular 
intervals and assayed for 14C-radioactivity by liquid scintillation counting (LSC) using a Wallac 
Pharmacia scintillation counter. Directly after each sampling the original volume of the 
receptor fluid was restored by adding 500 μL fresh receptor fluid to each well. The amount 
of test substance that had penetrated the skin was plotted against time and the penetration 
rate was calculated by linear regression analysis. At the end of each experiment, the test 
substance was removed from the skin surface by washing off the test substance using four 
cotton swabs humidified with a 3% Teepol solution and subsequently drying the epidermal 
membranes using a dry cotton swabs. For the  
infinite dose experiments the remaining dose was first removed by means of a pipette. For 
the finite dose experiments, recovery was determined by measurement of radioactivity in 
the remaining dose, the cotton swabs fraction (cotton swabs were extracted with ethanol 
and a sub-fraction was counted for radioactivity) and the epidermal membrane fraction 
(epidermal membranes were dissolved in 1.5 M KOH in 20% ethanol and a sub-fraction was 
counted for radioactivity). Each series of experiments with a single substance was 
performed with skin from one single donor. 
6.3.2 Selection of the chemicals 
The radiolabelled chemicals were selected in such a way as to obtain a representative 
sample of small organic molecules with respect to the main chemical specific determinants 
of skin penetration used in most QSPRs: MW and log KOW (see a.o. Bouwman et al., 2008). 
6.3.3 Calculation of kp and lag time in in vitro infinite dose experiments 
The calculations were performed using a standardised Excel spreadsheet. A cumulative 
amount penetrated per unit skin area versus time curve was constructed from the amount 
of test substance in the receptor fluid, and the maximum penetration rate was determined 
from the steepest, linear portion of this curve (see Figure 6-2). kp values were calculated by 
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dividing the maximum penetration rate by the (initial) concentration of test substance 
applied to the epidermal membrane. The lag time was determined by extrapolating the 
steepest linear portion of the curve to a cumulative amount penetrated of 0 mg/cm2. 
Basic differential equation for flux (modified Fick's 
law) 
−
dMdon
dt
= C × kp × A ∙∙∙∙∙ (1) 
Stratum corneum/water partitioning coefficient 
(KSC,W) 
KSC,W= 
CSC
Cdon
= 
MSC
VSC⁄
Mdon
Vdon⁄
 ∙∙∙∙∙ (2) 
Correction factor (f) for steady state distribution into 
the stratum corneum  
f = Mdon
MSC + Mdon
= Vdon
VSC × KSC,W + Vdon
 ∙∙∙∙∙ (3) 
Calculation of KSC,W 
For alkanols (Abraham et al., 1995): 
log KSC,W = 0.514 log KOW + 0.104 ∙∙∙∙∙ (4) 
For all other chemicals (Hui et al., 1995): 
log KSC,W = 0.078 (log KOW)
2 + 0.868 log MW – 
 2.04 ∙∙∙∙∙ (5) 
Prediction of cumulative penetration (Mrec,t) 
Mrec,t = Mdon,0 (1 - e
− 
f × kp
'  × A
 Vdon
 × (t − tlag)) ∙∙∙∙∙ (6) 
Prediction of the in vitro skin reservoir (MSC) 
MSC = (Mdon,0 – Mrec,t) × (1 – f) ∙∙∙∙∙ (7) 
QSPRs for kp  
Potts and Guy, 1992: 
Log kp = -2.72 + 0.71log KOW – 0.0061MW ∙∙∙∙∙ (8) 
Patel et al., 2002 : 
Log kp = –2.3 + 0.652log KOW – 0.00603MW – 
 0.623ABSQon – 0.313SsssCH ∙∙∙∙∙ (9) 
Cleek & Bunge (1993) correction: 
kp, corrected = 
kp
1+ 
kp ×  MW
2.6
 ∙∙∙∙∙ (10) 
Explanation of symbols used  
A  = exposed skin area in cm2 
ABSQon  = the sum of absolute values of charges on 
  nitrogen and oxygen atoms of the  
  penetrant 
f  = fraction of substance present in donor 
  fluid (relative to the total amount present 
  in donor fluid and stratum corneum) 
kp  = measured permeation constant in cm/h  
KSC,W  = stratum corneum/water partition 
  coefficient 
Log KOW  = logarithm of octanol/water partition  
  coefficient 
LSC  = thickness of stratum corneum = 0.002 cm 
  (default, based on Xiao & Imhof (1997) 
Mdon,0  = initial mass of substance present in donor  
  fluid in mg  
Mrec,t  = amount of substance in receptor fluid in  
  mg at time t  
MSC  = amount of substance present in the  
  stratum corneum in mg  
SsssCH  = the sum of E-state indices for all methyl  
  groups of the penetrant  
t = exposure time in h 
tlag = measured lag time in h 
Vdon  = volume of donor fluid in mL 
Vsc  = volume of stratum corneum in mL = 
  A (cm2) × LSC (cm) = 0.64 × 0.002 =  
  0.00128 mL 
Figure 6-4 Equations 
 
6.3.4 Calculation of experimentally determined relative absorption 
In order to determine relative absorption, the amount of radio-label recovered from the 
epidermal membrane at the end of the experiment after washing was added to the amount 
of radiolabel accumulated in the receptor fluid. This sum was divided by the amount of 
radiolabel applied at the start of the experiment. 
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6.3.5 Prediction of absorption in vitro under finite dose conditions 
The absorption in finite dose in vitro experiments was predicted as follows from the kp and 
lag time, which were both measured in the infinite dose experiments: 
1. Correction of the measured kp for distribution into the stratum corneum: 
kp
' =
kp× (VSC × KSC,W + Vdon)
Vdon
 
2. Estimation of the cumulative amount penetrated after exposure: 
Mrec,t = Mdon,0 (1 - e
- 
f × kp
'  × A
 Vdon
 × (t - tlag)) 
3. Estimation of the amount still present in the stratum corneum, immediately after 
cessation of exposure: 
MSC = (Mdon,0 - Mrec,t) × (1 - f) 
4. Calculation of relative absorption in %: 
%Apot = 
Mrec,t + MSC
M0
 × 100 
These values were calculated for each combination of kp and lag time from the three to four 
replicates, and averaged. Also standard deviations were calculated based on these 
outcomes. 
The equations are described in Figure 6-4, and the calculation of a number of parameters is 
explained in more detail below. 
6.3.6 Correction factor (f) for steady state distribution into the stratum corneum 
The flux of a substance across the skin can be described by a modification of Fick’s law (Eq. 
(1) in Figure 6-4) (WHO, 2006). In this approximation, the amount of substance distributed 
into the stratum corneum is neglected. However, for finite dose conditions the amount of 
penetrant present in the stratum corneum may be significant compared to the amount still 
present in the donor cell. Under these circumstances, the initial distribution into the 
stratum corneum will significantly decrease the concentration of the penetrant in the donor 
cell. As this concentration is the force driving its flux across the skin, the flux will be lower 
than predicted by Eq. (1). Under steady state conditions, the distribution of the penetrant 
over donor fluid and stratum corneum is given by the stratum corneum/water partition 
coefficient (KSC,W, Eq. (2) in Figure 6-4) (WHO, 2006). From this equation the proportion (f) of 
the substance still present in the donor fluid after distribution into the stratum corneum can 
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be calculated, when the volumes of the stratum corneum, and of the donor and receptor 
cell fluids are known (see Eq. (3) in Figure 6-4).  
According to Xiao and Imhof (1997), the thickness of the stratum corneum of the volar side 
of the fore-arm is ca. 20 μm. As the exposed skin area in our in vitro set-up is 0.64 cm2, its 
volume (VSC) in our system would be 1.28 μL, assuming the abdominal skin we used 
possesses a stratum corneum of approximately the same thickness. In our calculations of f 
we used this value. 
As there are no data available on the KSC,W of the substances we investigated, with the 
exception of testosterone, we depended on QSARs to estimate the partition coefficients 
necessary to calculate f. These QSARs are listed in Figure 6-4 (Eqs. (4) and (5)). For 
testosterone we used the measured KSC,W reported by Abraham et al. (1995).  
6.3.6.1 Correction measured kp 
Usually, kp is determined under infinite dose conditions and calculated by dividing the 
measured flux by the (initial) driving concentration of the substance in the donor fluid. It is 
assumed that under these conditions no significant amount of substance will distribute into 
the stratum corneum relative to the amount remaining in the donor compartment. 
However, taking into account the parameters used in our infinite dose experiments, a 
substantial amount of substance will be present in the stratum corneum during steady state 
if the substance is rather lipophilic (see Figure 6-3). This means that also under infinite dose 
conditions the driving concentration may be significantly decreased by the distribution of 
substance into the stratum corneum, at least for lipophilic substances. Therefore, the kp 
measured in the infinite dose experiments was corrected by dividing it by the correction 
factor f for a donor cell volume of 500 μL. 
6.3.6.2 Prediction of cumulative penetration (Mrec,t) under finite dose conditions 
Cumulative penetration was calculated using a formula derived from the differential 
equation of the modified Fick’s law as shown in Figure 6-5. The correction factor (f for 
partitioning between donor cell fluid (10 μL) and stratum corneum was inserted in it as well 
as the lag time, measured under infinite dose conditions. The resulting formula is presented 
as Eq. (6) in Figure 6-4. 
6.3.6.3 Prediction of the in vitro skin reservoir (MSC) under finite dose conditions 
The amount of penetrant present in the stratum corneum under steady state conditions was 
used as an approximation for the total amount present in the epidermal membrane. It was 
calculated from the predicted amount in the receptor fluid, the initial amount applied and 
the partitioning between donor cell fluid (10 μL) and stratum corneum, using Eq. (7) (see 
Figure 6-4). 
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In equation (1) the concentration term can be substituted by Mdon/Vdon, in which Mdon is the mass of 
substance present in the donor cell on the skin in mg and Vdon is the volume in which it is dissolved in mL 
(cm3)/cm2. Subsequently, differential equation (1) can be solved in the following steps: 
−
dMdon
dt
= kp × 
Mdon
Vdon
 × A  
∫
dMdon
Mdon
= − ∫
kp × A 
Vdon
 × dt   
ln Mdon = −
kp × A 
Vdon
 × t + c  
Mdon, t = e
− 
kp × A 
Vdon
 × t + c
  
Mdon, t = Mdon, 0 e
− 
kp × A 
Vdon
 × t 
  
in which Mdon, 0 = initial mass of substance present on the skin in the donor cell in mg/cm
2. 
Also taking into account the lag time (tlag), the cumulative penetration into the receptor cell at time t (Mrec, t) 
in mg/cm2, assuming that the total mass present is equal to the sum of Mdon and Mrec (= Mdon, 0), is thus 
given by: 
Mrec,t =  Mdon, 0 −   Mdon, 0 e
− 
𝑘𝑘𝑝𝑝 × A
 Vdon
 × (t − tlag)= Mdon,0 (1 −  e
− 
𝑘𝑘𝑝𝑝 × A
 Vdon
 × (t − tlag))
When distribution into the stratum corneum is fast compared to the flux across the skin, the penetrant will 
accumulate in that skin compartment. In that case, the amount left in the donor cell at time t will be less 
than the difference between the applied amount (Mdon, 0) and the penetrated amount (Mrec, t). Equation (3) 
of figure 6-4 gives the fraction f of the substance initially present on the skin after distribution into the 
stratum corneum. To correct for the decreased concentration due to distribution into the stratum corneum, 
the driving concentration (C) is substituted by f × C in the derivation of the cumulative penetration equation 
above from equation (1). This yields equation (6) of figure 6-4. 
Figure 6-5  Derivation of Eq. (6) for cumulative penetration. 
The equation numbers refer to those used in Figure 6-4. The symbols used are explained in Figure 6-4. 
6.3.7 Log KOW 
Log KOW of the investigated substances were obtained using the KowWin software (Meylan 
and Howard, 1999). KowWin calculates log KOW of molecules based on its molecular 
structure, and also provides experimental values when available in its database. Unless 
otherwise stated, experimental values of log KOW were used. 
6.3.8 QSPRs for kp 
The evaluated QSPRs for kp are listed in Figure 6-4 (Eqs. (8-10)). E-state indices for the 
methyl groups in a particular chemical were calculated according to the method detailed by 
Hall and Kier (Hall and Kier, 1995; Kier and Hall, 1997), and summed to obtain SsssCH (i.e., 
the sum of the E-state indices) of that chemical. Optimised geometries for each of the 
chemicals within the dataset were obtained using the AM1 Hamiltonian described by Dewar 
et al. (1985) available within the software package Gaussian 03 (Frisch et al., 2003). The 
ABSQon descriptor was then obtained by summing the Mulliken charges upon the nitrogen 
and oxygen atoms present in a particular molecule as calculated with Gaussian 03. 
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6.3.9 Statistical analysis 
Correlations between concentration and kp were investigated using Spearman correlation 
coefficients. An absolute correlation coefficient that is higher than 0.8 was considered to 
reveal a good correlation, an absolute correlation coefficient between 0.6 and 0.8 was 
considered to reveal a moderate correlation. An absolute correlation below 0.6 was 
considered to be non-relevant. Differences in kp between levels of concentration were 
tested with ANOVA. A Tukey Kramer correction was performed to correct for multiple 
comparison. In all tests performed, the null hypothesis of no difference was rejected at the 
0.05 level of probability. 
Differences between measurements and predictions of absorption in the 8 h finite dose 
experiments were tested for statistical significance using SAS for Windows (SAS 9.1.3; SAS 
Institute Inc., Cary, USA). A two-sided exact non-parametric Kolomogov-Smirnov test for two 
samples was used to test whether the measurements and predictions had identical 
distributions. The null hypothesis was rejected at the 0.05 level of probability (α = 5%). 
 Results and discussion 6.4
6.4.1 Measured and predicted kp values 
kp values determined under infinite dose conditions are listed in Table 6-2 and Table 6-3; the 
latter also includes a complete overview of the measured infinite dose data. For the dataset 
described in this article, predictions of the kp values by two selected QSPRs (Patel et al., 
2002; Potts and Guy, 1992) were, in general, in the same order of magnitude as the 
measured values for hydrophilic substances, but not for very lipophilic substances (log KOW 
≥4). However, performance of these QSPRs improved considerably when the kp values were 
adjusted for lipophilicity according to the formula of Cleek and Bunge (1993; see Eq. (10) in 
Figure 6-4), at least when compared to measured values corrected for distribution into the 
stratum corneum. The kp values for decanol, ethacrynic acid, octylparaben and salicylic acid, 
which still were not well predicted in spite of the adjustment for lipophilicity, were 
overestimated by a factor 5-10 (see Table 6-3). 
6.4.2 Prediction of absorption 
In EU risk assessment procedures, dermal absorption based on in vitro experiments is 
calculated by adding the amount that penetrated the skin to the amount present in the skin 
(yielding absorption). This is a worst case approach, since especially lipophilic substances 
can be retained in the stratum corneum and therefore may not become systemically 
available (see a.o. Buist et al., 2007). In analogy, predictions of dermal absorption for risk 
assessment purposes should take the skin reservoir into account. Calculating the amount 
present in the stratum corneum under steady state conditions can give an indication of the 
total amount present in the membrane at the end of the experiment. Therefore, we used 
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our finite dose absorption prediction model to calculate the amounts present in the 
receptor fluid and the stratum corneum and summed them in order to estimate absorption. 
This approach was tested in a series of in vitro experiments, in which epidermal membranes 
were exposed for 8 h to finite dose conditions. The kp and lag times to be used in the 
prediction of absorption were determined in parallel experiments under infinite conditions. 
Measured and predicted values of relative absorption are listed in Table 6-4 and depicted in 
Figure 6-6. A complete overview of all measured finite dose data is given in Table 6-5. 
For six substances the predicted absorption was not statistically different from the 
measured values. For all substances for which the predictions were statistically different 
from the measured values, absorption was overpredicted. Even so, most of these 
overpredictions were still below the European default absorption value for these substances 
(see Table 6-4). 
Table 6-2 Concentration dependence of kp for seven substances. 
Substance Concentration (mg mL
-
1) kp (10
-3 cm/h ± SD) % of maximum Spearman correlation 
Acetic acid 9.6 x 101 4.0 ± 2.1 100 ± 43 Good positive 
correlation (ρ = 0.86)  2.1 x 101 3.2 ± 1.3 79 ± 31 
 4.7 x 100 1.4 ± 0.4 34 ± 11 
 8.2 x 10-1 0.9 ± 0.1 21 ± 2 
 2.6 x 10-1 0.8 ± 0.1 21 ± 3 
Butoxyethanol 4.5 x 102 5.4 ± 1.5 65 ± 18 No correlation 
(ρ = 0.18)  9.0 x 101 8.4 ± 2.5 100 ± 30 
 1.8 x 101 4.4 ± 0.2 53 ± 2 
 3.6 x 100 5.0 ± 1.5 60 ± 18 
 1.0 x 100 5.2 ± 1.0 62 ± 12 
Decanol 7.4 x 10-1 12.5 ± 0.8 71 ± 5 No correlation 
(ρ = -0.27)  1.4 x 10-1 16.0 ± 4.1 91 ± 23 
 2.6 x 10-2 13.2 ±0.2 75 ± 33 
 4.2 x 10-3 17.6 ±0.03 100 ± 35 
2,4-Dichlorophenol 3.8 x 10-1 95.2 ± 5.5 100 ± 5 No correlation 
(ρ = 0.47) 5.1 x 10-2 57.2 ± 9.7 60 ± 10 
 2.7 x 10-3 70.6 ± 3.2 74 ± 3 
 5.2 x 10-4 66.1 ± 4.5 69 ± 5 
Octylparaben 1.0 x 10-1 12.3 ± 0.6 76 ± 4 No correlation 
(ρ = 0.25)  1.9 x 10-2 16.3 ± 4.8 100 ± 30 
 3.1 x 10-3 15.1 ± 1.1 93 ± 7 
 1.0 x 10-4 10.5 ± 2.0 64 ± 12 
Propylparaben 5.0 x 10-1 27.8 ± 4.0 100 ± 14 Moderate positive 
correlation (ρ = 0.73)  1.0 x 10-1 23.8 ± 3.0 86 ± 11 
 2.1 x 10-2 24.4 ± 3.2 88 ± 12 
 4.9 x 10-3 19.7 ± 2.5 71 ± 9 
 9.9 x 10-4 19.7 ± 2.0 71 ± 7 
Testosterone 2.1 x 10-2 11.1 ± 3.4 100 ± 31 No correlation 
 8.0 x 10-3 9.7 ± 2.2 87 ± 19 (ρ = 0.51) 
 5.8 x 10-3 9.4 ± 2.0 85 ± 18  
 1.7 x 10-3 8.6 ± 1.4 77 ± 12  
 6.1 x 10-4 7.8 ± 1.2 70 ± 10  
ρ = Spearman correlation coefficient. 
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For acetic acid, no good predictions could be made for concentrations other than the one 
used to determine kp. The reason for this was that its kp value increased considerably with 
increasing concentration (ca. a factor 5 over the investigated concentration range; see Table 
6-2). This concentration dependency was not observed to this extent with any of the other 
substances tested, and is probably related to the corrosive nature of acetic acid, causing a 
decrease in the barrier function of the skin. 
Table 6-4 Prediction of potential absorption in finite dose experiments with 15 substances. 
Substance 
(%) Potential absorption 
Measured Predicted EU defaultb 
Acetic acid 43 ± 18 19 ± 26 100 
Benzoic acid 48 ± 7 93 ± 4 100 
Butoxyethanol 45 ± 10 57 ± 25 100 
Cortisone 21 ± 7 27 ± 1 100 
Decanol 60 ± 6 98 ± 0 100 
Diazinone 73 ± 6 89 ± 1 100 
2,4-Dichlorophenol 90 ± 5 93 ± 14 100 
Ethacrynic acid 54 ± 17 66 ± 0 100 
Linolenic acid 55 ± 14 100 ± 0 100 
Octylparaben 76 ± 12 97 ± 0 100 
Oleic acid 60 ± 9 100 ± 0 100 
Bis(2-ethylhexyl) 
phthalate 82 ± 11 100 ± 0 100 
Propylparaben 90 ± 5 99 ± 0 100 
Salicylic acid 20 ± 1 17 ± 0 100 
Testosterone 63 ± 5 84 ± 4a 100 
Donor cell solution volume, 10 μL; exposed area, 0.64 cm
2; exposure time, 8 h.  
Bold no statistical difference between measured and predicted value (p >0.05 in two-tailed Kolomogov-
Smirnov test for two samples (α = 5%).  
a Predicted using measured KSC,W (Abraham et al., 1995).  
b 10% for substances with MW > 500 and log KOW <-1 or >4, otherwise 100% (EU, 2004). 
 
Table 6-5 Mass balance of finite dose experiments. 
Substance Concentration (mg mL-1) n 
% of applied dose ± SD 
Donor cell Membrane Receptor cell Potential absorptiona Recovery 
Acetic acid 1.0 x 102 4 52 ± 18 15 ± 3.8 27   ± 15 43 ± 18 95 ± 2.2 
Benzoic acid 3.3 x 101 4 49 ± 8.0 24 ± 1.8 24   ± 5.8 48 ± 7.5 98 ± 0.8 
Bis(2-ethylhexyl) 
phthalate 2.5 x 10
-3 4 24 ± 4.4 77 ± 9.4 4.4   ± 2.5 82 ± 11 105 ± 11 
Butoxyethanol 4.5 x 102 4 55 ± 13 10 ± 1.3 35   ± 10 45 ± 10 100 ± 3.9 
Cortisone 2.2 x 10-2 4 78 ± 6.3 21 ± 6.8 0.6   ± 0.2 21 ± 7.0 99 ± 1.5 
Decanol 2.5 x 100 4 37 ± 7.9 29 ± 5.7 32   ± 1.6 60 ± 5.6 97 ± 7.4 
Diazinone 1.7 x 10-2 4 27 ± 3.2 53 ± 7.7 20   ± 4.0 73 ± 6.4 100 ± 5.2 
2,4-Dichlorophenol 3.7 x 10-1 3 15 ± 3.0 24 ± 2.4 66   ± 3.9 90 ± 5.0 104 ± 2.6 
Ethacrynic acid 1.1 x 10-2 3 33 ± 24 52 ± 17 1.1   ± 0.4 54 ± 17 89 ± 13 
Linolenic acid 1.1 x 10-2 4 41 ± 13 48 ± 15 7.4   ± 2.8 55 ± 14 96 ± 3.8 
Octylparaben 8.9 x 10-2 4 33 ± 8.3 58 ± 10 18   ± 3.9 76 ± 12 109 ± 12 
Oleic acid 1.1 x 10-2 4 36 ± 6.7 59 ± 9.1 1.2   ± 0.3 60 ± 9.3 96 ± 5.2 
Propylparaben 5.0 x 10-1 4 10 ± 3.8 26 ± 3.8 64   ± 6.9 90 ± 4.8 100 ± 1.2 
Salicylic acid 3.6 x 10-1 4 80 ± 3.3 16 ± 1.6 4.3   ± 0.8 20 ± 1.3 100 ± 3.7 
Testosterone 2.6 x 10-2 4 36 ± 7.4 22 ± 2.2 42   ± 4.0 63 ± 5.5 100 ± 2.2 
Donor cell solution volume, 10 μL; exposed area, 0.64 cm2; exposure time, 8 h.  
a Sum of relative amounts recovered from the skin membrane and the receptor cell. 
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The only other compounds classified by the EU as irritating (butoxyethanol) or corrosive 
(2,4-dichlorophenol) tested positive as pure undiluted substances (see Table 6-3). A 50% 
dilution of butoxyethanol in polyethylene glycol tested negative for skin irritancy, therefore 
the tested aqueous concentrations of this substance (up to 450 mg mL-1) are probably not 
skin irritating. 
In the skin irritation study used by the EU for 2,4-dichlorophenol, no dilutions were tested. 
The highest concentration of 2,4-dichlorophenol used in this paper (0.38 mg mL-1) showed a 
statistically significantly higher permeability coefficient than the other three concentrations 
(using ANOVA with Tukey correction for multicomparison). However, the increase compared 
to the other concentrations was small: ca. a factor 1.5. Concluding, these classified 
substances were probably not tested at skin damaging concentrations. 
For our predictions we used QSARs to estimate the KSC,W, a parameter necessary to calculate 
the impact of distribution into the stratum corneum. These are based on limited datasets: 
Hui et al. (1995) used seven lipophilic substances (five pesticides, one steroid hormone and 
aminopyrine) and five hydrophilic substances (dopamine, glycine, urea, glyphosate and 
theophylline), whilst Abraham et al. (1995) used a dataset of eight aliphatic alcohols (C1-C8) 
and 14 steroid hormones. Judging by their log KOW and MW, the substances tested in this 
study are inside or at least close to the applicability domain of these QSARs. However, for 
wider application of our method, the QSARs for KSC,W should be based on a larger and more 
varied dataset. Alternatively, KSC,W could be determined experimentally in vitro, as described 
by Hui et al. (1995) and Abraham et al. (1995). These QSARs do not take into account 
possible molecular interaction (e.g., binding, adsorption) between substances and the 
stratum corneum. For substances that have a great tendency to do so, this may lead to an 
underestimation of the amount associated with the stratum corneum. On the other hand, 
such substances will not easily migrate from the stratum corneum to the viable epidermis 
and from there, eventually, to the receptor fluid (which represents systemic circulation in 
the in vivo situation). As the reason for including the skin reservoir in the estimation of 
dermal absorption is the fact that it may migrate into the receptor fluid, neglecting these 
strong interactions may not lead to a serious underestimation of dermal absorption. This is 
illustrated by the example of DDAC, which shows a strong association with the stratum 
corneum, but hardly penetrates into the receptor fluid (Buist et al., 2007). 
Another critical parameter in our calculations is the thickness of the stratum corneum. We 
used a value of 0.002 cm, determined by Xiao and Imhof (1997) for the thickness of the 
stratum corneum of the volar side of the fore-arm. In order to test the influence of stratum 
corneum thickness on our prediction model, we executed the calculations with different 
thicknesses of the stratum corneum. Only in 3 out of 15 cases notable differences were 
observed between the predicted absorption values: in these cases, when assuming a 4x 
thicker stratum corneum, absorption was ca. twice as high (data not shown). Therefore, our 
model does not seem very sensitive to changes in stratum corneum thickness. 
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Our prediction method uses experimentally derived values for kp and lag time. However, 
these values could in principle also be obtained by using QSARs for the determination of 
KSC,W and kp. The lag time may be calculated using the fixed relationship between lag time 
(tlag), KSC,W, kp for the stratum corneum (kpSC) and thickness of the stratum corneum (LSC), 
derived by Shah et al. (1994): tlag = KSC,W × LSC/6kpSC. However, the predictive power of the 
tested QSPRs for kp does not seem very high, at least not for our data set, although their 
performance improves when adjusted for lipophilicity according to the method of Cleek and 
Bunge (1993; see Table 6-3). Poor performance of QSPRs for kp has also been observed for 
other data sets (Bouwman et al., 2008). Furthermore, the relationship of Shah et al. (1994) 
did not hold very well under the assumptions and simplifications we used: stratum corneum 
is rate limiting and a homogeneous barrier, neglecting the concentration gradient inside 
stratum corneum (data not shown). Therefore, at present, our prediction is insufficiently 
valid when using QSPR data only, and needs experimentally derived values for kp and lag 
time. 
Often very diverse scenarios need to be evaluated for regulatory risk assessment purposes. 
Therefore, our method provides an advantage for risk assessment, as one only has to 
determine kp and lag time under conditions of infinite dose to be able to calculate (relative) 
dermal absorption for a whole range of exposure scenarios, differing in exposure time, 
exposure concentration, dermal loading and exposed skin area. This eliminates the need to 
perform many dermal absorption experiments under different exposure conditions. 
Furthermore, the method can be used to more easily analyse which changes in, e.g., 
operational procedures may lead to a safe use scenario. 
 
Figure 6-6 Prediction of finite dose absorption. 
Predictions using kp and lag time measured under infinite dose conditions, with correction for distribution into 
the stratum corneum. The solid line represents the perfect prediction. 
 Conclusions 6.5
Our finite dose prediction model provides a tool to estimate dermal absorption for many 
different (finite) exposure scenarios, using kp and lag time measured under infinite dose 
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conditions and a QSAR for the stratum corneum/water partition coefficient (KSC,W). The 
model predicted values which were either not statistically different from measured in vitro 
values or overestimated them. Overestimated values still were most often less conservative 
than the default European approach. Therefore, our model provides a useful and cost-
effective estimate of dermal absorption, to be used in risk assessment for non-volatile 
substances dissolved in water at non-irritating13 concentrations. 
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 Glossary (including abbreviations) 6.7
ABSQon a molecular descriptor: the sum of absolute charges on the oxygen and 
nitrogen atoms in a molecule 
Corrosive to skin: capable of full-thickness destruction of skin tissue  
DDAC didecyldimethylammonium chloride 
Default 
absorption 
values 
absorption values used in absence of measured or predicted data 
Dermal 
absorption 
value 
in in vitro dermal absorption experiments: the amount of substance that 
has penetrated the skin plus the amount still present in the skin 
preparation 
Descriptor in this article: short for molecular descriptor = a specific characteristic of 
molecular structures, which can be expressed in a numeric value  
Donor 
compartment 
part of the diffusion cell positioned on the outside of the skin 
preparation to which the exposure solution is added  
Epidermal 
membrane 
Skin preparation consisting of stratum corneum and epidermis 
f amount of penetrant in the donor compartment divided by the sum of 
the amounts in the donor compartment and the stratum corneum  
Finite dose applied amount of donor solution for which of the concentration of the 
penetrant significantly decreases during dermal exposure  
Flux amount of penetrant that crosses the skin per unit of time and unit of 
exposed skin area, often expressed in mg/cm2/h 
In silico calculated or predicted by computer (analogous to in vitro and in vivo)  
Infinite dose applied amount of donor solution for which of the concentration of the 
penetrant remains (more or less) constant during dermal exposure 
Irritating to skin: causing significant inflammation of the skin  
KOW octanol/water partition coefficient 
kp permeation or permeability constant, often expressed in cm/h  
KSC,W stratum corneum/water partition coefficient 
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Lag time the time intercept for penetration equal to zero of the linear portion of 
the cumulative penetration versus time graph (see Figure 6-2) 
Limit value regulatory exposure value which should not be exceeded  
Log KOW 10-base logarithm of the octanol/water partition coefficient, also known 
as log P 
Mulliken 
charges 
Mulliken charges arise from the Mulliken population analysis and 
provide a means of estimating partial atomic charges from calculations 
carried out by computational chemistry packages like Gaussian 03. 
MW molecular weight 
Occluded in in vitro dermal absorption experiments: donor compartment covered 
in such a way that no evaporation of solvent can take place  
Penetrant in in vitro dermal absorption experiments: the substance of which the 
absorption value or kp is being determined  
Penetration in in vitro dermal absorption experiments: the crossing of the skin into 
the receptor compartment 
Permeability 
coefficient 
constant describing the permeability of a specific skin preparation for a 
specific molecule dissolved in water, usually expressed in cm/h 
QSAR Quantitative Structure-Activity Relationship 
REACH Registration, Evaluation Authorisation and restriction of CHemicals  
Receptor 
compartment 
part of the diffusion cell positioned on the inside of the skin preparation, 
filled with liquid in which the investigated chemical penetrates if the skin 
is permeable to it (and a concentration gradient is maintained across the 
skin). 
Skin reservoir amount of penetrant still present in the skin after cessation of exposure 
SsssCH a molecular descriptor: the sum of E-state indices for all methyl groups in 
a molecule 
Static diffusion 
cell 
apparatus to determine in vitro dermal absorption from which the liquid 
in the receptor compartment is not continuously refreshed, but only 
after specific time intervals 
Steady state in in vitro dermal absorption experiments: conditions under which 
penetration into the receptor fluid occurs at a constant rate  
Stratum 
corneum 
non-viable upper layer of the skin  
Systemic 
effects 
effects that occur if and when substances enter systemic circulation 
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 Introduction 7.1
Given the possible importance of the dermal exposure route, the state-of-the-art of models 
to estimate dermal absorption and the many factors influencing the efficiency of this 
exposure route outlined in chapter 1, the objective of this thesis was to further develop, 
evaluate and improve methods for including dermal absorption data in toxicological risk 
assessment. 
Adequate quantification of dermal absorption is an essential step in reducing the 
uncertainty of dermal risk assessment and essential to avoid unrealistic worst case 
assumptions. Many factors influence the rate of dermal absorption of a substance. In this 
thesis, four of these factors were investigated in more detail, i.e. dermal loading (chapter 2), 
irritative/corrosive potential (chapters 3 and 4), frequency of exposure (chapters 3-5), and 
the formulation used (chapter 5). To conclude, in chapter 6 of this thesis a model to 
extrapolate infinite dose absorption data to finite dose conditions, tentatively called Dermal 
Absorption Model for Extrapolation (DAME), was developed and tested. In the following 
sections the investigations described and discussed in chapters 2 to 6 will be put into 
perspective, the pitfalls and promises for toxicological risk assessment emerging from them 
will be discussed, future perspectives will be presented and general conclusions will be 
drawn. 
 Dermal loading and absorption 7.2
In regulatory risk assessment it is common practice to use relative dermal absorption 
determined at a specific dermal loading (amount of chemical per unit skin surface) to 
calculate internal exposure. In chapter 2 of this thesis, the relationship between dermal 
loading and relative absorption (e.g. expressed as percentage of the applied dose) was 
investigated using published data. Nearly two-thirds of the evaluated in vitro and in vivo 
absorption experiments showed an inverse relationship between dermal loading and 
relative absorption. It should be noted that in absolute terms dermal absorption still may 
increase with dermal loading. However, the focus was on relative dermal absorption (often 
expressed as percentage of the applied dose) as this is a measure frequently reported and 
used in toxicological risk assessment. 
A likely explanation for the inverse relationship between dermal loading and relative dermal 
absorption may be that in many cases the range of loadings tested represented (nearly) 
infinite dose conditions, meaning that the amount of chemical applied on the skin does not 
significantly decrease by the disappearance of chemical from the skin through the process 
of absorption. Under infinite conditions the amount of absorption is flux-limited, and under 
finite conditions the amount of absorption is delivery-limited, i.e. dependent on dermal 
loading. When absorption is flux-limited, the amount absorbed per unit time will be 
constant, irrespective of the dermal loading, meaning relative absorption will decrease with 
increasing dermal loading under these conditions.  
 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 145 
Kissel et al. (2011) have introduced the fraction Nderm to assess whether dose conditions are 
de facto infinite. For experimental exposures, Nderm is defined as the applied dermal load 
divided by the product of the maximum flux (Jmax) and the exposure time: 
Nderm= 
Dermal load (mg cm2⁄ )
Jmax (mg cm2⁄ h) ⁄ × exposure time (h)
 . Conditions of maximum flux are reached when the skin 
is exposed to saturated solutions of a chemical. Nderm was later redefined by Frasch et al. 
(2014) as dermal load divided by the product of steady state flux (JSS) and exposure time: 
Nderm= 
Dermal load (mg cm2⁄ )
JSS (mg cm2⁄ h) ⁄ × exposure time (h)
 . Steady state flux is the constant in vitro flux of a chemical 
across the skin preparation that is reached under (nearly) infinite dose conditions. Using this 
definition, Nderm is also applicable to dermal exposure to dilute solutions, which is more 
common. Infinite dose conditions are by definition, conditions under which the applied 
concentration of the chemical on the skin does not change noticeably, and the flux of the 
chemical is constant, determining the total amount of chemical being absorbed during the 
time exposure continues, in other words, the absorption is limited by the rate (flux) with 
which the chemical crosses the skin barrier, and will not increase when more chemical is 
added to the skin. By consequence, Nderm will be high as the amount that disappears from 
the dermal load is negligible compared to the load present, and a high Nderm is an indication 
of flux-limited absorption. In these circumstances, relative absorption is a meaningless 
figure, as the rate of absorption is independent of the applied dose. By definition, under 
finite dose conditions the concentration of the chemical on the skin will decrease due to 
absorption and the rate of absorption will decrease over time: Nderm will be low. In this case, 
absorption is delivery-limited as increasing the amount of chemical on the skin will increase 
the rate of absorption.  
Frasch et al. (2014) have reanalysed the data described in chapter 2, Table 2-1, by plotting 
Nderm calculated by them, against the measured percentage absorption reported in Table 
2-1. They found a distinctive decrease of percentage absorption with increasing Nderm, 
although a clear cut-off value between delivery- and flux-limited absorption was not found. 
Unfortunately, Nderm can only be calculated when measured values like kp, JSS or Jmax are 
available, since the predictive performance of Quantitative Structure-Permeability 
Relationships (QSPRs) for these variables is not good enough to be relied upon (section 
1.1.4.6.2). Therefore, Nderm is above all useful for the evaluation of (in vitro) dermal 
absorption experiments (Frasch et al., 2014). 
When in the studies evaluated in this thesis an inverse relation between relative absorption 
and dermal loading was observed, relative dermal absorption at low dermal loading could 
be up to a factor 100 higher than at high dermal loading. Therefore, a pitfall in risk 
assessment is to calculate internal exposure with relative absorption data determined at a 
dermal loading not representative for the actual loading, which may lead to an incorrect 
assessment of human systemic exposure and its resulting health risk. This is illustrated in 
Figure 2-1 (page 52), which depicts a generalized example of an inverse relation between 
dermal loading and relative absorption. It demonstrates that using a relative absorption 
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value derived from a high dermal loading will lead to an underestimation of systemic 
absorption at low dermal loading. Therefore, dermal absorption data should be derived as 
much as possible under exposure conditions reflecting the scenario to be evaluated or be 
extrapolated to these conditions, e.g. by using a model like DAME (section 7.6). 
 Skin irritants/corrosives and absorption 7.3
Skin irritants have been subject of discussion in chapters 2 to 6 of this thesis, and are 
substances that may cause reversible damage of the skin following their application for up 
to 4 hours, while corrosives may cause irreversible damage to the skin, all the way down to 
the dermis (OECD, 2015). These local effects are concentration driven, and substances that 
are corrosive at high concentrations may be merely irritants at intermediate concentrations 
or may cause no local effects at all at low concentrations. Hence, concentration limits have 
been established for this type of local toxicants under the Globally Harmonized System of 
Classification and Labelling of Chemicals (GHS) (UN, 2015). As an example, aqueous 
solutions of HCl with a concentration ≥25% (w/w) are classified as “skin corrosive”, when 
the HCl-concentration is ≥10% but <25%, the solution is classified as “skin irritant” and 
solutions with a concentration <10% are not classified with respect to this local toxic 
property14. 
It is generally assumed that skin corrosives and irritants may decrease the barrier function 
of the skin and hence increase its permeability (EFSA, 2011; WHO, 2006). In various 
instances, this is supported by the results of our investigations. Classified skin irritants less 
often show an inverse effect between dermal loading and absorption: 46% against 83% of 
the positively identified non-irritants (Table 2-3C, page 64). This may be explained by the 
assumption that the decrease of relative absorption with increasing dermal loading is offset 
by an increase in absorption due to the rising skin permeability if dermal loading is increased 
by raising the concentration of the skin irritating chemical. 
Also the experimental research presented in this thesis (described in chapters 4 to 6) 
showed results indicative of altered, mostly decreased, barrier function by skin 
irritants/corrosives. Table 7-1 shows an overview of the classification for skin 
irritation/corrosion of the chemicals used in the experiments described in this thesis. The 
classification has been updated in 2015, as, since the REACH-regulation entered into force in 
the EU on 1 June 2007 (EU, 2006), many additional data have become publicly available 
through the ECHA-website (http://echa.europa.eu). 
                                                     
14 http://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/cl-inventory/view-notification-
summary/105223 
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Table 7-1 ECHA classifications for skin corrosion/irritation of the substances tested in this thesis for influence 
on skin permeability 
Name CASRN Classification ECHAa 
Harmo-
nisedb Remark Experiments in thesis 
ADBAC 8001-54-5 Skin Corr. 1B No  
[3H]H2O and 
[14C]propoxur permeabil-
ity (chapter 4) 
Boric acid 10043-35-3 
conclusive but not 
sufficient for classifica-
tion  
Yes 
study in ECHA 
registration 
dossier 
[3H]H2O and 
[14C]propoxur permeabil-
ity (chapter 4) 
DDAC 7173-51-5 Skin Corr. 1B  Yes  
[3H]H2O and 
[14C]propoxur permeabil-
ity (chapter 4) 
Deltamethrin 52918-63-5 No data  Yes no ECHA regis-tration dossier 
[3H]H2O and 
[14C]propoxur permeabil-
ity (chapter 4) 
Permethrin 52645-53-1 No data  Yes no ECHA regis-tration dossier 
[3H]H2O and 
[14C]propoxur permeabil-
ity (chapter 4) 
Piperonyl 
butoxide 51-03-6 
conclusive but not 
sufficient for classifica-
tion  
No study in regis-tration dossier 
[3H]H2O and 
[14C]propoxur permeabil-
ity (chapter 4) 
Sodium bro-
mide 7647-15-6 
conclusive but not 
sufficient for classifica-
tion  
No 
study in ECHA 
registration 
dossier 
[3H]H2O and 
[14C]propoxur permeabil-
ity (chapter 4) 
Tebuconazole 107534-96-3 No data  Yes no ECHA regis-tration dossier 
[3H]H2O and 
[14C]propoxur permeabil-
ity (chapter 4) 
Formaldehyde 50-00-0 
Skin Corr. 1B: C ≥ 25% 
Skin Irrit. 2: 5% ≤ C < 
25% 
Yes  
[3H]H2O and 
[14C]propoxur permeabil-
ity (chapter 4) 
influence on DDAC 
dermatokinetics (chap-
ter 5) 
Glutaraldehyde 111-30-8 
Skin Corr. 1B: C ≥ 10%  
Skin Irrit. 2 : 0.5% ≤ C < 
10% 
Yes  
influence on DDAC 
dermatokinetics (chap-
ter 5) 
2,4-Dichloro-
phenol 120-83-2 Skin Corr. 1B  Yes 
tested with 
undiluted pure 
substance and 
as an 80% solu-
tion in water 
concentration depend-
ency of kp (chapter 6) 
Acetic acid 64-19-7 
Skin Corr. 1A: C ≥ 90%  
Skin Corr. 1B: 25% ≤ C 
< 90% 
Skin Irrit. 2: 10% ≤ C < 
25% 
Yes  
concentration depend-
ency of kp (chapter 6) 
Butoxyethanol 111-76-2 Skin Irrit. 2  Yes 
pure substance, 
50% solution in 
PEG not irritat-
ing, not in ECHA 
registration 
dossier.  
concentration depend-
ency of kp (chapter 6) 
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Table 7-1 continued 
Name CASRN Classification ECHAa Harmo-nisedb Remark Experiments in thesis 
Decanol 112-30-1 / 36729-58-5 
Skin Irrit. 2 / conclu-
sive but not sufficient 
for classification  
No 
pure substance, 
5 adequate 
studies in REACH 
registration 
dossier: 4 nega-
tive, 1 positive 
(all borderline) 
concentration depend-
ency of kp (chapter 6) 
Octylparaben 1219-38-1 Skin Irrit. 2  No 
One other entry: 
no classification 
due to lack of 
data; no ECHA 
registration 
dossier 
concentration depend-
ency of kp (chapter 6) 
Propylparaben 94-13-3 
conclusive but not 
sufficient for classifica-
tion  
No 
ECHA registra-
tion dossier: 
propylparaben 
tested in hydro-
philic ointment 
and read-across 
to pure ethyl- 
and 
methylparaben 
tested as pow-
ders. 
concentration depend-
ency of kp (chapter 6) 
Testosterone 58-22-0 
conclusive but not 
sufficient for classifica-
tion  
No 
ECHA registra-
tion dossier: 
based on read-
across to an-
drost-4-ene-
3,17-dione 
concentration depend-
ency of kp (chapter 6) 
% = concentration in % (w/w); C = concentration; CASRN = Chemical Association Substance Registry Number; 
Corr. = corrosive; Irrit. = irritative 
a 
1A = Corrosive responses in at least one animal following exposure ≤ 3 min during an observation period ≤ 1 h; 
1B = Corrosive responses in at least one animal following exposure > 3 min and ≤ 1 h and observations ≤14 
days; 2 = Irritative responses in 2 out of 3 animals (or in 1 out of 3 if clearly positive and pronounced variability 
between animals exists); conclusive but not sufficient for classification = not corrosive/irritative to skin, based 
on adequate data. 
b Substances have a harmonized classification when included in Part 3 of Annex VI to Regulation (EC) No 
1272/2008 on the classification, labelling and packaging of substances and mixtures (CLP). Part of the harmo-
nization procedure is evaluation by experts of the EU member states. 
In the skin permeability assays with biocidal active substances presented in chapter 4 of this 
thesis, two out of three substances classified for skin corrosion/irritancy, the quaternary 
ammonium chloride compounds didecyldimethylammonium chloride (DDAC) and 
alkyldimethylbenzylammonium chloride (ADBAC), caused a clear concentration-dependent 
increase in skin permeability for [14C]propoxur and tritiated water, both after single and 
repeated application. The third corrosive compound tested, formaldehyde, did not show 
such an effect, but showed a tendency to decrease skin permeability for [14C]propoxur and 
tritiated water, although not in a statistically significant manner. This effect observed for 
formaldehyde was confirmed by the experiments carried out with different biocidal 
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formulations of DDAC, some of which contained aldehydes (chapter 5). These formulations 
tended to reduce DDAC dermal absorption as compared to pure water as a vehicle (Figure 
7-1). A possible explanation for this phenomenon is the ability of formaldehyde and 
glutaraldehyde to crosslink proteins (Usha and Ramasami 2005). Crosslinking of proteins, 
such as keratins, in the stratum corneum could turn the skin less permeable. This is 
corroborated by our observation that the digestion of skin preparations15 exposed to MS 
Macrodes, the  commercial biocidal formulation used with the highest concentration of 
aldehydes, took more time than the digestion of skin preparations exposed to one of the 
other formulations.  
 
 
Figure 7-1 Relative flux of DDAC across the skin versus the aldehyde concentration in the formulations 
used 
The flux is expressed relative to the flux of the same amount of DDAC dissolved in propanol/water instead of 
formulation. Data from Table 5-6 of chapter 5. 
In principle, the permeation constant kp is independent of the concentration of the chemical 
(Equation 1-2, page 30), provided the chemical does not influence the skin barrier. 
Therefore, for compounds that do change skin permeability in a concentration related 
manner, the kp values should depend on their concentration. Indeed, the corrosive/irritative 
potency of the tested substances and the degree to which their kp-value is influenced by 
their concentration, does show a positive correlation between the corrosion/irritation 
potency and skin permeability (R = 0.76, Table 7-2). 
Concluding, by and large our results confirm the influence of skin corrosives/irritants on skin 
permeability. This influence does not necessarily imply an increase in permeability, as is 
illustrated by the permeability decreasing effect of two corrosive aldehydes, formaldehyde 
and glutaraldehyde. It should be noticed that skin corrosion or irritation is not only 
determined by the chemical nature of the substances the skin is exposed to, but also by 
their concentration, meaning that even a corrosive substance like acetic acid may not 
increase skin permeability, provided its concentration is sufficiently low. A distinct pitfall in 
                                                     
15 This digestion was performed in order to analyse the DDAC concentration in the skin preparations. 
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the case of skin corrosives/irritants is to assume that their kp is independent of 
concentration and extrapolate absorption values obtained at one concentration to another, 
as can be done with substances that do not influence skin permeability. Therefore, skin 
absorption data to be used in risk assessment of substances classified for skin corrosion/ 
irritation should be obtained at exposure concentrations representative of the exposure 
scenarios to be evaluated. 
Table 7-2 Relation between corrosion/irritation potency and concentration dependence of kp. 
Substance Corrosion/Irritation potencya Degree of concentration dependence of kp
b  
2,4-Dichlorophenol 2 1  
Acetic acid 3 2  
Butoxyethanol 0.5 0  
Decanol 0.5 0  
Octylparaben 1 0  
Propylparaben 0 1  
Testosterone 0 0  
Correlation (Pearson)  R = 0.76  
a Based on the following grading of highest classification of a substance: corrosive 1A = 3; corrosive 1B = 2; 
irritant 2 = 1; borderline irritant 2 = 0.5. The classifications are listed in Table 7-1 (page 147). 
b Based on the following grading of the concentration dependence: 2 = good correlation between kp and con-
centration; 1 = moderate correlation or statistically significant difference between kp at highest concentra-
tion and lower concentrations; 0 = no influence of concentration on kp. The concentration dependencies are 
listed in Table 6-2 (page 134). 
c The Pearson correlation between corrosion/irritation potency and degree of concentration dependence was 
calculated using the “CORREL” function of MS-Excel from MS-Office Professional Plus 2010. 
 Repeated dermal exposure and absorption 7.4
In chapters 3 to 5 of this thesis the effect of repeated dermal exposure on absorption was 
investigated. The OECD guidelines on in vivo and in vitro dermal absorption studies (OECD 
2004a, OECD 2004b) are not explicit on whether single or repeated exposure should be 
investigated. However, common practice is that dermal absorption studies submitted within 
the EU regulatory frameworks are restricted to single exposure, while in practice dermal 
exposure of workers and consumers may be repeated in nature, e.g. in professional cleaning 
and in use of cosmetics.  
A literature search presented in chapter 3, revealed that repeated dermal exposure often 
has a cumulative effect on daily systemic absorption, although less than would be expected 
based on addition of daily doses. The magnitude of this effect cannot be exactly predicted 
based on dermal absorption data alone since it will depend on the net effect of absorption, 
distribution, metabolism and excretion. However, it is a potential pitfall in dermal route 
toxicological risk assessment, since the use of single exposure dermal absorption data may 
lead to underestimation of systemic exposure, and consequently of the risk associated with 
it.  
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In various guidelines for dermal absorption the amount retained in the skin after cessation 
of exposure is considered to be (potentially) absorbed (EFSA, 2012; OECD, 2004a; USEPA, 
2007). This may, at least partly, compensate for cumulative effects of repeated exposure. 
For instance, this is the case for repeated dermal exposure to DDAC : After single in vitro 
dermal exposure, the amount present in the skin (excluding tape strips) is approx. 15 μg 
while after three exposures only approximately 3 μg has fully penetrated into the receptor 
fluid (equivalent of systemic circulation, see Figure 5-4, page 118). Consequently, in this 
example, including the skin reservoir after single exposure in the dermal absorption value, 
as demanded by the cited guidelines, would prevent an underestimation of systemic 
exposure after repeated exposure, and ultimately an underestimation of the risk. It also 
shows that, certainly for a reservoir forming substance like DDAC, systemic absorption may 
be considerably overestimated by including the skin reservoir in the absorption estimation. 
Furthermore, the ratio of the amount of chemical encountered in the skin preparation and 
the amount of chemical encountered in the receptor fluid in finite dose experiments 
indicates that including the amount retained in the skin in the dermally absorbed dose 
would compensate for the cumulative effects of repeated dermal exposure for at least half 
of the chemicals (Figure 7-2), when assuming accumulation of doses by repeated exposure 
will increase daily systemic absorption with a factor 1 to 5 (based on the data depicted in 
Figure 3-1, page 77). Probably, the chemicals in Figure 7-2 showing a lower ratio are also the 
substances with a smaller cumulative effect, since the skin reservoir is the source of the 
cumulation. However, more consistent and complete data are needed to reach a definitive 
conclusion.  
 
Figure 7-2 Ratio chemical retained in skin and receptor fluid in finite dose absorption experiments 
Data taken from Table 6-5, page 136. 
Furthermore, in vitro skin permeability experiments with a number of biocides indicated 
that repeated exposure to high concentrations of corrosive substances like quaternary 
ammonium chlorides may increase skin permeability more than single exposure (chapter 4). 
The degree of increase after three times repeated exposure compared to single exposure 
was approximately a factor 1.2 to 3 (Table 4-4, page 103). Non-corrosives/irritants do not 
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seem to influence skin permeability to a higher degree after repeated exposure, if at all. 
More data on the effects of other corrosive, irritant and non-irritant substances are needed 
to obtain a more general picture on the influence of repeated exposure to these categories 
of substances.  
Since from these few results it appears that only high concentrations of corrosive 
substances may (further) increase skin permeability after repeated exposure, its practical 
relevance could be low, as only professional users may be expected to be repeatedly 
exposed to high concentrations of corrosives for prolonged times, and they will be likely to 
wear protective clothing.  
 Formulations and absorption 7.5
As already indicated in chapter 1, the vehicle in which the chemical is applied to the skin 
may influence its absorption. This was investigated in some more detail in chapter 5 of the 
thesis. In case a vehicle is a more or less complex mixture designed for a specific purpose 
(e.g. pest control, drug delivery), it is called a formulation. In principle, when a vehicle does 
not alter skin permeability or enhances the solubility of the chemical in the skin, the 
permeation constant, kp, of a chemical in a specific vehicle can be derived from its 
saturation concentration in that vehicle and its maximum flux, Jmax, in another vehicle, e.g. 
water. This follows from Equation 1-1 (Fick’s first law) and Equation 1-2 (relation between 
permeation constant and partition coefficient, diffusivity and diffusion path) (page 16 and 
30, respectively). Adapting Equation 1-1 to obtain Jmax (expressed per unit skin area) yields: 
Jmax = Cveh, sat × kp,veh  Equation 7-1 Calculating Jmax 
in which  
Jmax = maximum mass flux across the membrane in mg/h, 
Cveh, sat = the saturation concentration of the substance in the vehicle in mg/cm3, and  
kp, veh  = permeation constant for a specific vehicle in cm/h  
Filling out the result of Equation 1-3 for kp (kp = KSC/veh x DSC/LSC) in Equation 7-1 gives: 
As by definition KSC/veh = CSC, sat / Cveh, sat, Jmax is given by: 
Since all the independent variables in Equation 7-2 are constants for a given chemical and 
skin preparation, the Jmax of a chemical is the same for every vehicle. This is illustrated by 
Jmax = Cveh, sat x KSC/veh x DSC/LSC   
in which 
KSC/veh  = vehicle/stratum corneum partition coefficient (unitless)  
DSC  = diffusivity of the penetrant in the stratum corneum in cm2/h  
LSC  = length of the diffusion pathway through the stratum corneum in cm  
Jmax = CSC, sat x DSC/LSC  Equation 7-2 Jmax determined by constants 
in which 
CSC, sat = the saturation concentration of the substance in the stratum corneum in mg/cm3 
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Guy (2010), who used the constancy of Jmax (determined in aqueous solutions) to predict the 
absorption under infinite dose conditions of 14 fragrances from formulations in which they 
were (assumed to be) dissolved to saturation. With two exceptions, his predictions were 
within one order of magnitude of the experimentally derived values; most of them overesti-
mating the experimental values (Figure 7-3). Therefore, extrapolation of dermal absorption 
of a chemical from one formulation to another on the basis of measured Jmax and saturation 
concentration of the chemical in the formulation would seem a viable approach. 
The pitfall of this approach is that vehicles indeed may change skin permeability and the 
solubility of the chemical in the skin, as pointed out in chapter 1 (section 1.1.5.1, pages 33 to 
36) and as illustrated by the skin permeability changing corrosive substances discussed in 
section 7.3. Instead of enhancing absorption, some formulations may also limit absorption, 
e.g. when they contain aldehydes (as observed in chapters 4 and 5 of this thesis).  
In short, there are various ways in which a vehicle may influence dermal absorption of 
chemicals and thus violate the condition under which the kp derived for one vehicle can be 
extrapolated to another using Jmax and its saturation concentration in the vehicle of interest. 
This perhaps explains why QSPRs developed to predict dermal absorption from different 
mixtures have not been very successful (section 1.1.4.6.2, page 25). Therefore, measuring 
dermal absorption of chemicals using the vehicles/formulations in which they will be 
exposed to the skin, is at present the only viable option, unless one can be certain the 
vehicles will not alter the skin’s properties. 
 Prediction of dermal absorption for risk assessment 7.6
In chapter 6 of this thesis a Dermal Absorption Model for Extrapolation (DAME) was 
 
Figure 7-3 Ratios of measured and predicted absorption for 14 fragrances, plotted against log KOW  
Data derived from Guy (2010). Most fragrances were tested under one set of exposure conditions (that is a 
single combination of quantity, exposed area and exposure time) (triangles), while some were tested under 
two different sets of conditions (bullets). (Two bullets at the same log KOW represent one fragrance) 
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introduced. DAME basically models the Franz diffusion cell (Figure 1-2, page 18) and predicts 
in vitro dermal absorption from aqueous solutions, defined as the sum of the amounts of a 
chemical encountered in the epidermis and the receptor fluid. The Franz cell dimensions 
represented in DAME are the donor cell volume, that is the amount of liquid applied to the 
skin, and the exposed skin area, set at 1 cm2. Finite testing conditions typically concern 
volumes of up to 10 µL/cm2 (OECD, 2004b), while a maximum capacity of the donor cell of 
500-1000 µL/cm2 usually represent infinite dose conditions. Chemical-specific inputs needed 
by DAME are the measured permeation constant (kp), lag time and stratum corneum/water 
partition coefficient (KSC,W). The permeation constant and lag time should be measured in an 
infinite dose in vitro absorption experiment. Usually, a measured KSC,W is not available, in 
which case the model uses a QSAR to calculate it. For this QSAR two additional chemical-
specific parameters are needed: its MW and log KOW.  
In comparison with in vivo dermal absorption, in vitro dermal absorption experiments cost 
less time and money to perform, can be characterised by just a few parameters and may be 
executed with human skin, while in the EU human in vivo data, even if obtained in an 
ethically sound way, are not allowed to be used (EFSA, 2012). This means it is easier to 
construct and validate an in silico model for in vitro than for in vivo absorption via human 
skin. Furthermore, in vitro data correlate well with in vivo data (Godin and Touitou, 2007; 
Jakasa and Kezic, 2008), and the in vitro dermal absorption test with human skin is the 
experimental method preferred by the European Food Safety Authority (EFSA, 2012). Still, 
building in silico models on in vitro data introduces an additional uncertainty in the 
outcome, since in the end it is the in vivo situation one wants to assess. However, since in 
general, in vitro dermal absorption overestimates in vivo dermal absorption, one would err 
on the safe site, since a higher dermal absorption is assumed than will be reached in vivo. 
Since the publication of our DAME model, presented in chapter 6 of the thesis, the US 
Centers for Disease Control and Prevention (CDC) have made the Finite Dose Skin 
Permeation (FDSP) model available on the internet16. This model was developed by 
Fedorowicz et al. (2011) and published in peer-reviewed literature (Dancik et al., 2013; 
Kasting and Miller, 2006; Kasting et al., 2008; Miller and Kasting, 2010; Wang et al., 2007). 
Besides predicting skin permeation under finite conditions, this FDSP model also facilitates 
predictions based on measured permeation constants. According to calculations of Dancik et 
al. (2013), the kp-predictions of the FDSP model highly correlate with those based on the 
Potts & Guy QSPR (Potts and Guy, 1992) with the Cleek & Bunge correction (Cleek and 
Bunge, 1993) (R2 = 0.99). In comparison with DAME, the FDSP model has the advantage of 
taking evaporation into account and can therefore be applied to volatile compounds as well. 
                                                     
16 http://www.cdc.gov/niosh/topics/skin/finiteSkinPermCalc.html 
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To compare its performance with DAME, the FDSP model was applied to predict the results 
of the finite experiments reported in chapter 6, using the kp’s from our infinite dose 
experiments as input parameter instead of the kp calculated by the FDSP model based on 
physicochemical parameters. Since these experiments were executed under occlusion, 
meaning the applied dose was coated with a cover preventing evaporation, the FDSP model 
was run with vapour pressure set to 0, to exclude evaporation as factor. 
In general, the predictions by the FDSP model do not correlate well with the results of our 
experiments (R2 = 0.12), and are outperformed by the DAME predictions (R2 = 0.64) (Figure 
7-4). The FDSP model does not use lag time, that is the time between the start of exposure 
and the first appearance of the permeating chemical in the receptor fluid, as an input 
parameter, while DAME uses measured lag time as input parameter. Dancik et al. (2013) 
noted the lag times predicted by FDSP, using Fick’s second law and estimations of KSC,W 
(Wang et al., 2007), may deviate substantially from the experimental values, and also our 
experimental lag times were not well predicted using a comparable method derived by Shah 
et al. (1994)(section 6.4.2). This may, at least in part, explain the better correlation obtained 
with DAME, which uses experimental lag times from infinite dose experiments. For a more 
definitive assessment of the merits of both models, more finite dose experiments should be 
evaluated applying both models. In addition, including the approach used by the FDSP 
model for volatile substances in DAME could be a next step forward. 
 
Figure 7-4 Prediction of finite dose results of Buist et al. (2010) using DAME and the FDSP model. 
Potential absorption predicted by the FDSP model was obtained by summing the percentages predicted to be 
retained in the stratum corneum and the viable epidermis and the percentage predicted to be systemically 
absorbed. Line with short dashes: linear regression on the data calculated with DAME (taken from chapter 6 of 
this thesis). Line with long and short dashes: linear regression on the data computed with the FDSP model.  
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 Application in regulatory risk assessment 7.7
Eventually the dermal absorption data discussed in this thesis are to be used in regulatory 
risk assessment of chemicals. In the final paragraphs of this discussion, it will be pointed out 
how the results obtained could be applied to refine the use of dermal absorption data in 
regulatory risk assessment. The EU has developed and published a tiered approach for such 
use (EC, 2004; Figure 7-5, page 158). This tiered approach was developed within the legal 
framework regarding the admittance of Plant Protection Products on the EU market, and 
focuses on dermal exposure of workers, comparing at each tier the internal exposure via the 
dermal route, calculated using an assumed or estimated relative absorption, with the 
systemic Acceptable Operator Exposure Level (AOEL). The AOEL is the maximum amount of 
active substance, expressed on a bodyweight basis, to which the operator may be exposed 
without any adverse health effects (CRD, 2013). When at a certain tier it is concluded that 
internal exposure via the dermal route is lower than the systemic AOEL, no further 
refinement of the evaluation is deemed necessary, since no adverse health effects are to be 
expected as a result of this dermal exposure. The higher the tier the more refined (and more 
costly) the assessment becomes. At each tier, the worst case (highest) dermal absorption is 
assumed given the available information. 
At the first tier, it is simply assumed that 100% of the substance to be evaluated is absorbed. 
In principle, this may occur within the standard exposure time of six or twenty-four hours, 
under finite dose conditions. Some substances indeed approach this value (e.g. 2,4-
dichlorophenol and propylparaben of which 90% is absorbed under finite dose conditions 
(Table 6-4, page 136)). In practice, e.g. in case of pesticides, this value will hardly be 
reached: Dewhurst et al. (2010) analysed all dermal absorption values reported for 64 
pesticides evaluated in the EU, and found only one pesticide reaching a highest value of 70% 
(benthiavalicarb, when diluted); average relative absorption for in-use dilutions of pesticide 
formulations was 13 ± 14% and for the concentrated formulations it was even less 
(4.7 ± 6.1%). So there is sufficient room for refinement of this first crude tier. 
In the second tier, a reduced relative absorption of 10% of the applied dose is assumed for 
chemicals with a MW >500 and a log KOW <-1 or >4. All other molecules are still assumed to 
be 100% absorbed. This rule of thumb is rather coarse, and leads to classification of most 
pesticidal active substances in the 100% absorption category (62 out of 64 in the database 
published by Dewhurst et al. (2010)). Also absorption data obtained from the survey 
reported in chapter 2 clearly show this: for all substances considered in tier II to have a 
default dermal absorption of 100% the actual dermal absorption ranged from 1 to 78%, the 
average maximum absorption being 39 ± 24% (Table 7-4). Consequently, tier II constitutes 
only a small improvement over the first tier. Furthermore, the scientific basis for the 
selection of the cut off values is not clear (OECD, 2011). 
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Further refinement of tier II could be achieved by employing DAME, using the Potts & Guy 
QSPR predictions of kp (Potts and Guy, 1992) as input, ignoring lag time and putting in 
 
Figure 7-5 Tiered approach for dermal risk assessment (reproduced from EC, 2004)  
AOEL = Acceptable Operator Exposure Level 
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default parameters for in vitro finite dose dermal absorption conditions to generate 
different categories of default absorption values based on the log KOW and MW of chemicals 
(Figure 7-6, page 160). The reason to ignore lag time is that it cannot be well predicted 
(section 7.6, page 153). The introduction of this worst case assumption (that absorption 
starts immediately at t = 0) is offset by also ignoring a potential skin reservoir. The output of 
this adapted DAME could then be used to classify the chemical in a default absorption 
category of, e.g., 10, 25, 50, 75 or 100% (Figure 7-6). Currently this model is being tested 
and fine-tuned using a number of different datasets (Buist et al., in preparation).  
For tier III of the approach depicted in Figure 7-5, it is advised in current regulatory practice 
to perform dermal absorption experiments reflecting actual exposure conditions (e.g. with 
respect to dermal loading, chemical concentration and exposure time) (EFSA, 2012; OECD, 
2004a). When many different exposure conditions are to be tested, either substantially 
higher costs are incurred due to an increased number of experiments to be performed, or 
one has to restrict oneself to the (finite dose) conditions expected to lead to the highest 
percentage absorption, as suggested by EFSA (2012), thus accepting an overestimation of 
absorption for other exposure conditions. As has been demonstrated in chapter 2, different 
conditions of dermal loading may cause substantial differences in relative absorption. Also 
differences in exposure time will lead to differences in relative absorption (Figure 1-5, page 
Table 7-4 Actual dermal absorption percentages for a number of substances with default dermal 
absorption of 100% 
Substance MW Log KOW Dermal absorption range (%) Species 
4,4'-methylenedianiline (MDA) 198 1.59 14 - 54 rat 
cyclohexane 84 3.44 4 - 60 rat 
methyl-t-butyl ether 88 0.94 16 - 34 rat 
di(2-ethylhexyl) phthalate (DEHP) 391 7.6 39 - 47 guinea pig 
pyrene 202 4.88 41 - 70 guinea pig 
benzo[a]pyrene 252 6.13 40 - 67 guinea pig 
diethylene glycol butyl ether 
(DEGBE) 
162 0.56 6 - 65 rat 
testosterone 288 3.32 1 - 18 monkey 
benzoic acid 122 1.87 17 - 34 monkey 
testosterone 288 3.32 3 - 12 man 
hydrocortisone 362 1.61 1 - 2 man 
benzoic acid 122 1.87 14 - 37 man 
methoxyethanol 76 -0.77 19 - 27 rat 
ethoxyethanol 90 -0.32 17 - 27 rat 
butoxyethanol 118 0.83 21 - 26 rat 
fluazifop-butyl 383 4.5 2 - 8 man 
fluazifop-butyl 383 4.5 40 - 74 rat 
propoxur 209 1.52 27 - 71 man 
lindane 291 3.72 5 - 28 rat 
cyromazine 166 -0.155 7 - 11 rat 
bentazone 240 2.34 1 - 2 rat 
trinexapac-ethyl 252 -0.38 48 - 78 rat 
Data derived from Table 2-1 in chapter 2. Percentages rounded off to the nearest integer. Differences 
between minimum and maximum absorption are caused by differences in dermal loading. 
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39). As an alternative, one could perform an in vitro infinite dose dermal absorption 
experiment with human skin in order to determine kp and lag time of the chemical. 
Subsequently, for each of the different exposure conditions, one may calculate potential 
absorption using DAME. The model can handle finite as well as infinite dose conditions: for 
the latter one simply has to increase the donor cell volume in accordance with the expected 
exposure volume. 
When all possible refinements of the assessment of dermal absorption are exhausted and 
still the estimated internal level of the skin chemical is higher than the systemic AOEL, 
external exposure assessment can be refined (tier IV). A variety of measurement strategies 
and mathematical models can be used (see WHO, 2013 for a comprehensive review), but 
that discussion is outside the scope of this thesis, as the aim of external exposure 
assessment is purely to establish dermal loading, without considering the possibility of 
absorption. 
In 2012, EFSA updated the tiered approach for dermal risk assessment of pesticides (Figure 
7-7). Tier I was eliminated and the approach for molecules with a MW <500 and/or a log KOW 
between -1 and 4 was changed. In this changed approach for concentrates (defined as 
formulations with a concentration of active substance >5%), dermal absorption is now 
assumed to be 25% while for dilutions (defined as (in-use) dilutions with a concentration of 
active substance ≤5%), a default of 75% was set. These modifications are based on the 
observation made by Dewhurst et al. (2010) that for the pesticides evaluated by the EU no 
concentrate and no in-use dilution measured exceeded their respective cut-off value for 
 
A% = absorption relative to applied dose expressed in % 
f = fraction of unpenetrated chemical still in donor cell volume 
kpP&G = permeation constant, calculated using the Potts & Guy QSPR (Potts and Guy 1992) 
KSC,W = partition coefficient stratum corneum/water, calculated using the QSPR of Hui et al. (1995) 
log KOW = partition coefficient octanol/water of chemical 
MW = molecular weight of chemical 
t = exposure time = 8 h 
VDON = donor cell volume = 0.01 mL (“finite dose volume”) 
VSC = volume of 1 cm
2 stratum corneum = 0.002 mL (Xiao and Imhof 1997) 
Figure 7-6 Establishing different dermal absorption classes for finite dose, based on MW and Log KOW 
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dermal absorption. For concentrated pesticides, this is a sizeable improvement compared to 
the old tier II default values as it considerably reduces the overestimation of their 
 
Figure 7-7 Current EFSA tiered approach for dermal risk assessment (adapted from EFSA 2012b) 
AOEL = Acceptable Operator Exposure Level. Active substance is the pesticidal chemical present in the 
pesticide formulation. 
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absorption, which in the old tier II was set at 100%, but for in-use dilutions the improvement 
is marginal. Tier III is now explicitly expanded with the possibility to read across to similar 
formulations containing the active substance or even “unformulated” active substance (that 
is contained in a simple vehicle like water), instead of immediately having to generate 
dermal absorption data. 
 Future perspectives 7.8
In this section possible future developments on the main issues discussed in this thesis are 
described. 
7.8.1 Dermal loading and relative absorption 
The issue of the influence of dermal loading on relative absorption can be addressed by 
using the Dermal Absorption Model for Extrapolation (DAME) to extrapolate from the 
conditions under which absorption was measured to those under which consumers or 
workers are expected to be exposed, provided measured kp and lag time are available. As 
pointed out in section 7.6 of this thesis, before employing DAME for such extrapolations, its 
predictive performance needs to be evaluated more elaborately (section 7.8.5). 
7.8.2 Skin corrosive/irritant substances 
Data on skin corrosion/irritation are included in the basic data requirements for chemicals 
falling under REACH (ECHA, 2012), as well as for pesticides (EU, 2013), which are evaluated 
by the European Food Safety Authority (EFSA). While under REACH toxicokinetic studies, like 
dermal absorption studies, are not mandatory at any production/importation level, for 
pesticides dermal absorption studies are mandatory. Since more data on the effects of skin 
corrosive/irritant substances are needed to obtain a more general picture on the influence 
of single and repeated exposure to this kind of substances (section 7.3 of this thesis), 
especially publicly available risk assessments of pesticides could be a data source. However, 
whether a substance will exert corrosive or irritant effects is highly dependent upon its 
concentration, while regulatory studies are not aimed at establishing a dose-response curve, 
but just at categorising, and liquids and solids are applied in their pure form in these studies 
(OECD, 2015). Therefore, additional applied research aimed at establishing the relation 
between the dose-response of skin corrosive/irritant effects and skin permeability after 
single and repeated exposure will probably be needed to complete the picture. 
7.8.3 Repeated dermal exposure 
The approach to include the amount retained in the skin (skin reservoir) in the dermally 
absorbed dose obtained from single exposure in vitro experiments in order to compensate 
for the cumulative effect of repeated dermal exposure, needs to be analysed for a more 
consistent and complete dataset before it can be applied with confidence in risk assessment 
(section 7.4 of this thesis). Special attention needs to be given to chemicals showing a low 
ratio of skin reservoir versus amount recovered from the receptor fluid (representing 
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systemic absorption). Starting point for such an evaluation could be the in vivo data on 
dermal absorption after repeated dosing listed in Table 3-1 (page 80). Subsequently single 
exposure in vitro absorption data for the listed substances could be collected from public 
literature or experimentally generated, so that it can be checked whether combining skin 
reservoir and amount recovered from the receptor fluid would provide an adequate 
prediction of in vivo dermal absorption in the context of regulatory risk assessment. 
Since at the end of the day, the effect of repeated daily dermal exposure on daily absorption 
will depend upon the net result of absorption, distribution, metabolism and excretion, 
prediction of absorption using a generic Physiology Based Pharmacokinetic (PBPK) model 
that can be run with a few, easily obtainable physicochemical parameters would be an 
important next step. A recent example of a generic PBPK model is the IndusChemFate model 
developed by Jongeneelen and ten Berge (2011). The model addresses the three main 
routes of exposure: the oral, dermal and respiratory routes, is implemented in MS-Excel™ 
and is freely available from the website of the European Chemical Industry Council (CEFIC)17. 
Currently, its output is limited to the time courses of alveolar air, blood and urine 
concentrations of the parent compound and possible metabolites, but since the datasheets 
and Visual Basic source code are not password-protected, it can be easily adapted to 
provide e.g. blood AUC’s as a measure of absorption. Furthermore, in IndusChemFate 
dermal absorption is calculated using a modified version of the QSPRs developed by ten 
Berge (2009) and Wilschut et al. (1995) (see also Table 1-1). In principle, these predictions 
can be substituted by measured kp values by adapting the Visual Basic code, so that 
substance-specific data are used, reducing uncertainty.  
7.8.4 Vehicles and formulations 
A vehicle is the solvent in which the chemical to be absorbed is applied to the skin, while a 
formulation is a more complex vehicle consisting of a chemical mixture in which an active 
pharmacological, biocidal or pesticidal substance is applied. In the text below, formulations 
are included when the term “vehicle” is used. 
Measuring dermal absorption of chemicals using the vehicles in which they will be exposed 
to the skin, is at present the only reliable option, unless one can be certain the vehicles will 
not alter the skin’s barrier properties (section 7.5 of this thesis). As a first approach, one 
could assume that vehicles not classified for skin corrosion or irritancy will not alter the 
barrier properties of the skin, and hence dermal absorption of active substances from these 
vehicles can be extrapolated from e.g. experiments with water as a vehicle or another non-
irritant vehicle. This approach could be initially evaluated using data on pesticides, since 
pesticide regulatory dossiers will contain both data on vehicle skin corrosion/irritation and 
                                                     
17 http://cefic-lri.org/lri_toolbox/induschemfate/ 
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dermal absorption data on undiluted and diluted vehicles. Pesticide risk assessment reports 
containing summaries of all submitted studies are available at the EFSA website18.  
Another approach could be to test the influence of the vehicle on skin permeability by using 
radiolabelled model substances like tritiated water, as has been reported in chapter 4 of this 
thesis. If these tests show that the vehicle does not influence skin permeability, 
extrapolation of dermal absorption values is a possibility. One could, of course, opt to use 
the radiolabelled active substance to begin with, but producing radiolabelled chemicals on 
demand is costly, while radiolabelled model substances will be available on the commercial 
market at lower costs.  
As indicated in section 7.5, at present modelling approaches predicting dermal absorption of 
chemicals from different vehicles have not been very successful so far. In view of the great 
variability in formulations with respect to the nature and concentrations of ingredients and 
solvents and the many different ways formulations may influence permeability and 
absorption (e.g. solvent drag, damaging the barrier by delipidation or dehydration, protein 
crosslinking), only developing very local models (that are valid for a limited group of similar 
formulations) is likely to offer some perspective, but the development of more universally 
valid, global models for prediction of dermal absorption from different vehicles would 
require too many data to be feasible, at least in the short run. 
To conclude, future development of efficient, animal-free, dermal toxicological risk 
assessment of vehicles and active substances can expected to be spearheaded by the 
cosmetics industry, since the EU has implemented a ban on marketing finished cosmetic 
products and ingredients that have been tested on animals19.  
7.8.5 Prediction of dermal absorption 
For a more definitive assessment of the merits of DAME, more finite dose experiments 
should be evaluated applying the model (section 7.6 of this thesis). For such an evaluation, 
the on-line available EDETOX-database20 could give access to relevant data. Unfortunately, 
one has to revert to the original papers from which the in vitro absorption data were 
extracted, since the database does not list some of the variables needed by DAME, e.g. 
concentration of the chemical to be tested and the volume applied in the donor cell.  
In future, the present QSPRs for kp could be replaced by models with better predictive 
qualities. When that is the case, DAME may use predicted instead of measured kp values. 
Based on the overview presented in section 1.1.4.6.2 (pages 23-29), it can be concluded that 
besides log KOW and MW, the physical parameters that are used in most of the presented 
QSPRs, an additional predictive independent variable is needed which describes the 
                                                     
18 http://dar.efsa.europa.eu/dar-web/provision 
19 http://ec.europa.eu/growth/sectors/cosmetics/animal-testing/index_en.htm 
20 http://edetox.ncl.ac.uk 
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chemical reactivity of the substance, e.g. hydrogen bonding (Geinoz et al., 2004; Moss and 
Cronin, 2002). Furthermore, the kp model to be developed should be non-linear with respect 
to the relationships between kp and the predictive independent variables, since non-linear 
models seem to outperform the traditionally developed linear models (Moss et al., 2011; 
Russell and Guy, 2009). A disadvantage of non-linear models is that more data are needed 
to develop them than for linear models, and that they are more prone to overfitting. 
Therefore, existing dermal absorption datasets, both public and private, should be 
combined, curated and filtered to build a large homogeneous and consistent dataset that 
can be used to develop such non-linear models to predict kp. The on-line available EDETOX-
database21 provides a good structure to gather these data and already a fair number of 
curated kp data.  
 General conclusions 7.9
The influence of vehicles on absorption and the impact of irritative or corrosive vehicles or 
chemicals on the skin barrier have been demonstrated in this thesis. Until to date the 
significance and magnitude of these effects can only be experimentally established. The 
impact of vehicles and of corrosive of irritative vehicles or chemicals on absorption appears 
to be modest judging by the results presented in this thesis. However, more data on the 
effects of skin corrosive/irritant chemicals and formulations are needed to obtain a more 
general picture on their influence on dermal absorption after single or repeated exposure. 
Expressing dermal absorption as a single percentage is a misleading practice as it suggests 
universal validity, although under different conditions relative absorption of the same 
chemical may be considerably higher or lower, as demonstrated in chapter 2 of this thesis.  
An in silico model called DAME was developed that is able to account for a number of these 
different conditions, based on the measured kp, the measured lag time, the MW and the log 
KOW of the chemical. DAME enables the user to evaluate a variety of dermal exposure 
scenarios with limited experimental data and easy to obtain physico-chemical properties. At 
present, the applicability of DAME is restricted to non-volatile substances dissolved in 
aqueous solvents that do not affect the barrier function of the skin.  
Altogether, it is concluded that dermal exposure can be an important factor in risks posed 
by chemicals and should be taken into account in risk assessment. The methods to actually 
do this are still open for further improvement to better account for the various factors 
influencing dermal absorption and to develop adequate combinations of in vitro and in silico 
models that can accurately predict human systemic exposure.  
                                                     
21 http://edetox.ncl.ac.uk 
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n chapter 1 of this thesis, the background of the research reported in chapters 2 to 6 is 
presented and the research objectives are set out. 
The role of dermal absorption in toxicological risk assessment is relevant because dermal 
contact can be an important exposure route, as people are exposed to a variety of 
substances and products via the skin, either directly or indirectly, while at work, at home or 
in public space. Under occupational conditions, dermal exposure occurs mainly as a result of 
splashes, spills or drifts, during the application itself or from contact with contaminated 
surfaces. Pesticides, organic solvents and metalworking fluids are seen to be important 
contributors to adverse health effects due to occupational exposure via the dermal route. In 
non-occupational settings, cosmetics, clothing and household products are the most 
relevant commodities with respect to dermal exposure, because of their conditions of use.  
In the context of dermal exposure, three different types of toxicological effects can be 
distinguished: local skin effects, skin sensitization and systemic effects. This thesis is centred 
around the process of dermal absorption, which is principally relevant for the assessment of 
systemic toxicological effects, since local effects do not require absorption and the 
importance of absorption (or rather penetration into the viable dermis ) for skin sensitiza-
tion appears to be limited. 
Given the possible importance of the dermal exposure route in toxicological risk 
assessment, the state-of-the-art of models to estimate dermal absorption and the many 
factors influencing the efficiency of this exposure route, the objective of this thesis was to 
further develop, evaluate and improve methods for including dermal absorption data in 
toxicological risk assessment. 
In this thesis, four factors influencing dermal absorption, namely dermal loading (chapters 3 
and 6), irritative/corrosive potential (chapters 3 and 4), frequency of exposure (chapters 3, 4 
and 5) and the vehicle used (chapter 5), were investigated in more detail. Furthermore, a 
model to extrapolate infinite dose absorption data to finite dose conditions, baptized 
Dermal Absorption Model for Extrapolation (DAME), was developed and tested. 
n chapter 2 of this thesis, the relationship between relative dermal absorption and dermal 
loading was investigated. Hundred-and-thirty-eight dermal publicly available absorption 
experiments with 98 substances were evaluated. The results obtained revealed that dermal 
loading ranged mostly between 0.001 and 10 mg/cm2. In 87 experiments (63%), an inverse 
relationship was observed between relative dermal absorption and dermal loading. On 
average, relative absorption at high dermal loading was 33 times lower than at low dermal 
loading. Known skin irritating and volatile substances less frequently showed an inverse 
relationship between dermal loading and relative absorption. It was concluded that when 
using relative dermal absorption in regulatory risk assessment, its value should be 
determined at or extrapolated to dermal loadings relevant for the exposure conditions 
being evaluated. 
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n chapter 3 of this thesis, a literature search was presented with the aim to investigate 
whether neglecting the effects of repeated exposure may lead to an incorrect estimate of 
dermal absorption. The results demonstrated that the effect of repeated versus single 
exposure does not demonstrate a unique trend. Nevertheless, an increase in daily 
absorption was frequently observed upon repeated daily exposure. The little information 
available mostly concerned pharmaceuticals. However, consumers and workers may be 
repeatedly exposed to other types of chemicals, like disinfectants and cleaning products, 
which often contain biocidal active substances that may decrease the barrier function of the 
skin, especially after repeated exposure. These biocidal products, therefore, may present a 
safety risk that is not covered by the current risk assessment practice since absorption data 
are usually obtained by single exposure experiments. Consequently, it was decided to 
investigate the importance of this issue for biocide safety evaluation. As the literature 
search revealed that hardly any data on absorption upon repeated dermal exposure to 
biocides are available, it was concluded that data need to be generated by testing. 
To cover the entire range of biocidal products in such testing, a representative series of 
biocidal substances should be tested, making in vitro testing of dermal absorption the 
preferred choice over in vivo testing. Based on an inventory made, it appeared that the 16 
product types represented among the biocidal products authorised in the Netherlands could 
be clustered into 6 more or less homogeneous categories based on similarity in active 
substances. This result could facilitate experimental testing by providing a basis for selection 
of a limited number of representative compounds to be evaluated. 
n chapter 4 of this thesis, the importance of the effect of repeated dermal exposure on 
skin permeability for biocide safety evaluation was investigated, using a selection of nine 
representative biocides from the inventory made in chapter 3. The in vitro dermal 
penetration of tritiated water and [14C]propoxur was chosen as a measure of the 
permeability and integrity of human abdominal skin after single and repeated exposure. The 
results indicated that single and repeated exposure to specific biocidal products (e.g. the 
quaternary ammonium chlorides DDAC and ADBAC) may significantly increase skin 
permeability, especially when the compounds are applied at high concentrations, while a 
substance like formaldehyde may reduce skin permeability under specific conditions.  
n chapter 5 of this thesis, the in vitro dermal absorption kinetics of the quaternary 
ammonium compound didecyldimethylammonium chloride (DDAC) during single and 
repeated exposure was studied in more detail. In addition, the influence of biocidal 
formulations on the absorption of DDAC was investigated, because it was expected that 
formulation characteristics may be another factor influencing its dermal absorption. The 
analysis of biocidal products on the Dutch market, reported in chapter 3, indicated that 
DDAC is often used in combination with other active ingredients. DDAC was most frequently 
combined with formaldehyde, glutaraldehyde and/or alkyldimethylbenzylammonium 
chloride (ADBAC). Consequently, commercial formulations containing one or more of these 
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additional active ingredients were selected, in addition to one formulation containing only 
DDAC as an active ingredient. The selected commercial formulations tended to reduce skin 
penetration of DDAC. This was most pronounced with the formulation containing the 
highest concentration of formaldehyde (196 mg/mL) and glutaraldehyde (106 mg/mL), 
which reduced the flux of DDAC across the skin by 95%. The reduction caused by the only 
tested formulation containing no other active ingredients than DDAC, and thus 
incorporating no aldehydes, was smallest, and did not reach statistical significance. 
n chapter 6 of this thesis, a simple in silico model to predict finite dose dermal absorption 
from infinite dose data (kp and lag time) and the stratum corneum/water partition 
coefficient (KSC,W) was developed. This model was tentatively called Dermal Absorption 
Model for Extrapolation (DAME). As dermal exposure may occur under a large variety of 
conditions leading to quite different rates of absorption, such a predictive model using 
simple experimental or physicochemical inputs provides a cost-effective means to estimate 
dermal absorption under different conditions.  
To evaluate the DAME, a series of in vitro dermal absorption experiments was performed 
under both infinite and finite dose conditions using a variety of different substances. The 
kp’s and lag times determined in the infinite dose experiments were entered into DAME to 
predict relative dermal absorption value under finite dose conditions. For six substances, the 
predicted relative dermal absorption under finite dose conditions was not statistically 
different from the measured value. For all other substances, measured absorption was 
overpredicted by DAME, but most of the overpredicted values were still lower than 100%, 
the European default absorption value for the tested compounds. 
In conclusion, our finite dose prediction model (DAME) provides a useful and cost-effective 
estimate of in vitro dermal absorption, to be used in risk assessment for non-volatile 
substances dissolved in water at non-irritating concentrations. 
n chapter 7 of this thesis, the results of the research reported in chapters 2 to 6 were put 
into perspective, the pitfalls and promises emanating from them discussed and general 
conclusions drawn. The possible influence of vehicles on absorption and the possible impact 
of irritative or corrosive vehicles or chemicals on the skin barrier have been demonstrated in 
this thesis. An in silico predictive model tentatively called DAME was developed, which 
enables the user to evaluate a variety of dermal exposure scenarios with limited 
experimental data (kp and lag time) and easy to obtain physicochemical properties (MW and 
log KOW). The predictions of our experiments reported in chapter 6 were compared to those 
of the Finite Dose Skin Permeation (FDSP) model published on the internet by the US 
Centers for Disease Control and Prevention (CDC). DAME outperformed FDSP (R2 of the 
correlation predicted/measured potential absorption 0.64 and 0.12, respectively). At 
present, the applicability domain of DAME is limited to non-volatile substances dissolved in 
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aqueous solvents. However, in future the model will be adapted to include volatile 
substances as well. 
Altogether, it is concluded that dermal exposure can be an important factor in risks posed 
by chemicals and should be taken into account in risk assessment. The methods to actually 
do this are still open for further improvement to better account for the various factors 
influencing skin penetration and to develop adequate combinations of in vitro and in silico 
models that can accurately predict human dermal absorption.  
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In this thesis the definitions and abbreviations as applied by the OECD (2011, 2004a, 2004b, 
2004c) and the WHO (2006) have been used as much as feasible.  
 Glossary 9.1
absorption decrease factor  the relative dermal absorption at low dermal loading divided 
by the relative dermal absorption at high dermal loading 
allergen a molecule that may elicit an allergic reaction, that is a dis-
proportionate immune reaction 
amphipathic having a hydrophobic and a hydrophilic part (said of mole-
cules) 
apolar not having separate positive and negative (partial) charges 
appendageal route dermal absorption route via skin appendages like hair follicles 
and sweat glands 
applied dose mass of permeant applied to the skin  
arthropodicide biocidal product designed to kill arthropods (animals with 
jointed appendages like insects and spiders) 
Bakta Steril a commercial biocidal product 
biocidal product product used to protect humans, animals, materials or 
articles against harmful organisms like pests or bacteria 
(definition of biocidal product according to EU Regulation 
528/2012) 
biocide chemical used to kill organisms 
charge as a molecular descriptor: the sum of the absolute values of 
the partial charges in a molecule (calculation method 
described in Pugh et al. (2000) 
corneocytes cornified keratinocytes of the stratum corneum 
corrosive to skin: capable of full-thickness destruction of skin tissue  
Dalton unit of molecular weight 
default absorption values absorption values used in absence of measured or predicted 
data 
dendritic cell immune cell that presents antigens 
dermal absorption transport of chemicals from the outer surface of the skin into 
the systemic circulation 
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dermal absorption value in in vitro dermal absorption experiments: the amount of 
substance that has penetrated the skin plus the amount still 
present in the skin preparation 
dermal load(ing) amount of applied dose per unit skin surface (e.g. expressed 
in mg/cm2) 
dermatokinetics the processes by which permeants move through the skin 
dermatomed skin skin preparation from which the lower part of the dermis has 
been removed with a dermatome (an instrument to finely 
and precisely cut skin) 
dermis the lowest layer of the skin, containing a.o. the skin capillary 
network 
descriptor in this thesis: short for molecular descriptor = a specific 
characteristic of molecular structures, which can be 
expressed in a numeric value  
diffusion movement of molecules down a concentration gradient 
donor compartment compartment of a diffusion cell to which the permeant is 
added in an in vitro dermal absorption experiment 
elicitation phase in skin sensitisation experiments: the phase during which a 
possibly sensitised individual is challenged with the sensitizer 
in order to elicit an immune reaction of the skin 
epidermal membrane skin preparation consisting only of the epidermis 
epidermis upper layer of the skin, consisting of a viable part and the 
non-viable stratum corneum 
esterase an enzyme capable hydrolysing an ester bond (a bond 
originating from the condensation reaction between an 
alcoholic hydroxyl group and an acid hydroxylic group) 
facilitated diffusion movement of molecules down a concentration gradient aided 
by a transporter protein 
finite dose applied amount of donor solution for which the 
concentration of the penetrant significantly decreases during 
dermal exposure  
flow-through cell apparatus to measure dermal absorption in which the 
receptor fluid passes continuously below the skin preparation 
flux amount of penetrant that crosses the skin per unit of time 
and unit of exposed skin area, often expressed in mg/cm2/h 
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formulation chemical mixture in which an active pharmacological, biocidal 
or pesticidal substance is contained 
Franz cell apparatus to measure dermal absorption in which a donor 
cell is separated from a receptor cell by the skin preparation 
to be investigated 
full-thickness skin skin preparation consisting of the epidermis and the entire 
dermis 
haptenation the linking of (part of) an allergen to an immune protein, 
turning it capable of eliciting an immune response 
Henry’s law constant physical constant of a molecule describing the relation 
between its partial gas pressure and its solubility in water 
heteroscedastic when applied to a statistical test: comparison of two groups 
of measurements with different variabilities 
homologous series series of chemically similar molecules which are obtained by 
repeatedly adding an identical chemical group to the 
molecular chain (e.g. alkanoic acids) 
homoscedastic when applied to a statistical test: comparison of two groups 
of measurements with similar variabilities 
hydrophilic preferably dissolving in water 
in silico calculated or predicted by computer (analogous to in vitro 
and in vivo)  
in vitro measured/executed in labware 
in vivo measured/executed in/with living organisms 
induction in skin sensitisation experiments: the phase during which a 
non-sensitised individual exposed to a possible sensitizer in 
order to try to make him immunoresponsive to this molecule 
infinite dose applied amount of donor solution for which the 
concentration of the penetrant remains (more or less) 
constant during dermal exposure 
intercellular route in dermal absorption: passage of the permeant between the 
cells of the skin (also called paracellular) 
irritating to skin: causing significant inflammation of the skin  
keratin structural protein produced by the keratinocytes 
keratinocytes cells that constitute the epidermis 
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kinetics in physiology: the process in the body by which a molecule is 
absorbed, distributed, metabolised and excreted  
lag time the time intercept for penetration equal to zero of the linear 
portion of the cumulative penetration versus time graph (see 
Figure 6-2) 
Langerhans cell dendritic cell (=immune cell that presents antigens) of the 
skin 
limit value regulatory exposure value which should not be exceeded  
lipophilic preferably dissolving in lipids 
log KOW 10-base logarithm of the octanol/water partition coefficient, 
also known as log P or log KOW 
melanocytes pigment producing cells of the skin 
microdialysis miniature dialysis instrument which is inserted below the skin 
surface on which the permeant is applied, to measure dermal 
absorption in vivo 
mitotic cell division cell division in which the daughter cells maintain the original 
(diploid) number of chromosomes 
MS Macrodes a commercial biocidal product 
Mulliken charges Mulliken charges arise from the Mulliken population analysis 
and provide a means of estimating partial atomic charges 
from calculations carried out by computational chemistry 
packages like Gaussian 03. 
non-occluded dermal exposure in which the skin is not covered, or covered 
in such a way that evaporation is not prevented 
occluded dermal exposure in which the skin is covered in such a way 
that evaporation is prevented 
passive diffusion unaided movement of molecules down a concentration 
gradient 
penetration the entry of a substance in a particular layer or structure 
percutaneous absorption transport of chemicals from the outer surface of the skin into 
the systemic circulation 
permeability coefficient constant describing the permeability of a specific skin 
preparation for a specific molecule dissolved in water, usually 
expressed in cm/ h 
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permeant chemical that penetrates through one layer into a second, 
functionally and structurally different, layer 
permeation penetration through one layer into a second, functionally and 
structurally different, layer 
pesticide biocidal product used to protect plants against harmful 
organisms (pesticides are not encompassed by the definition 
of biocidal products under EU Regulation 528/2012) 
phase I enzymes enzymes of the first phase of detoxification, in which 
toxicants are made more polar 
phase II enzymes enzymes of the first phase of detoxification, in which 
toxicants are conjugated to endogenous molecules, 
facilitating their excretion 
polarizability a molecular descriptor: ratio of the induced dipole moment of 
a molecule and the electrical field that produces it (a measure 
of the degree to which electrical charges in a molecule may 
be separated) 
portal of entry the site where a molecule enters the body (e.g. lungs, 
intestines, skin) 
potential absorption in dermal absorption: the sum of the amount of permeant 
that has entered systemic circulation (in vivo) or the receptor 
fluid (in vitro) and the amount remaining in the skin after 
exposure has ceased. 
receptor compartment part of the diffusion cell positioned on the inside of the skin 
preparation, filled with liquid in which the investigated 
chemical penetrates if the skin is permeable to it (and a 
concentration gradient is maintained across the skin). 
receptor compartment compartment of a diffusion cell to which the permeant is 
transported in an in vitro dermal absorption experiment 
refractive index ratio between the speed of light in a pure substance and the 
speed of light in vacuum 
rodenticide biocidal product designed to kill rodents 
Roloxid 50 a commercial biocidal product 
semi-occluded dermal exposure in which the skin is covered in such a way 
that evaporation is only partially prevented 
semipermeable membrane a membrane that is permeable to a limited number of smaller 
molecules (e.g. water) 
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skin absorption transport of chemicals from the outer surface of the skin into 
the systemic circulation 
skin reservoir amount of penetrant that remains in the skin after exposure 
has finished and in principle still may be systemically 
absorbed 
skin reservoir the amount of permeant present in the skin after cessation of 
exposure 
skin sensitization the process by which the skin is rendered sensitive to a skin 
allergen 
slimicide biocidal product designed to kill micro-organisms that 
produce slime 
solvatochromic properties molecular properties linked to its changing colour in solvents 
of different polarity 
split-thickness skin skin preparation from which the lower part of the dermis has 
been removed with a dermatome (an instrument to finely 
and precisely cut skin) 
static diffusion cell apparatus to determine in vitro dermal absorption from 
which the liquid in the receptor compartment is not 
continuously refreshed, but only after specific time intervals 
static Franz cell diffusion cell to measure dermal absorption in which the 
receptor fluid remains immobile 
steady state in in vitro dermal absorption experiments: conditions under 
which penetration into the receptor fluid occurs at a constant 
rate  
Strat-M™ a commercial synthetic membrane used to imitate human 
skin, consisting of two layers of polyethersulfone and one 
layer of polyolefin 
stratum corneum non-viable upper layer of the skin  
stratum germinativum the germinal layer of the epidermis, it is its innermost layer 
stratum granulosum epidermal layer with a granular appearance, located just 
below the stratum corneum 
stratum spinosum epidermal layer with a spiny appearance, located just above 
the stratum germinativum 
surfactant surface active substance, that is a substance that when 
dissolved in water will reduce its surface tension 
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systemic absorption uptake of a chemical into systemic circulation after having 
been transported across an outer body surface (e.g. skin, lung 
epithelium) 
systemic effects effects that occur if and when substances enter systemic 
circulation 
Teepol a commercial detergent 
transcellular route in dermal absorption: passage of the permeant across the 
cells of the skin 
trough plasma concentration plasma concentrations at the dip in the plasma concentration 
time curve of a periodically administered drug 
t-statistic statistical measure of the deviation of a measured parameter 
value from an expected of predicted value, in relation to the 
standard error of the measured value 
unoccluded dermal exposure in which the skin is not covered or covered 
in such a way that evaporation is not prevented 
vehicle solvent in which the permeant is administered 
xenobiotic a chemical normally not present in a specific species in 
appreciable concentrations (literal meaning: “strange to life”) 
 Abbreviations 9.2
ABSQon a molecular descriptor: the sum of absolute charges on the oxygen and 
nitrogen atoms in a molecule 
ADBAC AlkylDimethylBenzylAmmonium Chloride 
ANOVA ANalysis Of VAriance 
AOEL Acceptable Operator Exposure Level 
AUC Area Under the Curve 
BR Number of rotable bonds 
BSA Bovine Serum Albumin 
cb the number of carbons not involved in a C= O bond 
CD-ROM Compact Disk - Read-Only Memory 
Csat Concentration in water at saturation (expressed in mg/cm3) 
CTGB Dutch Board for the Authorisation of Plant Protection Products and Biocides 
CV Coefficient of Variation 
DAME Dermal Absorption Model for Extrapolation 
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DDAC DidecylDimethylAmmonium Chloride 
DMSO DiMethyl SulfOxide 
Dow distribution coefficient or apparent partition coefficient of ionogenic 
molecules 
DSC  diffusivity of the penetrant in the stratum corneum in cm2/h 
EFSA European Food Safety Authority 
EPA Environmental Protection Agency 
EU European Union 
f amount of penetrant in the donor compartment divided by the sum of the 
amounts in the donor compartment and the stratum corneum  
FDSP Finite Dose Skin Permeation 
GHS Globally Harmonized System of Classification and Labelling of Chemicals 
HA Hydrogen bond acceptor activity 
Hb number of hydrogen bonds 
HBA hydrogen bond acceptors 
HBD hydrogen bond donors 
HD Hydrogen bond donor activity 
LSC  length of the diffusion pathway through the stratum corneum in cm 
HSDB Hazardous Substances Data Bank 
IB a molecular descriptor: Balaban index 
IPM IsoPropyl Myristate 
Jmax maximum flux 
JSS steady-state flux 
kg bw/d kg bodyweight/day 
KOW octanol/water partition coefficient (in some publications also abbreviated as 
Poct, in many publications log KOW is designated as log P). 
kp permeation or permeability constant, often expressed in cm/h  
kp,SC stratum corneum permeation constant in cm/h  
KSC,W stratum corneum/water partition coefficient 
KSC/veh vehicle/stratum corneum partition coefficient 
LD50 lethal dose for 50% of the individuals in the exposed group 
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LMV a molecular descriptor: Liquid Molar Volume 
LSC thickness of the stratum corneum 
Mpt melting point 
MR a molecular descriptor: molecular refractivity 
MV a molecular descriptor: molar volume 
MW molecular weight 
N when used as a molecular descriptor: Number of affected hydrogen bonds, 
calculated by summing the number of N and O atoms (aliphatic twice, 
aromatic once) (Bodor and Buchwald, 1997)  
Nderm dermal load divided by the product of steady state flux (JSS) and exposure 
time (Frasch et al., 2014) 
OECD Organisation for Economic Co-operation and Development 
PBPK Physiology Based Pharmacokinetic (model) 
PDMS polydimethylsiloxane 
π2
H a molecular descriptor: Solute dipolarity/polarizability 
pKa negative 10-base logarithm of the acid dissociation constant 
PT for biocidal products: Product Type 
QSAR Quantitative Structure-Activity Relationship 
QSPeR Quantitative Structure-Permeation Relationship 
QSPR Quantitative Structure-Permeability Relationship 
R2 a molecular descriptor: Excess molar refraction 
REACH Registration, Evaluation Authorisation and restriction of CHemicals  
RISKOFDERM Acronym of a model for Risk Assessment of Occupational Dermal Exposure 
to Chemicals 
∑α2
H a molecular descriptor: Effective/overall hydrogen bond acidity 
∑β2
H a molecular descriptor: Effective/overall hydrogen bond basicity 
∑Ca a molecular descriptor: HYBOT-PLUS H-bond acceptor free energy factor 
SD Standard Deviation 
∑(Q+)/α a molecular descriptor: HYBOT-PLUS positive charge per unit volume 
SRC Syracuse Research Corporation 
SsssCH a molecular descriptor: the sum of E-state indices for all methyl groups/ 
Electrotopological atom-type index for singly bonded CH 
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SsssOH a molecular descriptor: Electrotopological atom-type index for singly 
bonded OH 
STW Surface Tension in Water 
tlag lag time (expressed in hours) = time needed to establish the steady state  
US United States 
Ve a molecular descriptor: Van der Waals effective molecular volumes, 
calculated according to Buchwald and Bodor (1998) 
Vx a molecular descriptor: McGowan characteristic volume 
 References 9.3
Bodor, N., Buchwald, P., 1997. Molecular size based approach to estimate partition 
properties for organic solutes. J. Phys. Chem. B 101, 3404–3412. 
Buchwald, P., Bodor, N., 1998. Octanol-water partition: Searching for predictive models. 
Curr. Med. Chem. 5, 353–380. 
Frasch, H.F., Dotson, G.S., Bunge, A.L., Chen, C.-P., Cherrie, J.W., Kasting, G.B., Kissel, J.C., 
Sahmel, J., Semple, S., Wilkinson, S., 2014. Analysis of finite dose dermal absorption data: 
Implications for dermal exposure assessment. J. Expo. Sci. Environ. Epidemiol. 24, 65–73. 
OECD, 2011. Series on Testing and Assessment No. 156. Guidance notes on dermal 
absorption. OECD, Paris, France. 
OECD, 2004a. OECD Guidelines for the testing of chemicals 427: Skin absorpion: in vivo 
method. OECD, Paris, France. 
OECD, 2004b. Series on Testing and Assessment No. 28.Guidance document for the conduct 
of skin absorption studies. OECD, Paris, France. 
OECD, 2004c. OECD Guidelines for the testing of chemicals 428: Skin absorpion: in vitro 
method. OECD, Paris, France. 
Pugh, W.J., Degim, I.T., Hadgraft, J., 2000. Epidermal permeability-penetrant structure 
relationships: 4, QSAR of permeant diffusion across human stratum corneum in terms of 
molecular weight, H-bonding and electronic charge. Int. J. Pharm. 197, 203–211. 
WHO, 2006. Dermal absorption, Environmental Health Criteria. WHO, Geneva, Switzerland. 

 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 187 
Acknowledgements 
  
 
 
 
Acknowledgements 
page 188 
It is a cliché, but only because it is true: I could not have written this thesis alone. Many 
people have contributed directly and indirectly towards this achievement, and I would like 
to thank some of them explicitly and many more implicitly. 
First of all, I would like thank my PhD thesis supervisors, Ivonne Rietjens and Ruud 
Woutersen. Ivonne, I really appreciate your prompt, incisive, clear and no-nonsense feed-
back. Ruud, you started me on the path that led to this thesis and gave me the confidence 
that I would reach the end. Your poise and calm in front any adversity was especially 
reassuring. Of course I also owe this thesis in a large part to my PhD co-supervisor, Han van 
de Sandt. Han was not only a co-supervisor but also a co-author of the four papers and one 
report that form the core of this thesis. Han, at times I would miss the forest for the trees 
and I appreciate that you were able to strip away the details to get to the heart of the 
matter. 
This brings me to another group of people for whose contribution I am very grateful: my co-
authors. Cees de Heer introduced me to the art of toxicological risk assessment and the role 
played by dermal absorption. Han van de Sandt taught me about the theory and practice of 
dermal absorption experiments. Johan van Burgsteden performed the experiments that are 
the core of chapters 4, 5 and 6, a role Wilfred Maas took over when Johan left TNO. Their 
contribution was crucial, as I am not known for my dexterity in the laboratory. Jos Bessems 
introduced me to the intricacies of toxicokinetics and I enjoyed our many discussions on the 
fundamentals of toxicological risk assessment, as well as a broad range of other subjects. 
Andreas Freidig guided me on the path to DAME, the model described in chapter 6. Last but 
not least, I would like to thank Franziska Schurz and Gerwin Schaafsma who did a lot of work 
on chapters 3 and 2, respectively, and were as eager to learn from me as I was to learn from 
them. 
Others also directly contributed to the papers included in this thesis. My TNO-colleague 
Carina de Jong-Rhubing designed and performed the statistical analyses for chapters 2, 3 
and 6. My former TNO-colleague Jos Hagenaars completed the statistical work for chapter 4. 
Steve Enoch from the School of Pharmacy and Chemistry of Liverpool John Moores 
University calculated some of the chemical properties necessary for chapter 6. Finally, 
although I never met them in person, Matt Miller of the James L. Winkle College of 
Pharmacy of the University of Cincinnati and Adam Fedorowicz of the US National Institute 
for Occupational Safety and Health kindly guided me in the use of the Finite Dose Skin 
Permeation model, which I discussed in chapter 7. 
For over 16 years I have been working now in the group of regulatory toxicologists at TNO in 
Zeist, in several departments under more names than I care to remember, but there was 
always one constant factor, the presence of enthusiastic, involved, smart-ass and caring 
colleagues without whom I would not have had the pleasure and motivation to work on my 
 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 189 
thesis papers in addition to all of the other papers, statements and reports that desk jockeys 
like us produce. 
Also I would like to thank my paranymphs, Hilda Verhoog and Willy Spaan, for 
accompanying me while running the gauntlet of the promotion ceremony. We go a long way 
back and I hope there is still a long way ahead as well. 
To conclude I want thank Henriëtte, Gijs and Anne, who bore with me while cursing Bill 
Gates in general and MS-Word in particular. Without my stable home base I would not have 
started this thesis, let alone completed it.  
 
 

 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 191 
Curriculum vitae 
  
 
 
 
Curriculum vitae 
page 192 
Harrie Buist was born on January 12, 1955 in Delfzijl, and grew up in Utrecht and De Bilt. 
After graduating from grammar school, he started to study Biology at the University of 
Utrecht in 1973, with Chemistry as a second major. For his Master, he executed one major 
research project of 12 months in Chemical Animal Physiology on fumarate reductase in 
Mytilus edulis L. and two minor ones of six months each in Molecular Biology on the 
initiation of eukaryotic protein synthesis and Protozoology & Immunology on the transfer of 
protection against Babesia rodhaini by injection of spleen cells, and obtained his Teaching 
Certificate in Biology. He obtained his Master’s degree in 1981.  
After his studies, he started to work as a biology teacher, first at a secondary school in 
Barendrecht (1981-1982), then at two different secondary schools in Mozambique, one in 
Pemba (1983-1984) and one in Maputo (1985). During his stay in Mozambique he was asked 
to be a lecturer at the recently reopened Biology Faculty of the Eduardo Mondlane 
University in Maputo, where he taught Human Biology, Basic Biology, Animal Physiology and 
Molecular Cell Biology (1986-1990).  
Upon return to the Netherlands, in 1990, he stared to attend the Postgraduate Education in 
Toxicology courses, which he successfully concluded with obtaining the Certificate, in 1992. 
In the meanwhile, he was employed by the Free University of Amsterdam as Project Officer 
for its Centre for Development Cooperation Services in which capacity he managed 
interuniversity projects in the area of sciences (biology, chemistry, physics and 
mathematics) and medicine and developed biology teaching materials for use in third-world 
countries (1992-1995, 1999). During his employment by the Free University Amsterdam he 
was stationed as a biology lecturer at the Department of Biology of the School of Sciences of 
the University of Lusaka, Zambia (1996-1998). At this university he developed and taught a 
biology bridging course, aimed at bridging the gap between Zambian secondary school O-
level education and the A-level required by the University.  
In 1999, he was hired by TNO as a regulatory toxicologist, based in Zeist. In that function, he 
wrote numerous toxicological risk assessment reports on pesticides, biocides, industrial 
chemicals and chemicals in food and feed. Besides working as a risk assessor, he also has 
been project leader of knowledge investment and business-to-business projects and 
performed research on specific topics (e.g. dermal absorption, blood:air partitioning, 
prediction of nitrosamine carcinogenicity, health effect factors of nanomaterials), which was 
published in peer-reviewed journals. Part of these published papers formed the basis of this 
thesis. He is a Board Certified Toxicologist with the Netherlands Society of Toxicology since 
June 17, 2003 as well as with EUROTOX since November, 20, 2003. After completing his PhD, 
he will continue to work at TNO as a toxicologist.
 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 193 
List of publications 
  
 
 
 
List of publications 
page 194 
Buist, H.E., Hischier, R., Westerhout, J., Brouwer, D. (2016). Derivation of health effect 
factors for nanoparticles to be used in LCIA. Toxicology and Applied Pharmacology (accepted 
for publication). 
Fransman, W., Buist, H., Kuijpers, E., Walser, T., Meyer, D., Zondervan, E., Westerhout, J., 
Klein-Entink, R., Brouwer, D. (2016). Implementing Comparative Human Health Impact 
Assessment of Engineered Nanomaterials in the framework of Life Cycle Assessment. 
Manuscript submitted for publication. 
Buist, H.E., Krul, L., Leeman, W.R. (2016). A TTC threshold for acute oral exposure to non-
genotoxic substances, Regulatory Toxicology and Pharmacology, Available online 4 February 
2016, DOI: 10.1016/j.yrtph.2016.01.022. 
EFSA (European Food Safety Authority), 2015. Scientific report of EFSA on the assessment of 
new scientific studies on human in vitro dermal absorption. EFSA Journal 2015;13(11):4304, 
13 pp. doi:10.2903/j.efsa.2015.4304. 
Kroese, E.D., Bosgra, S., Buist, H.E., Lewin, G., van der Linden, S.C., Man, H.-Y., Piersma, A.H., 
Rorije, E., Schulpen, S.H.W., Schwarz, M., Uibel, F., van Vugt-Lussenburg, B.M.A., 
Wolterbeek, A.P.M., van der Burg, B. (2015). Evaluation of an alternative in vitro test battery 
for detecting reproductive toxicants in a grouping context.  Reproductive Toxicology, 55, pp. 
11-19. DOI: 10.1016/j.reprotox.2014.10.003 
Walser, T., Meyer, D., Fransman, W., Buist, H., Kuijpers, E., Brouwer, D. (2015). Life-cycle 
assessment framework for indoor emissions of synthetic nanoparticles.  Journal of 
Nanoparticle Research, 17 (6), art. no. 245, 18 p. DOI: 10.1007/s11051-015-3053-y 
Buist, H.E., Devito, S., Goldbohm, R.A., Stierum, R.H., Venhorst, J., Kroese, E.D. (2015). 
Hazard assessment of nitrosamine and nitramine by-products of amine-based CCS: 
alternative approaches.  Regulatory toxicology and pharmacology, 71 (3), pp. 601-623. DOI: 
10.1016/j.yrtph.2014.01.017 
van der Burg, B., Pieterse, B., Buist, H., Lewin, G., van der Linden, S.C., Man, H.-Y., Rorije, E., 
Piersma, A.H., Mangelsdorf, I., Wolterbeek, A.P.M., Kroese, E.D., van Vugt-Lussenburg, B. 
(2014). A high throughput screening system for predicting chemically-induced reproductive 
organ deformities.  Reproductive Toxicology, 55, pp. 95-103. DOI: 
10.1016/j.reprotox.2014.11.011 
Rorije, E., Aldenberg, T., Buist, H., Kroese, D., Schüürmann, G. (2013). The OSIRIS Weight of 
Evidence approach: ITS for skin sensitisation.  Regulatory Toxicology and Pharmacology, 67 
(2), pp. 146-156. DOI: 10.1016/j.yrtph.2013.06.003 
Vermeire, T., Aldenberg, T., Buist, H., Escher, S., Mangelsdorf, I., Pauné, E., Rorije, E., Kroese, 
D. (2013). OSIRIS, a quest for proof of principle for integrated testing strategies of chemicals 
 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 195 
for four human health endpoints.  Regulatory Toxicology and Pharmacology, 67 (2), pp. 136-
145. DOI: 10.1016/j.yrtph.2013.01.007 
Tluczkiewicz, I., Batke, M., Kroese, D., Buist, H., Aldenberg, T., Pauné, E., Grimm, H., Kühne, 
R., Schüürmann, G., Mangelsdorf, I., Escher, S.E. (2013). The OSIRIS Weight of Evidence 
approach: ITS for the endpoints repeated-dose toxicity (RepDose ITS).  Regulatory 
Toxicology and Pharmacology, 67 (2), pp. 157-169. DOI: 10.1016/j.yrtph.2013.02.004 
Buist, H., Aldenberg, T., Batke, M., Escher, S., Klein Entink, R., Kühne, R., Marquart, H., 
Pauné, E., Rorije, E., Schüürmann, G., Kroese, D. (2013). The OSIRIS Weight of Evidence 
approach: ITS mutagenicity and ITS carcinogenicity.  Regulatory Toxicology and 
Pharmacology, 67 (2), pp. 170-181. DOI: 10.1016/j.yrtph.2013.01.002 
Buist, H.E., Wit-Bos, L.D., Bouwman, T., Vaes, W.H.J. (2012). Predicting blood:air partition 
coefficients using basic physicochemical properties.  Regulatory Toxicology and 
Pharmacology, 62 (1), pp. 23-28. DOI: 10.1016/j.yrtph.2011.11.019 
Allergen Bureau, 2011. Summary of the VITAL Scientific Expert Panel Recommendations. 
Allergen Bureau, Australia/New Zealand (http://www.allergenbureau.net/) 
Tluczkiewicz, I., Buist, H.E., Martin, M.T., Mangelsdorf, I., Escher, S.E. (2011). Improvement 
of the Cramer classification for oral exposure using the database TTC RepDose - A strategy 
description.  Regulatory Toxicology and Pharmacology, 61 (3), pp. 340-350. DOI: 
10.1016/j.yrtph.2011.09.005 
WHO, 2010. Characterization and application of physiologically based pharmacokinetic 
models in risk assessment. Harmonization Project Document No. 9. ISBN 978 92 4 150090 6. 
World Health Organization, Geneva, Switzerland. 
Escher, S.E., Tluczkiewicz, I., Batke, M., Bitsch, A., Melber, C., Kroese, E.D., Buist, H.E., 
Mangelsdorf, I. (2010). Evaluation of inhalation TTC values with the database RepDose.  
Regulatory Toxicology and Pharmacology, 58 (2), pp. 259-274. DOI: 
10.1016/j.yrtph.2010.06.009 
Buist, H.E., van Burgsteden, J.A., Freidig, A.P., Maas, W.J.M., van de Sandt, J.J.M. (2010). 
New in vitro dermal absorption database and the prediction of dermal absorption under 
finite conditions for risk assessment purposes.  Regulatory Toxicology and Pharmacology, 57 
(2-3), pp. 200-209. DOI: 10.1016/j.yrtph.2010.02.008 
Buist, H.E., von Bölcsházy, G.Frhr., Dammann, M., Telman, J., Rennen, M.A.J. (2009). 
Derivation of the minimal magnitude of the Critical Effect Size for continuous toxicological 
parameters from within-animal variation in control group data.  Regulatory Toxicology and 
Pharmacology, 55 (2), pp. 139-150. DOI: 10.1016/j.yrtph.2009.06.009 
 
 
 
List of publications 
page 196 
Buist, H.E., Schaafsma, G., van de Sandt, J.J.M. (2009). Relative absorption and dermal 
loading of chemical substances: Consequences for risk assessment.  Regulatory Toxicology 
and Pharmacology, 54 (3), pp. 221-228. DOI: 10.1016/j.yrtph.2009.04.002 
Loizou, G., Spendiff, M., Barton, H.A., Bessems, J., Bois, F.Y., d'Yvoire, M.B., Buist, H., Clewell 
III, H.J., Meek, B., Gundert-Remy, U., Goerlitz, G., Schmitt, W. (2008). Development of good 
modelling practice for physiologically based pharmacokinetic models for use in risk 
assessment: The first steps.  Regulatory Toxicology and Pharmacology, 50 (3), pp. 400-411. 
DOI: 10.1016/j.yrtph.2008.01.011 
Buist, H.E., de Heer, C., van Burgsteden, J.A., van de Sandt, J.J.M. (2007). Dermatokinetics of 
didecyldimethylammonium chloride and the influence of some commercial biocidal 
formulations on its dermal absorption in vitro.  Regulatory Toxicology and Pharmacology, 48 
(1), pp. 87-92. DOI: 10.1016/j.yrtph.2007.01.007 
Buist, H.E., Schaafsma, G., van de Sandt, H., 2007. Relative absorption and dermal loading: 
Consequences for risk assessment. Toxicology Letters, Volume 172, Supplement 1, Page S13 
Tukker, A., Buist, H., van Oers, L., van der Voet, E. (2006). Risks to health and environment of 
the use of lead in products in the EU.  Resources, Conservation and Recycling, 49 (2), pp. 89-
109. DOI: 10.1016/j.resconrec.2006.03.005 
Dekkers, S., Telman J., Rennen, M.A.J., Appel, M.J., Buist, H.E., Heer, C. de, 2006. P8-16 
Within-animal variation as a minimal Critical Effect Size for continuous toxicological 
parameters applicable in the Benchmark dose approach. Abstracts / Toxicology Letters 164: 
S146. 
Buist, H.E., Van De Sandt, J.J.M., Van Burgsteden, J.A., De Heer, C. (2005). Effects of single 
and repeated exposure to biocidal active substances on the barrier function of the skin in 
vitro.  Regulatory Toxicology and Pharmacology, 43 (1), pp. 76-84. DOI: 10.1016/ 
j.yrtph.2005.06.006. 
Buist H.E., de Heer C., Bessems J.G.M., Bouwman T., Chou S., Pohl H.R., and Van de Sandt 
J.J.M. Dermal absorption in risk assessment: the use of relative absorption versus 
permeation coefficient (Kp). Occupational and Environmental Exposures of Skin to Chemicals 
- 2005. Abstract for poster 25 
http://www.cdc.gov/niosh/topics/skin/OEESC2/AbPost025Buist.html. 
 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 197 
Overview of completed training activities 
  
 
 
 
Overview of completed training activities 
page 198 
Discipline specific activities 
Name of the course Graduate school/institute Year 
Postgraduate training Toxicology / Clinical Toxicology Utrecht University 1990 
Postgraduate training Toxicology / Epidemiology Utrecht University 1990 
Postgraduate training Toxicology / Introduction into 
Toxicology Wageningen University 1991 
Postgraduate training Toxicology / Laboratory Animal 
Science Utrecht University 1991 
Postgraduate training Toxicology / Occupational 
Toxicology Nijmegen University 1991 
Postgraduate training Toxicology / Pathobiology Utrecht University 1991 
Postgraduate training Toxicology / Risk Assessment Wageningen University 1991 
Postgraduate training Toxicology / Cell Toxicology Limburg University 1992 
Postgraduate training Toxicology / Ecotoxicology Free University Amsterdam 1992 
Postgraduate training Toxicology / Genetic Toxicology Leiden University 1992 
Postgraduate training Toxicology / Internship Genetic 
Toxicology 
Wageningen University/ Duphar B.V. 
Weesp 1992 
Postgraduate training Toxicology / Molecular 
Toxicology Free University Amsterdam 1992 
Introduction Completeness check pesticide 
notification dossiers in the Netherlands CTB 2000 
Symposium New developments in Risk Assessment NVT 2001 
Workshop Reproduction toxicity RIVM 2001 
Conference Food safety & dietary risk AgChem Forum 2002 
Symposium New developments in Risk Assessment NVT 2002 
Forum Tox '03 Toxicology in the Pharma Industry Vision in Business 2003 
Conference on Occupational and Environmental 
Exposures of Skin to Chemicals (OEESC 2005) NIOSH, Karolinska Institutet (Stockholm) 2005 
Short course Assessment of dermal exposure (part of 
OEESC 2005) TNO 2005 
Short course In vivo studies for prediction of 
percutaneous penetration (part of OEESC 2005) 
Dept. of Dermatology, University of 
Copenhagen 2005 
Short course Modelling percutaneous penetration 
(part of OEESC 2005) Colorado School of Mines, USA 2005 
Symposium Combination Toxicology and Risk 
Assessment NVT 2005 
Workshop Consequences of pesticides for 
immunologic health Europit (Maastricht University) 2005 
REACH workshop TNO 2006 
Course Benchmark-Dose Modelling IRAS/RIVM, University of Utrecht 2007 
Course exposure modelling TNO 2007 
Integrated Probabilistic Risk Assessment RIVM, Bilthoven, Netherlands 2008 
Long range Research Initiative symposium CEFIC, Brussels, Belgium 2008 
Mode of Action workshop John Moores University, Liverpool, UK 2008 
Structural Alerts workshop OECD, Utrecht, Netherlands 2008 
Hearing Toxicological Threshold of Concern EU, EU Health and Consumer Protection 
Directorate General, Brussels, Belgium 2009 
Workshop PBPK modelling and risk assessment WHO/IPCS, Berlin, Germany 2009 
Conference on Nanotoxicology (2 days) An international scientific committee of 
nanotoxicologists 2014 
 
 
 
 
Dermal absorption and toxicological risk assessment - Pitfalls and promises 
page 199 
General courses  
Name of the course Graduate school/institute Year 
Course small fire extinguishers TNO 2001 
Course SAP for project leaders TNO 2002 
Spider training TNO 2006 
Course Communication styles GITPL, Amsterdam, Netherlands 2008 
Course Data mining (4 days) School of Mathematics and Informatics, Technical University of 
Eindhoven, Netherlands 2011 
 
Optionals  
member PBPK working group WHO (2006-2010) 
member dermal absorption working group EFSA (2015-now) 
 
  
 
 
 
Colofon 
page 200 
 
The studies described in this thesis were executed at TNO, location Zeist, with financial 
support of the Dutch Ministry of Social Affairs and Employment. 
Financial support of Wageningen University and TNO for the printing of this thesis is 
gratefully acknowledged. 
This thesis was printed by GVO drukkers en vormgevers B.V. 
Harrie Buist, 2016 

Dermal absorption and
toxicological risk assessment:
Pitfalls and Promises
D
erm
al ab
so
rp
tio
n
 an
d
 to
xico
lo
g
ical risk
 assessm
en
t: P
itfalls an
d
 P
ro
m
ises
H
arrie B
u
ist
Harrie Buist
